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s U M M  A R Y
The morphological and cytochemical changes occurring in liver of male 
Sprague-Dawley rats receiving clofibrate, diethylnitrosamine (DENA) 
followed by phénobarbital (PB) and PB alone were studied after adminis­
tration periods varying from 3 days to 103 weeks.
All treated rats showed liver enlargement and enzyme induction.
While the rats receiving clofibrate showed ultrastructural and enzymic 
changes consistent with an enhanced lipid metabolism, all the rats 
treated with PB displayed morphological and cytochemical modifications 
indicative of stimulated drug detoxicating microsomal activity.
Rats treated with clofibrate revealed foci of cellular alteration 
occurring sooner (week 42) than untreated controls (week 60).
Approximatly half of the rats which had received 68 or more weeks of 
continuous treatment with clofibrate developed hepatic nodules. None of 
the foci and nodules examined cytochemically showed Y-GT or aerobic 
G6PDH activities. Most of the other enzymes assayed showed an heteroge­
neous pattern characteristic of these liver lesions. In the rats withdrawn 
from clofibrate for 16 to 18 weeks, after 68 to 95 weeks of treatment 
no nodules were found.
Although the number of Y-GT positive foci was increased, phénobarbital 
alone had little effect on the incidence of foci of cellular alteration. 
DENA followed by PB led to the early appearance of foci of cellular alte­
ration (from week 4), of nodules (from week 12) and hepatocellular 
carcincxnas (from week 21). These lesions had acquired y-GT and aerobic 
G6PDH, and in addition exhibited cytochemical changes reflecting a 
sustained activity of the microsomal drug metabolizing system and conjuga- 
tive processes. DENA-PB for 17 to 30 weeks induced essentially the same 
lesions. Withdrawal of PB treatment for periods of 22 and 26 weeks did not 
diminished the incidence of liver lesions nor changed their morphological 
and cytochemical characteristics.
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A - GENERAL ASPECTS
Of all the diseases that afflict mankind those described as cancer 
evoke the strongest emotions. Because cancer implies pain, protacted 
suffering, hideous growth and death it is widely and justifiably feared. 
In medically advanded countries one in five people die of cancer.
Diseases of the cardiovascular system, such as atherosclerosis and dege­
nerative heart disease cause more victimes. Although they are responsible
for approximately 50 per cent of all deaths, their psychological impact 
is less, due mainly to the nature of the disease.
There is increasing focus on the concept that many cancers are caused 
by environmental agents. Diet, chemicals, radiation and viruses are some 
of known factors that appear to be involved in this emphasis on environ­
mental factors. A progressive shift in emphasis from the individual to 
the environment in the perception of the aetiology and pathogenesis of 
cancer has occurred during the past 20 years. The early hypothesis of 
spontaneous malignancy as a result of intrinsic genetic instability has 
progressively been replaced by the concept of an interaction of both 
genetic and environmental factors. This change is bringing a more compre­
hensive approach to the role played by, on the one hand, the genetic 
make up, and, on the other hand, the environment and both these risk 
components are now receiving increasing attention in the prevention 
of cancer.
Among the factors contributing to this radical shift in perception, 
one of the more important is the accumulating evidence that cigarette 
smoking is a major factor in the aetiology of lung cancer. Another point 
of great interest in environmental carcinogenesis is the large diffe­
rences in incidences of specific cancers from country to country and 
even within countries. These differences are not determined by genetic 
factors as shown by the fact that the cancer of migrants, and especially 
those of their children, change from those which are characteristic 
for inhabitants of the mother country toward those of the inhabitants
of their new country. With the exception of skin cancer, for which 
solar ultraviolet radiation is an important aetiological factor, 
emphasis has been placed on environmental chemicals and in particular 
dietary factors as a major influence on human cancer. There has been 
insufficient data, until recently, on the role of infectious viruses 
in the genesis of human malignant neoplasia. Over 30 specific chemicals 
or mixtures have been identified as the cause of some type of human 
cancer. In addition, an increasing number of environmental substances, 
such as pesticides, fungicides and other compounds widely used in 
food production are being recognized as agents that can promote the 
development of neoplasms (Miller, 1978 ; Farber, 1982).
Early observations
The oldest available evidence of chemicals inducing cancer goes back 
to the XVIII century. During the second half of this century the 
British physician John Hill observed a clear link between excessive 
tobacco snuff taking and nasal cancer (quoted by Miller, 1978). Later, 
Percival Pott (quoted by Miller, 1978) reported an unusual high inci­
dence of cancer of the skin of the scrotum among young men employed 
as chimney sweeps in their childhood. The development of different 
types of cancer towards the end of the 19th century in certain wor­
kers was shown to be associated with exposure to specific chemicals. 
Cancer of the skin was demonstrated to be induced by cutaneous contact 
with tar and paraffin oils by von Volkman and Bell (quoted by Haddow and 
Kon, 1947). Later many observations were reported in several countries 
on the association between human bladder cancer and occupations that 
resulted in large exposures to 2-naphthylamine benzidine or 4-aminobi- 
phenyl (Clayson, 1962). These observations stimulated attempts to induce 
tumours in experimental animals by exposure to the implicated substan­
ces and related compounds.
Experimental studies
A number of investigators sought to demonstrate the carcinogenic capacity 
of soots ans tars in experimental animals (Haddow and Kon, 1947). Their 
findings led to the search for the active agents in this complex mixtures. 
Subsequent chemical studies suggested that polycyclic aromatic hydrocar­
bons were the active material. Among these, benzo(a)pyrene, 3-methylcho- 
lanthrene, dibenz(a,h)anthracene, and 7, 12-dimethylbenz(a)anthracene 
have been most widely used in subsequent experimental studies of carci­
nogenesis. Following the early work of Fisher in 1906 (quoted by Miller, 
1978), Yoshida showed in 1933 that exposure to 0-aminoazotoluene induced 
liver tumours in rats. Shortly after, Kinosita (1936) demonstrated the 
strong carcinogenicity of NN-dimethyl-4-aminoazobenzene. In 1938, urinary 
bladder cancer was induced in dogs fed 2-naphthylamine (Hueper et al., 
1938). By 1940 the epidemiological data on the carcinogenicity of aro­
matic amines and of coal tars and soots for man had been complemented 
by definitive data on the carcinogenicity in experimental animals of the 
pure chemicals contained in these mixtures.
The list of known carcinogenic chemicals expanded markedly in this 
period as a result of a great increase in the number of animal studies. 
The ability to induce tumours with 2-acetylaminofluorene and a number of
related amides was demonstrated by Wilson and coworkers, 1941. Also
reported was the induction of "hepatomas" in mice by carbon tetrachlo­
ride (Edwards, 1941) and pulmonary adenomas in the same species, by 
urethane (Nettleship and Henshaw, 1943). Similarly the carcinogenicity 
of thiourea, thioacetamide and nitrogen mustard were first observed in 
this decade (Boyland and Horning, 1949 ; Fitzhugh and Nelson, 1948 ;
Purves and Griesbach, 1947). Oncogenicity studies undertaken during 
the fifties revealed the carcinogenic properties of a wide range of 
alkylating agents such as dialkylnitrosamines ; ethionine and pyrrolizi- 
dine alkaloids (Magee et al., 1976 ; Farber, 1963 ; Cook et al., 1950 ;
Schoental, 1976). The carcinogenic of these last substances, like that
of oestrogen, has proved that carcinogenic agents are not solely produced
by chemists or are products of high temperature combustion. Nowadays 
a number of metabolites of plants and microorganisms are known to induce 
cancer in experimental animals (safrole, aflatoxins, cycasin, griseo- 
fulvin) (Miller, 1978). Furthermore it is probable that a large number 
of naturally occurring carcinogens exist among the vast quantities 
of unknown non nutrient metabolites of living cells. A proportion of 
these are expected to come into contact with human tissues in low doses 
through food or as products of the intestinal flora.
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B - MECHANISM OF CANCER
During the forties Rous and coworkers (Rous and Kidd, 1941 ; Friedwald 
and Rous, 1944) demonstrated that local application of coal tar to the 
ears of rabbits for a period of time, followed by wounding, resulted in 
the appearance of tumour growing along the edge of the wound. Either 
treatment on its own resulted in no neoplasia. These investigations 
provided the first experimental evidence suggesting a two-stage mechanism 
for carcinogenesis. Rous used the terms initiation for the process 
resulting from tar application and promotion for the function of the 
wounding. Shortly after, these findings were confirmed by Beremblum 
and Shubik (1947, 1949). Later the term progression was proposed by 
Foulds (1964), for all the development stages following the initial 
event in the conversion of a normal to a neoplastic cell. Initially 
the development of cancer was considered as a continuous process arbitra­
rily divided into several phases. Nowadays is generally accepted that 
promotion and progression are distinct processes (Pitot, 1981).
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Characteristics of agents inducing, enhancing or modifying carcinogenesis
Based on the pathogenesis of epidermal carcinoma, agents inducing and 
affecting the development of neoplasm of a specific histogenetic origin 
C6in be divided into three categories : complete carcinogens, incomplete 
carcinogens and promoting agents. Complete carcinogens are chemical, 
physical or biological agents having the ability to induce neoplastic 
transformation in the absence of other environmental agents. Such agents 
have the capacity both to initiate cells and to promote such initiated 
cells to neoplasia. One of the most important properties of initiating 
agents is that a cell once initiated, does not lose this acquired 
characteristic with time. Thus the initiating agent provokes an irrever­
sible change in one or more of the cells of the target tissue. In 
contrast, promotion is reversible and, as shown by Boutwell (1964, 1974), 
capable of modulation by diet, hormones and environmental factors.
Since tumour promotion depends on continued application of the promoting 
agent, it is not surprising that this treatment sometimes gives rise to 
a low incidence of neoplasms. Based on these observations Roe and Clack 
(1964) have suggested that tumour promoters, specifically croton oil 
and related compounds, are simply very weak carcinogens. On the other 
hand initiated cells may remain dormant for extended periods, even more 
than a year in mouse skin, consequently efficient promoting agents would 
be expected to promote the development of neoplasms from a small minority 
of cells initiated either by environmental factors such as background 
radiations, dietary contaminants or naturally occurring mutations 
(Van Duuren et al., 1975). Unfortunately, no critical experiment to 
distinguish these two mechanisms for any particular promoting agent has 
thus far been reported.
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c -MOLECULAR MECHANISM
I Initiation
According to Pitot (1981) an initiating agent is defined as a chemical, 
physical or biological agent that is capable of directly altering ir­
reversibly the native molecular structure of the genetic component (DNA) 
of the cell. Such alteration(s) may be the result of a covalent reaction 
of DNA with the initiating agent itself or with one of its metabolites 
but this alteration may also include a distortion of the structure of 
DNA without covalent binding of the agent to DNA. Finally, the agent 
may cause one or more complete scissions, of the DNA chain, on elimina­
tion of one of its component parts (e.g., bases or sugars) or errors 
in DNA repair. All such capabilities of an initiating agent, however do 
not in themselves prove that alteration of DNA is the only or the 
absolute requirement for the neoplastic transformation. The term geno- 
toxic has been coined to cover the effects of such agents on cellular 
DNA.
Genotoxic agents
Until recently, one of the most puzzling and confusing aspects of 
chemical carcinogenesis was the diversity in the chemical structures of 
carcinogens. This problem has now been largely resolved by the discovery 
of metabolic conversion of many carcinogens to highly reactive metabo­
lites (Miller, 1978).Much of the work on the identification of the meta­
bolic species that might be involved in the induction of cancer has 
stemmed from the original proposal of Miller and Miller (1976), who 
suggested that these species are positively charged (i.e. electrophiles) 
that react at a negatively charged nucleophilic centers in protein 
and nucleic acids. Although it is now clear that such reactions are 
important in initiation, little is known of their relationship to the 
subsequent development of malignancy. Metabolic activation reactions 
appear to take place in many cell types.
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A minority of chemical carcinogens such as some nitrosamides (e.g. alkyl- 
nitrosoureas), bis-chlormethyl/ether, and nitrogen mustard, are active 
per se,and do not seem to require any metabolic conversion to more 
reactive metabolites (Lawley, 1976).
Activation of procarcinogens
It has become evident that the majority of the chemical carcinogens are 
procarcinogens. These susbtances must be converted in vivo to chemically 
reactive derivatives.
The processes by which chemical carcinogens are activated are often complex 
and may involve two or more metabolic steps. The products formed in the 
early steps are called proximate carcinogens, whilst, the final products 
that are directly concerned in reactions with cellular macromolecules 
are designated ultimate carcinogens (Miller and Miller, 1976). The 
electrophilic species generated within cells usually arise through reac­
tions catalysed by enzymes that are part of the detoxication mechanisms 
of the cells, but not all of these reactive species are involved in 
reactions with macromolecules. Most are converted into inactive products 
by secondary metabolic processes and it is only those products that escape 
these secondary processes that are likely to react with cellular macromole­
cules, may be because they are produced faster than they can be further 
metabolized.
The first type of metabolic activation discovered was the conversion 
of an aromatic amine, 2-acetylaminofluorene (2-AAF), by oxidation to 
an N-OH derivative (Miller, 1978). This reactive product may in turn be 
esterified to a more reactive form, a, N-O-ester, which is believed to 
be the ultimate carcinogen for this and various other aromatic 
amines (e.g. benzidine).
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More recently, much effort has been placed on the clarification of the 
activation of benzo(a)pyrene (B(a)P) and other polycyclic aromatic 
hydrocarbons (PaHs) (Sims and Grover, 1974 ; Yang et al.,*1978 ; Phillips 
and Sims, 1979). Many PAHs are generated by combustion, are therefore 
widely distributed in our environment and are thought to be responsible, 
in part at least, for the carcinogenicity of coal tar products. These 
compounds undergo epoxidation by microsomal mixed function oxidases to 
form reactive epoxides, some forms of which are considered to be ultimate 
carcinogens (Gelboin and Ts'O, 1978). In the case of B(a)P and probably 
other PAHs, the initial site of epoxidation may undergo hydration to form 
a dihydrodiol, this reaction is catalyzed by epoxide hydrolase. This 
inactive dihydrodiol in turn can be converted to another epoxide at a 
second site to form a dihydrodiol epoxide (Booth and Sims, 1974). B(a)P 
yields three trans-dihydrodiols epoxides. Bay region epoxides, that is 
epoxides which are adjacent to the region between an angular benzo ring 
and the rest of the molecule are the more chemically reactive and are 
considered to be the most likely ultimate carcinogens (Jerina and Daly, 
1977).
Another potentially important carcinogen for humans that is subject to 
activation via epoxidation is aflatoxin B1 (Miller, 1978). Aflatoxin 
undergoes oxidation at its 8,9-position ; and this derivative, the 8,9- 
oxide, appears to be one form of ultimate carcinogen of this mycotoxin 
(Garner, 1980)
The general accepted scheme for metabolic activation of N-nitrosamines 
is based on the one originally postulated by Druckrey (1973) for dimethyl- 
nitrosamine. According to this scheme, dimethylnitrosamine is metabolized 
by dimethylnitrosamine N-demethylase, a mixed function oxidase enzyme, 
to methyl diazonium hydroxide, the presumed carcinogenic intermediate, and 
formaldehyde. The former readily degrades to form nitrogen and methyl 
carbonium ions, an electrophilic alkylating species. Recent published data 
suggest that the bioactivation of N-nitrosamines involves an N-oxidative 
step mediated by an amine oxidase-type enzyme (Lake et al., 1978 ; Gangolli, 
1981). '
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Vinyl chloride is also activated via epoxidation (Miller, 1978). These 
reactions with B(a)P, aflatoxin Bl, and vinyl chloride are illustrative 
of the probable activation of many other aliphatic, aromatic or heterocy­
clic compounds to form both carcinogenic and other toxic reactions 
(e.g. bromobenzene).
The principal enzymes involved in the activation of chemical carcinogens
The first stage in the metabolism of many foreign compounds involves 
the mono-oxygenases. These enzymes are present in the cells of most 
tissues in man and animals but particularly in liver cells. The mono­
oxygenases are situated in the endoplasmic reticulum and are thus 
present in the microsomal fractions obtained when tissue homogenates are 
subjected to differential centrifugation. They require NADPH and molecu­
lar oxygen and they consist of an electron-transporting system together 
with a terminal cytochrome P-450 (Atlas and Nebert, 1978 ; Gillette, 1978) 
The enzyme system is induced in animals treated with any one of a large 
number of organic compounds, including polycyclic aromatic carcinogens 
and barbituric drugs (Conney, 1967 ; Daly et al., 1972 ; Gillette et al. 
1974 ; Conney and Burns, 1972 ; Gelboin, 1980). With many polycyclic 
hydrocarbons particular cytochromes often termed cytochrome P-448, are 
induced preferentially (Alvares et al., 1967). These increases in the 
levels of the mono-oxygenases may be of importance in the activation of 
carcinogens, since the levels of other enzymes concerned in detoxifica­
tion may not be increased to the same extent (Van Cantfort et al., 1979). 
The mono-oxygenases present in some tissues have been purified and appear 
to exist in multiple forms (Alvares and Kappas, 1977 ; Thomas et al..1976 ; 
Volker and Kremers, 1977 ; Lu and West, 1980). There is increasing evi­
dence that the mono-oxygenases are located within the nuclear membrane 
as well as on the endoplasmic reticulum of cells and that the enzymes 
in both locations have similar metabolic capabilities (Bresnick et al., 
1977). The presence of cytochrome P-448 in the nuclei of rat hepatocytes
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has been established by an immunochemical method (Thomas et al., 1979). 
If, as seems likely, mono-oxygenases are also present in the nuclei of 
cells of other tissues, then the generation from carcinogens of reactive 
species, in close proximity to genetic material within the nucleus 
rather than outside the nuclear membranes may be of importance in rela­
tion to the reactions with DNA that take place with these compounds. It 
is also possible that proximate carcinogens are formed in the cytoplasm 
and are converted into ultimate carcinogens within the nucleus.
The microsomal mono-oxygenases function by adding an atom of oxygen to a 
molecule of the substrate, so that relatively non-polar lipid-soluble 
compounds are converted eventually into more polar water-soluble products 
that can be excreted from the body. Two main types of products are 
initially formed, either by hydroxylation at aliphatic or aromatic carbon 
atoms or at hetero-atoms such as nitrogen or by epoxidation at aromatic 
or olefinic double bonds (Parke, 1974). Hydroxylation of aromatic 
carbon atoms often involves the initial formation of intermediate 
epoxides (Sims and Grover, 1974). Hydroxylated products are usually 
conjugated with either glucuronyltransferases (Parke, 1974) or sulpho- 
transferases (Roy, 1971) respectively. Although these enzymes are mostly 
concerned with detoxification, one or both types of conjugate may be 
involved in the metabolic activation of some carcinogens such as the 
aromatic amines. Epoxides, both aliphatic and aromatic are further 
metabolized by one of two routes. The first involves the enzymic addition 
of GSH to the expoxide to produce glutathione conjugates that are further 
metabolized at the peptide side chain followed by acétylation to yield 
mainly-N-acetyl-cysteine derivatives (i.e. mercapturic acids) which are 
excreted in the urine (Chasseaud, 1976). The glutathione-S-transferases 
are a group of cytoplasmic enzymes that catalyse reactions between GSH 
and substrates having electrophilic centres. A number have been recently 
isolated and purified (Jacoby, 1978). The glutathione-conjugation pathway 
appears to be entirely concerned with the detoxification of electrophilic 
species.
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The second route concerned in the further metabolism of epoxides involves 
epoxide hydratase (Oesch, 1973) which Is also present on the endoplasmic 
reticulum and in purified rat liver nuclei (Bornstein et al., 1978). This 
enzyme detoxifies the electrophilic epoxides by converting them into more 
polar dihydrodiols by addition of water. However, as mentioned above in 
the case of the polycyclic hydrocarbons , the hydration of simple epoxi­
des is sometimes one step in the production of ultimate carcinogens.
Cellular targets
Correlation between the carcinogenicity of certain chemicals and their 
covalent fixation to macromolecules was established during the sixties 
(Brookes and Lawley, 1964). Since then a number of types of interaction 
between carcinogens and proteins have been studied. Some have been iden­
tified as covalent, others as non-covalent. Those interactions which are 
very stable are usually assumed to be covalent (Craddock, 1965 ; Ketterer 
and Christodoulides, 1969 ; Miller and Miller, 1977 ; Ketterer, 1980). 
l\vo well-characterized cellular proteins that bind many chemicals inclu­
ding carcinogens non-covalently are the intracellular proteins ligandin 
and fatty acid binding protein. They have relatively unspecific binding 
sites that are capable of competing with the lipid phase of intracellular 
membranes for lipophilic carcinogens and their metabolites (Ketterer, 
1980). It has been proposed that these proteins could enhance the trans­
port of lipophilic chemicals in the cell and thus increase the efficiency 
of their metabolism (Ketterer, 1980). All nuclear protein fractions inte­
ract with carcinogens (Rees et al., 1965 ; Albert and Warwick, 1972 ; 
Gronow and Lincoln, 1978 ; Jungmann and Schweppe, 1972). Interactions 
with individual proteins may be carcinogen specific, however there is 
at least one interaction which is relatively common namely that resulting 
in the inactivation of RNA polymerase II. Transcribing chromatin seems 
particularly vulnerable to carcinogens. In addition the products of 
transcription, nuclear riboprotein particles, bind a number of carcino­
gens more effectively than do most other macromolecules (Moses et al., 
1976 ; Ketterer, 1980). Non covalent binding to histones has been clearly
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demonstrated in vitro (Sluyser, 1968) and to both histones and non­
histones in vivo (Ketterer, 1980). Persistant binding, assumed to be 
covalent, also occurs (Sonnenbichler and Reichart, 1978). Measurement of 
the reactions of a number of labelled carcinogens with cellular macro­
molecules has revealed not only the ability of almost all known carcino­
gens to react with DNA but has in addition shown that generally only the 
extent of binding to DNA tends to correlate best with the subsequent 
biological effects observed. Reactions with RNA and proteins are usually in­
sufficient to inactivate all classes of RNA and to inhibit enzyme activity 
(Roberts, 1980) thus their biological sigificance is questionable. This 
view has been considerably reinforced by observations that representatives 
of all classes of chemical carcinogens such as dialkyInitrosamines, poly­
cyclic aromatic hydrocarbons, vinyl chloride, aflatoxins can be demonstra­
ted to induce changes in DNA (Venitt, 1980). Positive results in mutageni­
city tests have provided a useful sensitive index of whether carcinogens 
or their metabolites can react with DNA.
Molecular targets
More recently, attention has been directed towards identifying quantita­
tive correlations between DNA reactions in vivo and carcinogenesis, both 
with respect to the total DNA binding and to specific sites within DNA. 
Although the chemistry of the interactions between carcinogens and nucleic 
acid is not fully understood, several aspects of the reactivity towards 
different nucleophiles have been summarized (Swain and Scott, 1953 ;
Ross, 1962 ; Lawley, 1976 ; Hemminki, 1983). In nucleophilic substitutions 
the kinetics of the reaction may depend on the concentration of the elec- 
trophile (unimolecular kinetics, Snl mechanism) or on the concentration 
of both electrophile and nucleophile (bimolecular kinetics, Sn2 mechanism). 
Nucleophiles in nucleic acids include ring-nitrogens, particularly N-7 of 
guanine which has a relatively high nucleophilic strength, as well as 
hydroxyl groups and amino groups with lower nucleophilic strength (Lawley, 
1976 ; Royer et al., 1979). Electrophiles acting through the Sn2 mechanism
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usually prefer nucleophiles of high nucleophilic strength such as N-7 
of guanine. In contrast, compounds reacting mainly through the Snl mecha­
nism are usually less selective for nucleophilic strength and may cause 
alkylation at hydroxyl groups (Loveless, 1969 ; Osterman-Golkar et al. 
1970). Alkylating agents of simple chemical structure not requiring meta­
bolic activation to enable their reaction with DNA have been valuable in 
in vitro carcinogenesis studies ; they show that chemical reactivity cor­
relates with tumorogenic action (Lawley, 1980). Although guanine is a 
frequent target on the nucleic acid molecule, adenine, cytosine and 
thymine may also be attacked (Magee et al., 1981 ; Weinstein, 1981 ; 
Hemminki, 1983). In order to assign a possible role to individual reac­
tions with DNA attempts have been made to correlate total méthylation of 
DNA, or méthylation at the N-7 position of guanine residues with incidence 
of tumours of various organs of the rat (Margison and O'Connor, 1979). It 
has become evident although the major product (7-alkyIguanine) was the 
same for a number of closely related chemicals, that the proportion of 
minor products of alkylation may vary considerably. This has focussed 
attention on the minor products as being of possibly great importance in 
the genesis of alkylation induced neoplasia. The reaction which has emerged 
as a main determinant of carcinogenicity initiation is alkylation of 
the 0-6 atom of guanine on DNA, as proposed by Loveless (1969). This 
potentiates mis-pairing of alkylated guanine with thymine, thus accounting 
for the predominance of GC - AT transition mutagenesis by alkylating agents 
(Lawley, 1980). Alkylating agents can also induce AT-GC transitions 
(Neale, 1976) and the complementary mispairing between 0 -alkylthymine and 
guanine (Lawley, 1980) is expected to contribute to the totality of muta­
tions. These aspects of carcinogen-nucleic acid interactions seem to apply 
to simple alkylating agents, however is not clear how well this concept 
can.be extended to more complex carcinogens such as polycyclic aromatic 
hydrocarbons and aromatic amines. With more complex carcinogens modifica­
tions in other sites appear important. Aflatoxin and sterigmatocystin, 
two potent hepatocarcinogens (Meselson and Russell, 1977 ; Lutz, 1979), 
seem to react predominantly at the N-7 of guanine. Polycyclic aromatic
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2hydrocarbons react preferently at the N of guanine. With the electrophi­
lic metabolites of arylamines and arylamides the major reactions with 
the nucleic acids accur at the 8-position of guanine (Miller, 1970, 1978 ; 
Miller and Miller, 1976) (N.B. N-substitution of C-8 in guanosine and 
deoxyguanosine by the carcinogen-N-benzoyloxy-N-methyl-4-aminoazobenzene 
has also been demonstrated in vitro). Two particular 2-acetylaminofluorene 
adducts in rat liver DNA have been identified by Kriek (1972). The major
adduct has been found at the C-8 position in deoxyguanosine, the minor
2 2 
one reacts at the N position of deoxyguanosine. N adducts appear more
significant in terms of malignancy as suggested by their greater persis­
tence. This is probably due to the greater efficiency of excision repair 
mechanisms brought about by the more ready recognition of lesions with 
large conformational distortions such as C-8 adducts.
Reactions of alkylating agents or arylamine derivatives with the tertiary 
phosphate groups of nucleic acids also occur (Price et al.,1968 ; Lawley, 
1973 ; King et al., 1975 ; O'Connor et al., 1975) and these substitutions 
can lead to breaks in the sugar-phosphate backbone. Similarly as mentioned 
above reactions of chemical carcinogens with proteins in vivo occur at 
number of sites, including the methionyl, cystinyl, histidyl and thyrosyl 
residues (Miller and Miller, 1966 ; Lin et al., 1968 ; De Baun et al.,
1970 a). In these situations steric changes and non-covalent interactions 
may contribute the overall effect as much as the sites alkylated (Hemminki, 
1983). Thus the protein component of nucleoprotein might well affect the 
interaction of carcinogens with DNA by :
a) acting as a competing electrophile thereby reducing binding ;
b) hindering binding by steric means ;
c) increasing binding points by, for instance, providing a 
hydrophobic environment which facilitates the concentration of carcino­
gens .
As a consequence in general the linker region is more susceptible to the 
binding of some carcinogens than is nucleosomal DNA (Ketterer, 1980). The
conformation of the nucleosome exposes a short region of DNA which is 
more susceptible to binding than the rest (Me Ghee and Felsenfeld, 1979).
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Protooncogenes and oncogenes
The introduction of simplified assays systems for the study of somatic 
imitation and carcinogenesis has enabled the demonstration of a direct link 
between adduct formation with specific genes and the process of transfor­
mation. The point mutation responsible for the activation of the oncogene 
of human bladder carcinoma has been identified (Tabin et al., 1982 ; Reddy 
et al., 1982). The G-T transversion causes a remplacement of glycine by 
valine in the p21 protein encoded by the oncogene. Aromatic amines bind 
preferentially to guanine residues and may favour this G-T transversion.
The initial insight into cellular oncogenes come from studies of the Rous 
Sarcoma Virus (R.S.V.). Viruses such as R.S.V. have been studied intensive­
ly during the last decade, because of their unusual molecular biology 
involving reverse transcription and the efficient integration of their 
genomes into the cellular chromosome. Another of their characteristics 
has opened up investigations into cellular oncogenes : i.e. retroviruses 
are able to pick up and transduce cellular genetic information. It was 
found that the cellular genome contains a gene that can exhibit strong 
transforming properties when properly activated. This gene, termed proto­
oncogene is a normal cellular gene and an integral part of the genome 
( Stehelin et al., 1975 ; Hughes, 1979 ; Land et al., 1983). Proto-oncogene 
is transformed by the R.S.V. virus in a src gene, this oncogene enables 
the virus to induce sarcomas in vivo and to transform chicken fibroblasts 
in culture (Stehelin et al., 1976). More recent, experimental work has 
revealed a second group of cell-associated oncogenes. Samples of DNA were 
extracted from chemically transformed cells and introduced into an appro­
priate monolayer cell cultures. Foci of transformed cells appeared in the 
cell cultures indicating the presence of dominantly acting cell transfor­
ming information in the donor cell DNA. These gene transfer experiments 
showed that certain types of chemically transformed cells carry oncogenic 
sequences in their DNA (Shih et al., 1979). Many types of tumour cells 
develop transforming sequences in their DNA during their progression, 
these include carcinomas of the intestines, lung, bladder, skin and
22
mammary gland. This also occurs with different sarcomas, glioblastomas 
and a variety of hematopoietic neoplasms (Shih et al., 1979 : Weinberg, 
1982 ; Cooper, 1982 ; Land et al., 1983). The oncogenes associated with 
these tumours are presumed to be important in inducing the transformed 
phenotypes of neoplastic cells. However, the existing experiments thus 
far only demonstrate that these oncogenes can transform foreign cells 
into which they have been introduce by gene transfer. The isolation of 
several tumour oncogenes has shown that each oncogene is closely related 
to a counterpart DNA Sequence present in the normal cellular genome 
(Land et al. , 1983). Various molecular mechanisms are implicated in the 
activation of proto-oncogenes. Some of these involve over expression 
of a proto-oncogene following addition of a strong transcriptional 
promoter (Blair, 1981) or over expression due to amplification of the 
proto-oncogene or oncogene (Collins and Groudine, 1982). Another mecha­
nism depends on alteration in the structure of the oncogene protein. This 
mechanism is well documented in the case of the oncogene proteins
encoded by the rasgenes, and is involved in the already mentioned assumed,
mechanism of human bladder carcinoma. Recently, Marshall and coworkers 
(1984) have shown that reaction in vitro of the ras proto-oncogene with
benzo(a)pyrene diol-epoxide, an ultimate carcinogen, generates a trans­
forming oncogene when the modified DNA was introduced into NIH 3T3 cells. 
This body of work on cellular oncogenes and carcinogenesis, although it 
does not explain all the aspects of the cancer process in terms of onco­
genes, reinforces the hypothesis that the induction of mutations 
following carcinogen binding is a necessary step in the many multistage 
processes of tumour induction (Marshall et al., 1984 ; Land et al., 1983)
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DNA repair
Damage to DNA resulting from the binding of ultimate carcinogens includes 
breaks which may be single or double strand. Transmission of this altered 
and now faulty DNA is presumably responsible for carcinogenesis. Enzymes 
systems are known which can repair the fault by various processes. Repair 
can be faithful and the DNA molecule restored to normal, if the repair 
is accomplished in the initially altered cell. VJhen repair is attempted 
after the initially damaged cell has divided, it is less likely to restore 
the DNA to normal, leaving a permanent mutation.
Mechanism of DNA repair - excision repair processes
Adducts induced in the DNA of mammalian cell can be removed by excision 
repair processes. In the termed "nucleotide excision repair", nucleotide 
fragments of DNA are lost along with damaged-bases following phosphodies- 
ter chain scission. One of the most significant recent developments in 
DNA repair is the discovery of a new class of enzymes that affect the 
excision of damaged or inappropriate bases such as thymine, from DNA as 
the free base (Friedberg et al., 1981). These enzymes are collectively 
referred to as DNA glycosylases, since they catalyse the hydrolysis of 
the N-glycosylic bond linking the nitrogenous bases to the deoxyribose- 
phosphate backbone in DNA. So far seven distinct enzymes have been dis­
covered in E. Coli, and each glycosylase has been shown to be specific 
for a particular type of base damage or replacement in DNA.
Excision repair occurs in a large range of organisms but to different 
extents (Cleaver, 1977). During excision repair, damaged bases are 
recognized, a single-strand break is made in DNA, the damaged bases 
are excised, a replacement region, patch, is synthesized a process 
known either as repair replication or as unschedule synthesis, depending 
on the method of detection, and the single strand break is rejoined.
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The first step, recognition of damage, may be performed either by the 
endonuclease that breaks the DNA near the damage site or by a separate 
cofactor. Enzymes isolated from E. Coli and Micrococcus luteus that 
incise ultraviolet irradiated DNA do not break chemically modified DNAs. 
This suggests the existence of a whole spectrum of specific endonucleases 
each able to recognize particular types of chemically induced lesions 
(Roberts, 1980). Subsequent steps correspond to the sequential operation 
of a DNA exonuclease, a DNA polymerase and a DNA ligase.
While the latter steps of base excision repair pathway are analagous 
to the DNA glycosylases, it appears that the size of the repaired patches 
are different in the two systems.
An enzyme removing uracil residues from altered DNA, in which the 
cytosine residue has been deaminated spontaneously, has been isolated 
and purified from E. Coli, purified enzymes that can remove 3-methylade- 
nine residues from methylated DNA have also been obtained from E. Coli 
and in addition from M. Luteus (Roberts, 1980). Apurinic acid endonucle­
ases are widely distributed in nature and have been isolated from many 
sources, including plant, bacterial and mammalian cells (Roberts, 1978).
The final step for either excision repair pathway involves the joining 
up the 3'-hydroxyl group to the 5'-phosphodiester of the adjacent deoxy- 
ribonucleotide by means of a polynucleotide ligase. When an altered base 
such as 7-methylguanine is lost from DNA by hydrolysis, as are at much 
slower rate some normal bases, the apurinic site can be repaired by the 
above sequence of events involving an apurinic acid endonuclease. Recent 
observations indicate that an apurinic site may also be repaired by the 
insertion of a single base by means of an enzyme termed insertase 
(Roberts, 1980). Cleaver (1978) has pointed out the existence of a 
number of cofactors which act in damaged chromatin to allow the access of 
the repair enzymes to the damage sites these may be considered to regulate 
the repair processes. The activity of the excision repair pathways varies 
widely in different organisms and in different tissues of the same organism.
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In spite of the various mechanisms for excising damage to DNA, the 
removal of chemical groups from the DNA of mammalian cells is frequently 
a slow process. Moreover under condition of treatment with minimally 
toxic concentrations of chemicals, it may not be completed before the repli­
cation of DNA. Failure to replicate DNA can lead to chromosomal damage 
and thence cell death, the cell has therefore developed a mechanism that 
allows replication of DNA to occur on a template containing the unexcised 
damaged region (Roberts, 1980). Based on observations in DNA synthesis 
in ultraviolet irradiated bacteria it was proposed that this is achieved 
by "post-replication repair". DNA synthesized by bacteria deficient in 
carrying out repair immediately after ultraviolet irradiation is made 
in short pieces. The molecular weight of these pieces is inversely propor­
tional to the dose of ultraviolet irradiation. Replication seemed to be 
taking place between the thymidine dimers on the template strand of DNA, 
leaving gaps opposite the dimers. With time, after treatment, the low 
molecular weight pieces of DNA increase in size to form high molecular 
weight DNA of the same size as that of untreated control. On the evidence 
that it is the gap rather than the pyrimidine dimers that are the substrate 
for post-replication repair, the process is referred to as "daughter 
strand gap repair" (Hanawalt et al., 1979). In bacteria, this repair 
is mediated by sister strand exchanges which fill the gap in newly synthe­
sized DNA with undamaged DNA from the isopolar parental strand. The resul­
tant discontinuities in the parental strand can then be filled by repair 
synthesis using the undamaged region of the complementary daughter strand 
as template. Transfer of information between duplexes necessary to 
construct strands containing the entire base sequence of a functional chro­
mosome is provided in this way. However, many dimers still remain in the 
template DNA strands. A similar process of post-replication repair also 
occurs in a variety of mammalian cells. However, because of the greater 
complexity of the mammalian genome elucidation of the underlying repair 
mechanisms is less clear than with bacterial cells. Newly synthesized
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DNA in ultraviolet irradiated mammalian cells, is as in bacterial cells, 
of lower molecular weight than in control cell. As is the case with 
bacteria, subsequently, the molecular weight increases and eventually 
attains that of control cells. These discontinuities are assumed to arise 
by the DNA replication mechanism being halted for a time at the lesion, 
and then starting synthesis again at some point beyond it. The gaps 
in newly synthesized DNA are filled subsequently either by recombina- 
tional exchanges or by de-novo DNA synthesis. Nonetheless, not all the 
findings are entirely consistent with these models. For example there 
is evidence suggesting that the replication process stops initially at 
the lesion but then passes it by a mechanism requiring branch migration 
(Roberts, 1980).
Similar observations to those described above in ultraviolet irradiated 
cells have been reported for cells exposed to a variety of carcinogenic 
agents. These findings indicate that chemically induced lesions can be 
eluded by some form of post-replication repair (Roberts, 1980).
Observations indicate that perturbations in DNA synthesis are causally 
related to the cytotoxic action of a number of carcinogens such as alky­
lating agents and polycyclic hydrocarbons.
Inducible DNA repair processes
Most of the DNA damaging agents which block the progression of replica­
tion induce in bacteria a series of effects which are called "SOS functions" 
(Radman, 1974). These functions are under the coordinate control of recA, 
and lexAgenes. Treatment of E. Coli with DNA damaging agents drastically 
increases the synthesis of the Rec A protein. This protein in the presence 
of single-stranded DNA (due to DNA damage, or DNA repair of damage) 
is partly activated into protease. This protease activity cleaves the 
lexAgene product, which is the repressor of several SOS function genes 
(Mezzina etal., 1981).
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Both chemical carcinogens and ultraviolet irradiation have been found 
to induce typical SOS phenomena in bacteria (Moreau et al., 1976 ;
Sarasin et al., 1977).
The responses elicited by these chemical and physical agents include 
inhibition of post-irradiation DNA degradation, induced bacterial 
mutagenesis and filamentation. In addition they also induced the process 
whereby ultraviolet irradiated bacteriophages are able to survive better, 
but produce a greater number of mutant plaques when plated onto pre­
viously lightly irradiated E. Coli.
It appears that an analagous inducible error-prone repair mechanism 
can operate in response to irradiation or chemically induced damage in 
eukaryotic cells. Irradiation of host cells prior to viral infection 
results in an increased survival of ultraviolet irradiated herpes virus 
(Bockstahler and Lytle, 1970) or SV40 (Sarasin and Hanawalt, 1978 ; 
Mezzina et al., 1981). Furthermore, enhanced survival of ultraviolet 
irradiated SV40 has been found in cells exposed prior to infection to 
carcinogenic chemicals (Robert, 1980).
A number of effects on bacterial or mammalian cells pretreated with 
low doses of alkylating carcinogenic have been described recently.
These effects are apparently characteristic of the induction of a DNA 
repair process. Exposure of E. Coli to sublethal doses of N-methyl-N'- 
nitro-N-nitrosoguanidine resulted in higher survival, but in a lower 
mutation rate than occurs following use of lethal concentrations of 
the same agent (Samson and Cairms, 1977). This process has been called 
"adaptation" and is induced under conditions that do not generally 
alter cell growth or DNA synthesis, on the other hand SOS functions may 
also be induced under conditions that block DNA replication (Roberts, 
1980).
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Recently an indication of the possible existence of an analagous indu­
cible mechanism in mammalian cells has been reported (Pegg, 1978 ;
Montesano et al., 1979). For example it has been shown that the removal 
6of 0 -methylguanine from rat liver DNA is more rapid in animals that 
have had a prolonged exposure to low levels of dimethylnitrosamine 
prior to a large dose of the carcinogen (Nicoll et al., 1975 ; Kleihnes 
and Margison, 1976).
DNA base damage and mutagenesis
The concept that unexcised base damage in the DNA of target tissues of 
animals treated with chemical carcinogens can, sometimes, correlate 
with tumour response implies that there ought to be a similar correla­
tion between the presence of chemically induced potentially base- 
mispairing lesions in DNA produced by various agents and their mutagenic 
effect (Roberts, 1980 ; Weinstein, 1981 ; Weinstein et al., 1980 ; 
Montesano, 1981).
The relationship between mutagenicity and cytotoxicity suggests a 
mechanism for the induction of mutations by agents like reactive meta­
bolites of polycyclic hydrocarbons, which is different from the one 
involving mis-pairing that might result in point mutations. This latter 
mechanism however is a likely possibility for certain alkylating agents. 
The cytotoxic action of polycyclic aromatic hydrocarbons, like that of 
ultraviolet irradiation, is thought to result from the damage that 
these compounds induce in DNA leading to a selection block of DNA repli­
cation and thence chromosomal damage and cell death (Roberts, 1980).
Although the ability of physical and chemical carcinogens to induce 
either point or deletion mutations or a combination of both, in mammalian 
cells in vitro, is well established, there is still not enough evidence 
to indicate that similarly induced mutations are important initial events 
in the induction of tumours by chemical agents in vivo. The eventual
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change of a normal cell to a neoplastic cell is a heritable event, 
though in some cases apparently reversible, but this change is not mani­
fested until long after the effect of the initial chemical damage to 
DNA has been expressed or has been eliminated by various cellular repair 
processes. Thus transformation is unlikely to be solely attributable 
to a specific mutation taking place at the time of treatment, rather 
also involves a change in gene expression, thus affecting some feature 
of cell differentiation. This could be expected to occur through a 
change in the environment of the cell arising from alterations in the 
properties of the constituent tissue.
It is notable that extensive alkylation of DNA may occur without tumoro- 
genic effect, this has been observed consistently for liver of mice 
and rats. It is apparent that some additional stimulus is required, 
e.g., stimulation of DNA synthesis by partial hepatectomy (Craddock, 
1976). An important factor appears to be the removal of the potentially 
pro-mutagenic 0^-alkylguanine from the template before DNA replication 
(Lawley, 1980).
It is doubtful whether repair factors will be able to account entirely 
for the various species, strain and tissue dependences observed for 
alkylating agents. The fact that there is a positive association 
between induction of pro-mutagenic chemical modification of target DNA 
and neoplasm cannot necessarily be taken to imply predominance of muta­
genesis as a mechanism in this process. The alternative suggested acti­
vation of latent tumours virus (Gross, 1974) and derepression of onco­
genes provides one of a number of tenable alternative mechanisms 
(Huebner et al. , 1972).
Cytotoxicity and carcinogenesis
The question arises as to the mechanism by which mutant cells develop 
after toxic damage resulting from interaction of carcinogens with DNA. 
Prior to attempt to answer this question, Roberts (1980) defines cer­
tain features of DNA mediated toxicity that distinguish it from toxicity 
produced by cytotoxic non-carcinogenic substances or by physical damage 
to tissues. First, for many carcinogens very low levels of reaction
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with cellular macromolecules are required in order to produce a selec­
tive effect on DNA replication. Second, at minimally toxic doses of 
carcinogens the inhibition of DNA synthesis usually produces an increase 
in cell cycle time and cell enlargement. Thirdly nucleotoxicity will be 
only manifest when the cell undergoes DNA replication. For some cells 
of a target tissue this may occur some time after the initial reaction 
with DNA has taken place. Consequently, the environment of normal cells 
may be modified by the presence of large dying cells. This possibility 
occurs over a long period of time, long after the initial reaction 
with the carcinogen and when the cells immediatly affected have disap­
peared. Restorative hyperplasia subsequent to cell damage can be expected 
to take place during the prolonged toxic period. This may occur in an 
abnormal environment and may lack or be deficient in the normal regula­
tory feedback controls related to homeostasis. Hence, the hyperplasia 
that follows nucleotoxic damage to tissues may differ from that which 
follows damage by other types of toxicity or injury.
It is possible that under such abnormal conditions, cell division could 
result in non-disjunction and chromosomal aberrations in surviving cells 
that were otherwise normal. Progressive additional changes could then 
lead to more chromosomal damage or to alteration of gene expression 
giving rise to uncontrolled mutated cells. However, such a mechanism, 
although indirectly mediated by DNA interactions, does not necessarily 
require an alteration in the base sequence of DNA. It is very likely 
that with some carcinogens which require chronic administration for 
their effect,e^g^zo dyes , and for tissues that are normally non divi­
ding, e.g. liver, some initial tissue necrosis is important and that 
this is due to reactions with cell strutures other than DNA.
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In summary, chemical carcinogenesis involves specific modification of 
the DNA of target organs, the reactions positively associated with tumo- 
rogenesis are also those associated with mutagenesis, and subsequent 
miscoding and deletions of genetic material. However, not all DNA 
reactions lead to the induction of cancer since high levels of reactions 
with DNA are often observed in tissues not susceptible to the particular 
chemical carcinogen used. For example higher levels of DNA méthylation 
were found in the livers of rats treated with 1,2-dimethylhydrazine 
than were found in the colonic DNA of the same animals even though the 
colon is the target organ (Roger and Pegg, 1977). Thus whereas an ability 
to react with DNA has been proposed as a pre-requisite for all chemical 
carcinogens it does not in itself suffice to explain the induction 
of cancer and the nature of the subsequent process is not yet well 
specified. Moreover, carcinogenesis in the absence of covalent binding 
occurs in vivo, by agents such as plastic films, and in vitro by the 
spontaneous transformation of embryonic cells during passage in culture 
(Roberts, 1980 ; Rubin, 1980). However in these instances changes in 
the cellular environment occur that might induce modifications in chro­
mosomal structure and/or gene regulation leading eventually to malignancy 
(Roberts, 1980). Although, formation of covalent bond between a chemical 
and nucleic acid is not always an indication of carcinogenesis or muta­
genesis the many tests showing pyridine alkylation, guanosine alkylation 
and DNA binding in vivo by well-knoivn carcinogens suggest that this 
interaction can be a critical event in carcinogenesis. This does not 
rule out carcinogenicity in the absence of covalent binding, it merely 
states that chemicals capable of forming covalent bonds with nucleophi- 
lic sites in DNA, are likely to be carcinogenic and mutagenic (Hemminki, 
1983).
32
II Promotion
The major differences between initiators and promoters are that the former 
are thought to act by producing mutations, whereas promoters are not 
mutagenic. All promoters studied thus far appear to alter gene expression, 
through receptor mechanisms similar to those seen with hormones (Pitot 
et al., 1982). It has been suggested that all hormones are effective 
promoting agents although they may promote different neoplasms (Berenblum,
1978). The effect of tumour promoters is totally reversible in normal 
tissue (Boutwell et al, 1982 ; Pitot and Sirica, 1980 ; Pitot et al., 
1982). Reversibility also appears to exist although only to some extent, 
in previously initiated cells, indicating that promoting agents require 
a certain period of time to exert their full effect. In studies on mouse 
skin carcinogenesis (Boutwell, 1964) the administration of the total 
dose of the promoting agent to mice previously initiated with a complete 
carcinogen over a long period of time did not induce skin papillomas, 
whereas the same total dose given over a much shorter period resulted 
in the production of papillomas. Peraino and coworkers (1980) have 
reported that increasing the dosage of dietary phénobarbital given over 
the same period of time to rats initiated with 2-AAF, resulted in a 
larger yield of liver tumours. Also, it was shown by Pitot and associates 
(1982) that although the total dosage was the same altering the frequen­
cy of exposure to the promoting agent resulted in significant changes 
both in the number of foci and in their growth rate. Although tumour 
promoting agents are extremely heterogeneous with regard to chemical 
structures and biological effects, they have the common ability to 
stimulate liver growth (Schulte-Hermann et al., 1983 ; Crampton et al., 
1977 ; Grasso, 1979). Another characteristic shared by all of them is 
the induction of xenobiotic metabolism accompanied by proliferation of 
smooth endoplasmic reticulum (Pitot and Sirica, 1980 ; Schulte-Hermann 
et al., 1983). However, according to Peraino and associates (1977) such 
a function does not appear to be in itself sufficient to explain promotion 
during carcinogenesis.
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Mechanism of promotion
Two likely mechanisms have been postulated to underly the process of 
promotion :
a) promoters could complete the conversion of partially 
transformed cells to fully neoplastic cells capable of developing into 
tumours or,
b) promoters could act on initiated cells, already neoplastic, 
to enable them to proliferate into overt tumours. The first hypothesis 
has been supported by reports of promoter effects on cell differentiation 
(Diamond et al., 1978 ; O'Brien, 1976). Demonstration of such effects, 
however, has been limited so far to skin tumour promoters (Fujiki et al., 
1979). The second postulated mechanism corresponds to the original concept 
of Berenblum (1974) and is more compatible with the process of promotion 
in the liver. Cell replication appears as an essential requirement in
the process of promotion (Borek and Sachs, 1966 ; Sivak, 1979). The hall­
mark of promotion in liver tumorogenesis is liver enlargement due to a 
combination of transient cellular hyperplasia and sustained cellular 
hypertrophy (Grasso, 1978 ; Schulte-Hermann et al., 1983). Cell replica­
tion seems necessary to fix any alteration potentially leading to neo­
plasm, for the chances of fixing unexcised base damage in DNA before 
repair mechanisms can correct the chromosomal aberration are much greater 
during a rapid proliferation phase. Well-known tumour promoters for 
hepatocarcinogenes is such as phénobarbital and butylated hydroxytoluene 
have been shown to enhance chromosomal aberrations and to inhibit 
excision repair synthesis in human lymphocytes damaged by ultraviolet 
light (Nishi eta l ., 1978 ; Daugherty etal., 1978). Pitot and Sirica
(1980) have reported a significant increase in the number of foci of 
cellular alteration when phénobarbital was administered one day after 
initiation with diethylnitrosamine plus hepatectomy. If exposure to the 
promoter was delayed for one week the number of foci was reduced by 
half. This finding suggests that the promoting agent may prevent some 
repair mechanism when given just after the initiating agent. However, it
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should not be concluded that tumour promotion is a simple stimulation 
of cellular mitogenesis or cell division (Sivak, 1979 ; Argyris, 1982). 
Cellular hyperplasia is a complex developmental sequence which in 
addition to enhanced mitogenesis involves changes in the rate of cellular 
differentiation and cytomegaly with increases in cellular RNA and protein 
(Argyris, 1982). It also involves decreases or complete supression of 
specialized functions (Leffert et al, 1982). Although many liver tumour 
promoters induce enzyme activities, reflecting a modulation of gene 
expression, they apparently do not produce the same effects on differen­
tiation and chromosomes that have been reported for phorbol esters 
(Williams, 1981). Consequently, there is no single obvious mechanism 
which would complete the process of neoplastic conversion. Much interest 
has been centered on the effects of promoters on cell membranes (Boyland, 
1980 ; O'Brien, 1976 ; Boutwell, 1974 ; Yotti et al., 1979 ; Murray and 
Fitzgerald, 1979). These investigators have described the ability of 
tumour promoters to inhibit intercellular communications in fibroblast 
cell cultures. This has been confirmed in liver cell cultures exposed 
to promoting agents such as phénobarbital and DDT (Williams, 1980 a ; 
Williams et al., 1981). Communication appears to involve molecular move­
ment over a distance (hormone to target cells) or contact between cells 
(Potter, 1980). Cell to cell exchange of molecules occurs through mem­
brane organelles known as gap junctions (Flagg-Newton et al., 1980 ; 
Pitts, 1980 ; Revel et al., 1980). Regulation of various complex cellular 
functions susch as growth control, differentiation, immune responses 
and gene modulation appears to be affected by the modulation of cell 
surface components by various intracellular structural elements 
(Staehelin and Hull, 1978). By means of precisely coordinated series of 
feedback mechanisms between molecular signals, receptors, effectors, 
gene targets, and products, the delicately balanced communication mecha­
nisms can control proliferation and differentiation. Chalones (Builough, 
1965 ; Onda, 1979 ; De Parmentier et al., 1979) and controlled uptake 
of essential nutrients (Bhargava et al., 1979 ; Holley, 1972) are some 
of the several postulated means by which cell proliferation is regulated.
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Also, there is available evidence suggesting that three kinds of peptide 
families, EGF-like, insulin-like and glucagon, interact synergistically 
and temporally to alter normal proliferation rates (Leffert et al., 1982), 
Suppression of specialized functions during liver regeneration is regu­
lated by growth factors-related mechanisms that stimulate growth. In 
principle, either genetic (Roth et aL, 1979) or environmental factors 
could interfere with this regulatory control of proliferation and diffe­
rentiated functions (Trosko et al., 1982). This process can be measured 
in fibroblast cell culture by means of the metabolic cooperation test 
(described by Trosko and associates, 1980). This test is based on the 
transfer of a lethal metabolite generated by a precursor cell to a 
mutant cell that cannot produce it. When both types of cells are cocul­
tivated, as a result of the transfer metabolite the mutant cells are 
passively killed. On the other hand, when known tumour promoters are 
added to the medium the mutant cells are unaffected and form colonies.
It has been demonstrated in this manner that many tumour promoters have 
the property of blocking metabolic cooperation (Trosko et al., 1980 ; 
Yotty et al., 1979). Moreover, recently Trosko and coworkers (1982) 
have reported that labeled nucleotides could not be transfered from 
cell to cell in presence of a promoter. Verification of the principle 
and demonstration of a similar modification in rat liver cells have 
been reported by Williams (1981) using DDT and phénobarbital. Thus, the 
inhibition of intercellular communication between liver cells observed 
in vitro could possibly be at the basis for in vivo promotion of repres­
sed genetically altered cells. Cell proliferation in normal tissues 
is a precisely controlled process in which the production of new cells 
balances those lost through differentiation or death (Leffert et al., 
1982). The factors intervening in this process are not fully understood, 
but could involve intercellular transfer of substances that regulate 
growth such as chalones and other factors that induce differentiation 
and, thereby, loss of ability to profiterate. Several lines of evidence 
indicate that growth regulation is exerted on neoplastic cells. An 
interval of up to more than twelve months can be left between initiation 
and the commencement of promotion essentially with the same yield of
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tumours as when promotion immediately follows initiation (Williams, 1981). 
It seems certain that during the prolonged interval between initiation 
and promotion neoplastic cells undergo turnover in the liver at the 
same rate as normal cells and are kept under control by regulatory 
factors that act on normal cells (Nettesheim et al., 1981).
This concept have been strengthened by the demonstration that the number 
of altered cells produced by exposure to a carcinogen exceeds considera­
bly the number that will become manifest as neoplasms (Williams, 1981). 
Another example of the control of neoplastic cells is the induction of 
differentiation in cells receiving a transplanted nucleus from neoplastic 
cells (King and Di Bernardino, 1965). If the control of dormant neoplas­
tic cells is mediated by intercellular communication, as seems likely, 
then inhibition of communication can liberate the initiated cell for 
the progressive growth that leads to the formation of neoplasms.
Thus, the inhibition of intercellular communication could be the basis 
for tumour promotion. The process by which PB inhibits intercellular 
communication is not yet understood. It has been shown that PB affects 
the activity of several membrane associated enzymes in mouse liver 
tumours, namely y-GT and ATPase (Williams et al., 1980). More recently, 
it has been found that PB also affects membrane functions in cultured 
liver cells (Shimada et al., 1981). Based on these findings, Williams,
(1981) suggests that the action of phénobarbital is mediated by its 
effect on gene expression, giving rise to alterations in the composition 
of the cell membranes. DDT, on the other hand, which is lipophilic, 
probably accumulates in the lipid layer of the cell membranes altering 
its fluidity and interfering with the function of gap junctions 
(Williams, 1981).
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Ill The multistep model in liver relate evidence
It is now apparent that the three-stage concept of carcinogenesis as 
originally proposed, reviewed and extended by Boutwell (1974) is 
applicable to a variety of tissues during their conversion to malignant 
neoplasm (Pitot et al., 1978 ; Barbason, et al., 1983 ; Soit and Farber,
1976). Therefore we can consider the possibility that the characteristics 
and definitions of each of the stages in the natural history of carcino­
gens is applicable to virtually any cell type.
The first unequivocal demonstration that the induction of liver cancer 
could be separated into stages was reported by Peraino and associates 
in 1973. In this study a diet containing 0.02 % of 2-acetylaminofluorene 
was given to weanling rats for 18 days. One group of animals was kept 
on the control diet while several other groups were placed on diets 
containing 0.05 % of phénobarbital. The administration of the phénobar­
bital diet started at various times up to 30 days after cessation of the 
2-acetylaminofluorene exposure. Only 20 % of the animals exposed only 
to 2-acetylaminofluorene developed hepatic neoplasms within 180 days, 
while 70 % of the rats receiving phénobarbital at any time up to 30 days, 
developed hepatic tumours within the same period of time.
Later, the same group of investigators (1975) further showed that DDT 
had a promoting effect similar to that exhibited by phénobarbital.
However, other compounds including amobarbital and diphenylhydantion, 
which have similar effects on liver stmcture and metabolism to 
phénobarbital did not exhibit any. promoting activity during hepatocar- 
cinogenesis. It was shown that both, phénobarbital and DDT increased 
DNA synthesis and liver weights while the other compounds did not.
More recently, Peraino and coworkers (1977) demonstrated that the final 
number of tumours was more influenced by the duration of the phénobarbi­
tal treatment than by the length of the interval between the end of the 
initiation period and the beginning of the administration of the promoter.
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An interval up to 120 days did not significantly influenced the number 
of liver neoplasms induced. In addition is was shown that liver tumours 
developed after a promotion period of only 20 days. When this period 
was shortened to 5 days no liver tumours were detected. These studies 
on the promoting ability of phénobarbital in experimental hepatocarcino- 
genesis have been extended by many other investigators (Weisburger 
et al., 1975 ; Kitagawa and Sugano, 1978).
The promoting ability of phénobarbital was clearly confirmed by Pitot 
et al.,(1978). Groups of rats received a single oral dose of either 5 
or 10 mg/kg of DENA within 24 hours after partial hepatectomy. Two 
months later, the animals were fed a diet containing 0.05 % of phénobar­
bital for six months. While a large number of enzyme-altered foci deve­
loped, after the administration of either doses and hepatectomy, the 
number of foci was augmented almost 5-fold and hepatocellular carcinomas 
developed when the animals were fed phénobarbital. In previous experiments 
Scherer and Emmelot (1975 ; 1976) showed that single doses of DENA (5 
and 10 mg.kg) did not induced liver tumours after 24 months.
Other procedures demonstrating multiple stages during carcinogenesis
In addition to the systems described above showing the effect of promo­
ters on liver tumour development, other methods have been used which 
show the existence of multiple stages during hepatocarcinogenesis.
The cyclic treatment used by Teebor and Becker (1971) with 2-acetylamino- 
fluorene (described elsewhere), implies a two-stage process which is 
subject to the number of cycles. Later, Scherer and Emmelot (1975) 
showed that at levels up to 30 mg/kg DENA induced foci of altered cells 
but not carcinomas. IVhen the dose of DENA was increased to above 40 mg/kg 
the number of foci did not increase but hepatocellular carcinomas occurred, 
These two experiments have shown the ability of 2-acetylaminofluorene and
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DENA to act as both, initiating and promoting agents. More recently, 
Farber (1976) and associates have reported a post-initiation system 
involving a selection step and partial hepatectomy. In this model adult 
rats are exposed to a dose (if necessary to several doses) of an initia­
ting agent. After recovering from immediate toxic effect, the animals 
are fed a relative low dose of 2-acetylaminofluorene for one week. This 
stage is based on the hypothesis that neoplastic cells are relatively 
resistant to necrogenic and toxic effects of carcinogenic polycyclic 
aromatic hydrocarbons. The rats are then subjected to a stimulus for 
cell proliferation such as partial hepatectomy. By this procedure only 
initiated liver cells are capable of rapid proliferation forming foci 
and nodules within 10 days. Ultimately hepatocellular carcinomas develop 
within 8 months.
IV Promoting agents for hepatocarcinogenesis
In addition to phénobarbital a number of other compounds have been 
reported to possess the ability to promote liver tumours in rodents.
Three of these compounds, polychlorinated biphenyls, DDT and estradiol 
have been shown to have significant carcinogenic effects in the liver 
when given alone (Pitot and Sirica, 1980 ; Williams, 1981 ; Schulte- 
Hermann et_cd. , 1981 ; Schulte-Hermann et al., 1983). Others such as 
butylated hydroxytoluene (Peraino et al., 1977), 3 - (3.5 - dichlorophe- 
nyl) - 5.5 - dimethyloxazoline - 2.4 dione (Ito et ab, 1978) and estradiol- 
17-phenylpropionate and estradiol benzoate (Taper, 1978) only induced 
hepatocellular tumours in animals previously initiated with hepatocarci- 
nogens. Several well-known promoting agents have also been shown to 
induce a significant number of liver tumours after long periods of adminis­
tration (greater than 22 months). The question arising is : are agents 
such as DDT phénobarbital and polychlorinated biphenyls weak hepatocarci- 
nogens or simply highly efficient promoting agents ? In the later case.
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the tumours occurring after prolonged exposure to those chemicals could 
be explained as having been initiated by environmental factors such as 
diet, airborne particulates. Nitrosamine contamination has been demons­
trated in most commonly used laboratory animal diets (Edwards et al..
1979) and mycotoxins have often been detected. This clearly indicates 
the presence of initiating agents in the environment of laboratory 
animals. The possibility mentioned previously that oestrogens are promo­
ting agents (Schulte-Hermann et al., 1983 ; Pitot and Sirica, 1980) 
could indicate that promoting agents in the liver alter the expression 
of the genome by interaction with specific receptors (Pitot and Sirica, 
1980 ; Poland et al., 1976).
Characteristics of incomplete carcinogens in hepatocarcinogenesis.
Studies demonstrating the incomplete carcinogenic or pure initiating 
activity of urethane in mouse skin carcinogenesis (Salaman and Roe,
1953 ; Berenblum and Haran-Ghera, 1957) serve as a model for the 
identification of incomplete carcinogens in hepatocarcinogenesis. Accor­
ding to Pitot and associates (1982) these agents should conform the 
following criteria :
a) Produce significant numbers of neoplasms in liver only when followed 
by administration of promoter.
b) Be mutagenic "per se" or undergo metabolism to a mutagenic form in 
the liver.
c) A single dose following partial hepatectomy in the absence of a 
promoting agent induces a relatively small number of demonstrable foci 
of enzyme alteration in the liver.
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Studies directed towards the identification of actual and potential 
incomplete carcinogens in liver cancer development demonstrated that the 
azo dye, 2-methyl-N, N-dimethyl-4-aminoazobenzene (2-Me-DAB) fed for 
periods of 3 or 6 weeks to weanling rats, followed by phénobarbital in 
the diet for 66 further weeks induced tumours in virtually all animals, 
most of which were carcinomas (Kitagawa et al., 1979). In contrast, 
controls receiving only the azo dye for comparable periods of time showed 
very few tumours and only one carcinoma. Previously, Miller and Baumann 
(1945) had demonstrated that this chemical was not carcinogenic even 
when fed to adult rats for prolonged periods of time. However, if partial 
hepatectomy was performed during the dye-feeding period, it resulted in the 
production of liver tumours in most animals (Warwick, 1967). Thus both 
partial hepatectomy or phénobarbital are capable of promoting the develop­
ment of hepatocellular tumours after a short exposure to the azo dye. 
Furthermore, the administration of this compound alone, resulted in the 
production of a significant number of foci of enzyme alteration (Pitot 
et al., 1982). Later studies with dimethylbenz(a)anthracene (DMBA) have 
shown similar results. This chemical which is a complete carcinogen for 
the epidermis is carcinogenic in the liver only when given to neonatal 
mice followed by promotion with phénobarbital (Pitot et al., 1982).
More recently, Kitagawa and coworkers (1980) have shown the induction 
of hepatocellular carcinomas in animals given benzo(a)pyrene following 
partial hepatectomy and long term exposure to phénobarbital. The adminis­
tration of the hydrocarbon alone followed by partial hepatectomy resulted 
in a significant number of foci of enzyme alteration. Both DMBA and 
benzo(a)pyrene are mutagenic in the Ames system (Pitot et al., 1982) and 
therefore conform to the proposed criteria for incomplete hepatic carci­
nogens. Dimethylhydrazine has been also demonstrated to be an incomplete 
hepatocarcinogen by Tsuda and associates (1980). Other compounds with 
similar properties almost certainly exist but at the present time, the 
clear demonstration of other incomplete carcinogens for the liver awaits 
further investigation.
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D - TESTING PROCEDURES FOR DETECTION OF CARCINOGENS
I Short term studies
The last decade has seen the introduction of a series of short term in 
vitro and in vivo tests that have been used with varying degree of 
success to detect chemicals that are potentially genotoxic and carcino­
genic to man. These tests fall into the general category of tests based 
on the unifying concept that carcinogens characteristically react with, 
modify, induce the repair of, interrupt the replication of, or otherwise 
alter the structure function or subsequent fate of DNA (Miller and Miller, 
1971). Current practice is to use a battery of assays representing dif­
ferent genetic end points. Although the results of such series of tests 
are not totally accepted as firm evidence of the presence or absence of 
human cancer hazard, they have a number of valuable applications such as 
the screening of new chemicals at an early stage of development, elimi­
nating those which induce genetic alterations and are thus suspected 
of potential carcinogenicity. In a second age, those compounds which 
have not been demonstrated to be mutagenic are further tested in live 
animals for most of their lifespan in order to determine their eventual 
carcinogenesis by other mechanisms than genotoxicity. Although they 
undoubtedly have their limitations long term animal tests are still 
today the only ones capable of providing conclusive evidence of the 
carcinogenicity of a chemical (Tomatis, 1980).
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Mutagenicity tests
At present the scheme recommended for mutagenicity testing by the 
Committee on Proprietory Medicinal Products (CPMP) is the following
1. Detection of gene mutations in bacteria.
2. Chromosome damage to mammalian somatic cells in vitro.
3. Induction in vitro of gene mutation in mammalian cells.
4. Chromosome metaphase analysis in vivo or assessment of micronuclei.
The CPMP does not suggest that other tests are less suitable or that 
evidence from other tests would not be acceptable as an alternative 
to part of the package (Draper and Griffin, 1980). No single test can 
at the present time be accepted as sufficient to investigate all pos­
sible mechanisms by which genetic damage can be produced. A four tests 
system greatly improves the probability of demonstrating any mutagenic 
hazard.
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1. Detection of gene mutations in bacteria
In practice, mutations are assayed by methods which detect forward or 
reverse mutations. Forward mutations (from drug sensitivity to drug 
resistance) have theoretically, the advantage of presenting a large 
genetic target and should indicate many types of mutagenic effects, 
including deletions, all of which will be expressed in the same phenotype.
Reverse mutation assays use bacteria that are already mutated at an 
detectable locus (e.g., amino acid auxotrophy). Tests are based on the 
frequency with which the chemical tested induces a second mutation which 
supresses the previous mutation allowing the bacteria to recover all the 
characteristics of the parent microorganism. Thus, the genetic target is 
highly specific and selective.
* Salmonella/microsome test
This test involves use of several specially constructed strains of 
Salmonella typhimurium for detection of reverse mutation. In most 
studies rodent liver tissue (S9 preparations) are used to metabolize, 
chemicals to their active mutagenic form (Ames et al., 1973). Routinely, 
chemicals are tested in at least four different Salmonella strains with 
and without S9 preparations. None of these strains can grow unless his­
tidine is added to the medium (auxotrophic bacteria). The number of 
bacteria reverted back to an ability to grow without added histidine 
(phototrophic bacteria) is estimated by counting the revertant colonies 
on the plate after 48 hours of incubation. A chemical is positive in the 
test if it causes a reproducible dose response in at least one tester 
strain (Ames et al., 1975). The Salmonella/microsome test is currently 
the most widely used short-term test (Me Mahon et al.,1979 ; Donahue 
et al., 1978). This test detects almost all the known organic chemicals 
that are human carcinogens with the exception of benzene and diethylstil- 
boestrol.
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* Test with strains of Escherichia Coli
A wide variety of mutational systems in strains of E. Coli can be used. 
These include specific back-mutation systems from auxotrophy to proto­
trophy using E. Coli strains alone or a set of E. Coli in combination 
with several sets of Salmonella strains (Ashby and de Serres, 1980).
A number of forward mutation tests systems have also been investigated 
broadening the spectrum of genes under study, since they can be assayed 
simultaneously. Some examples are wild type genes in which mutations 
lead to resistance to antimetabolites (Yura and Wada, 1968 ; Hane and 
Wood, 1969 ; Glover, 1962) ; and mutated genes in which further mutations 
are detected because they lead to resistance to sugars such as galactose 
(Adhya and Shapiro, 1969) and fucose (Englesberg et al., 1962).
* Prophage induction
Most if not all bacteria are lysogenic : they contain the DNA of a 
virus, a phage, in their genome in a dormant state (prophage). One of 
the virus most extensively studied is phage lambda, whose host is 
E. Coli K 12 (Hershey, 1971). The dormant state of prophage lambda is 
maintained by a repressor protein which is produced by one of the pro­
phage genes. DNA damage, produced by various chemicals, causes the inac­
tivation of the repressor synthesized by the dormant prophage leading 
to its activation and development. Within a short period of time the 
host cell lyses and releases a large number of phages. When induced 
cells are mixed with indicator bacteria, the viruses released from the 
induced lysogenic cells lyse the indicator bacteria. Other bacterial 
assays using other tester strains based on the same principle are availa­
ble (Moreau and Devoret, 1977).
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2. Transformation in cell culture
The use of mammalian cell culture (in vitro) transformation systems is 
an important aspect of short-term testing for potential carcinogens, 
since such systems may be similar to the process of neoplastic transfor­
mation in vivo. The endpoint scored most frequently is morphological 
transformation ; with fibroblast cultures this is characterized by loss 
of growth inhibition and cell to cell orientation at confluency. 
Subsequent passages of such transformed cells result in the acquisition 
of other characteristics associated with the malignant state, these 
include the ability to grow in semi solid media and, most important, 
the capacity to produce tumours in syngenic or immuno supressed animals 
(Benedict et al., 1980). Several nonepithelial cell cultures have been 
used to study chemical transformation. The systems in which the largest 
diversity of chemicals have been tested are :
. Primary and secondary embryo cultures (Berwald and Sachs, 1963 ; 
Huberman and Sachs, 1966 ; Poiley et al., 1979 ; Evans and Di Paolo, 
1975).
. Fibroblast-like cell lines, BALB/3T3 (Benedict et al., 1980) 
and C3H/10T1/2 (Reznikoff et aL, 1973).
. Baby hamster Kidney (BHK21) (Bouck and Di Mayorca, 1976 ; Di Mayorca 
et al., 1973 ; Purchase et al., 1978).
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3. Induction of gene mutation in mammalian cells grown in culture
Several experimental systems have been developed to measure specific 
locus mutation in mammalian cells in culture (Abbondandolo, 1977 ; 
Arlett,1977 ; Siminovitch,1976 ; Thompson and Baker, 1973). For the 
isolation of mutants, choice of cell lines and genetic markers are 
extremely important. Chinese hamster cells and L5178Y mouse lymphoma 
cells appear to be the most suitable because of the relative ease with 
which mutants are isolated (Newbold et al., 1975). The more widely 
used markers indicating forward mutations induced by chemicals are resis­
tance to 8-azaguanine or to 6-thioguanine, which arises from loss of 
hypoxanthineguanine phosphoribosyl transferase (HGPRT) activity.
Resistance to 5-bromo-2 '-deoxyuridine, associated with a loss of thymi­
dine kinase activity (Clive et al., 1979 ; Davidson and Bick, 1973) 
and resistance to ouabain, which is assumed to be due to alteration of 
the membrane receptor site (Baker et al., 1974) are alternative methods 
of assessment. Mammalian cell mutagenesis systems are often supplemented 
with metabolic activation systems such as microsomes (Abbondandolo et al., 
1977 ; Clive et al., 1979 ; Umeda and Saito, 1975), cell and host 
mediated assays (Capizzi et al., 1974 ; Inui and Nishi, 1978 ; Inui 
and Tatekomi, 1977). Cell mediated assays appear to indicate better 
which metabolic pathway occurs in vivo, and they may reflect the organ 
specificity of chemicals (Longenbach et al., 1978 ; Huberman and 
Sachs, 1974 ; San and Williams, 1977).
Determination of the ability of chemical's to produce damage to the 
chromosomes of mammalian cells grown in vitro
The cytological principles involved in detecting chromosome damage 
microscopically depend upon the recognition and quantitative assessment 
of morphological alterations in chromosome or chromatin structure. The 
recognition and the development of such chromosome damage is limited to 
cells that undergo a proliferation cycle after exposure to the damaging 
agent (Evans et al., 1980) frequently in presence of a liver S9 fraction.
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Four types of damages can be assayed :
- Chromosomal aberrations in metaphase cells ; these are basically of 
two sorts : chromosome type aberrations and chromatid type aberrations.
- Sister chromatid exchange, which involves equal symmetrical exchange 
at one locus between sister chromatids.
- Bridges and fragments in anaphase cells.
- Micronuclei in interphase cells ; acentric fragments that are excluded 
from anaphase groups and the resulting daughter nuclei may form separate 
micronuclei readily observed in the cytoplasm. Micronuclei can be seen 
throughout the whole cell cycle. Chromosome aberrations, or damage 
resulting in sister chromatid exchange or micronucleus formation, can be 
detected, in a whole range of eukaryotes including insects and higher 
plant species. In general, however, diploid or near diploid human or 
rodent cells are used. The two principal systems used are : short term 
peripheral blood lymphocyte cultures and cultured fibroblasts.
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4. In vivo mammalian tests.
According to Draper and Griffin (1980), no battery of tests can be consi­
dered complete without one in vivo test in a mammal to assay the metabo­
lic fate of a chemical in the intact animal. Although different tests 
are available at present, the preferred are metaphase analysis of bone 
marrow in rodents or the dominant lethal test in rodents.
Studies in mouse bone marrow involve the detection of the same type of 
chromosome damage induced in cultured mammalian cells after exposure in 
vivo to the testing agent. However, the sensitivity varies according to 
the system, employed, micronuclei tests appear less sensitive than 
sister chromatid exchange in vivo (Bauknecht et al.,1977 ; Trzos et al., 
1978). Similarly, chromosome metaphase analysis appears to lack the sen­
sitivity required to detect the chromosome damaging potential of many 
compounds (Frank et al., 1978). A dominant lethal mutation in a mammal 
is a genetic change in a gamete, which kills the zygote produced by this 
gamete. The cause of dominant lethality is chromosome breakage ; cytolo- 
gical confirmation has been obtained in mice and hamsters (Binkert and 
Schmid, 1977 ; Biirki and Sheridan, 1978 ; Hitotsumachi and Kikuchi,
1977).
II Long term carcinogenicity studies
There have been many protocols or guidelines published in the past years 
on carcinogenicity studies (Berenblum, 1969 ; Boyland, 1968 ; Committee 
on carcinogenicity of chemicals in Food, Consumers Products and the 
Environment, 1978 ; Health and Welfare Canada, 1973 ; Munro, 1977 ;
WHO, 1969). In 1976, the food and Drug Administration has proposed 
the "Good Laboratory Practices (GLP's) for Nonclinical Laboratory Studies" 
One of the important issues is the standardization of carcinogenicity 
test procedures. The purpose of this is the rational garnering of the
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data required to assess the eventual carcinogenesis of a chemical. Also 
to facilitate the comparison of studies performed in different laborato­
ries of different countries. The main stages of long-term assays for car­
cinogenicity include design, conduct, analysis and reporting. These are 
proposed not in terms of rigid rules, but rather as guidelines that meet 
the basic requirements for carcinogenicity testing.
The appropriate tests and procedures vary with the use of the chemical 
and the resulting exposure pattern to man. The requirements are not the 
same for a food additive to which all groups of age are exposed for many 
years as for a pharmaceutical compound which is administered to a select 
group of people for a determined period of time in controlled quantities.
Animal species and strain
The ideal test animal is one similar to humans in pharmacokinetics, 
metabolism, and biological response to the chemical -under test. In 
practice, no such animal species is known, therefore it is generally 
recommended to test a material in at least two different species. The 
species more frequently used in carcinogenicity studies are rats, mice 
and Syriam hamsters. Rats and mice have been used more extensively than 
hamsters. The wide use of these three rodent species is mainly based on 
practical considerations such as relative short life span, small size 
and availability of large numbers of animals to allow adequate statisti­
cal assessment. Another major consideration is the existence of conside­
rable biological knowledge on these species, including their physiology, 
anatomy, genetics, husbandry, nutrition, spontaneous diseases, sponta­
neous tumour incidences, and susceptibility to tumour induction. In 
addition to species, strain selection is also controversial. Inbred 
strains offer greater uniformity of response, predictable spontaneous 
tumour incidence and better reproductibility. However, their homogeneity
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may also result in missing some effects that exist in outbred animals. 
There are great differences within species and strains not only in the 
incidence of spontaneous tumours but also in the response to carcinogenic 
chemicals (Page, 1977 ; Boyland and Sydnor, 1962).
Age of inception of test and duration of exposure
Usually, exposure to the test substance starts no later than a few weeks 
after weaning and is continued for the major portion of the lifespan 
of the animals (Food and Drug Administration, 1971 and the World Health 
Organization, 1978). Commonly the test agent is administered for 24 
months to rats and for 18 months to mice (Peck, 1974 ; World Health 
Organization, 1978).
Test substance
It is essential that the chemical under assay is properly characterized. 
The purity, composition and formulation of the test material and of any 
solvent or vehicle is determined prior to and during the test period. 
Also it must be assured that the chemical and test preparation is stable 
and accurate analyses for concentration and homogeneity are conducted.
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Route of administration
There is general agreement that the test compound should be administered 
by a route similar or as close as possible to the one by which human 
exposure occurs. The three main routes are :
1. Oral intake, mixed in the diet, in the drinking water, or by gastric 
intubation. These methods have been discussed (Committee on Carcinogene­
sis of chemicals in Food, Consumer Products and the Environment, 1978).
2. Skin absorption, to stimulate a main route of human exposure (e.g., 
cosmetics), or as a model for skin carcinogenicity (Weisburger and Weis- 
burger, 1967).
3. Inhalation. In humans the respiratory tract is an important route 
of entry of many substances. Intratracheal instillation is used as 
an alternative to inhalation exposure.
Other routes such as subcutaneous, intraperitoneal or intramuscular 
repeated injections are often regarded as inappropriate mainly because 
these routes are generally different from the one by which humans are 
exposed.
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Doses and dose levels
Dose and dose levels are established after due consideration of the test 
and the potential utilization of the test results. It is general practice 
to use a minimum of three dose levels for carcinogenicity tests. However, 
a test to assay potential carcinogenicity may involve only a single well 
selected dose, whereas tests for risk estimation or determination of a 
"no effect level" require several dose levels.
Dose selection
According to the "Food Safety Council" (1978) the highest dose in chronic 
and carcinogenicity testing is one which is expected to produce some toxi­
city when administered for the duration of the test period. It should 
not, however, induce overt toxicity, that is, toxic manifestations which 
can reduce the lifespan of the animals (except as a consequence of neo­
plasia) ; or 10 % or greater retardation in body weight gains.
Number of animals per group
In order to allow a meaningful biological and statistical evaluation a 
minimum of fifty males and fifty females in each test group and concur­
rent control group is generally accepted. However, some variations such 
as two groups of untreated male and female controls are often used. 
Accumulated background information (historical data) about the colony 
of animals used is of great importance. This provides valuable informa­
tion about cancer incidence, latency, seasonal variations and group 
variations of untreated control animals.
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Caging and animal housing
The animals can be caged individually or in groups, the advantages of 
either placement have been discussed (Hatch et al., 1965 ; Sigg et al., 
1966). The animals under test must be kept in well ventilated rooms 
with controlled lighting, temperature and humidity (Page, 1977).
Diet
Trace elements, vitamins and other nutritional factors play an important 
role in experimental carcinogenesis (Alcantara and Speckmann, 1976 ; 
Cameron et al., 1979 ; Newberne, 1978 ; Weisburger et al., 1977). 
Therefore, the basal diet used in carcinogenicity studies should be of 
constant quality and should contain the adequate amounts of essential 
macro and micronutrients. In addition, the concentrations of common 
dietary constituents which are known to be able to influence carcinoge- 
sesis such as antioxidants, unsaturated fatty acids, selenium, must be 
determined. Also assay for common contaminants such as pesticide residues, 
oestrogens, heavy metals and nitrosamines should be carry out regularly.
Assessment of potential carcinogenicity
The carcinogenicity of a compound is evaluated comparing the tumours 
arising in each potential target site in dosed and control groups. In 
general, it is accepted practice to group together tumours of the same 
histological type that arise in the same type of tissue for statistical 
purposes. However, not infrequently these lesions are evaluated in both 
ways i.e. divided and combined. Other important factors are also taken 
into consideration such as latency, number of tumours per animal and
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incidence of rare tumours even in low numbers. Preneoplastic lesions 
sometimes occur in an organ. These are lesions from which neoplasms deve­
lop, these lesions seem benign for a period of time but may ultimately 
progress into frank malignancy. Consequently, although if in most experi­
ments benign and malignant tumours are reported separately a marked inci­
dence in benign tumours is viewed by many authorities with as much suspi­
cion as a potential human hazard as if they were malignant. Having recorded 
for each animal the tumours present at death, appropriate statistical 
analyses are undertaken in order to determine the carcinogenicity of the 
compound tested.
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E - REASONS FOR THE PRESENT STUDY
It is recognized that compounds reacting positively in genotoxic "screens" 
are unlikely to enter life-span studies in pharmaceutical companies. 
However, there may be cases where the interpretation of mutagenicity 
tests is unclear, or the benefit-risk argument justifies progression 
despite evidence of a weak mutagenic effect. Furthermore, some compounds 
with no demonstrable genotoxicity induce tumours. These non-genotoxic 
compounds often produce tumours of late onset in the standard bioassay 
tests. These bioassays are expensive and time consuming, thus predictive 
short-term whole animal tests are needed to complement other short-term 
tests for cancer. These tests could never totally replace the two-years 
bioassays, but would hopefully identify the more dangerous toxic molecules 
at an earlier stage in their pharmaceutical development.
Possible approaches
The main advantage of using the whole animal is to avoid the uncertainties
of inappropriate pharmacokinetics and metabolic activation which may occur
during in vitro tests. Possible approaches, in which neoplasms are the
end-point, include trying to increase the sensitivity of the animal
model e.g., by starting dosing in uterus or in neonates, or by co-adminis-
tering immuno-suppressive agents. However, each of these methods is
subject to various criticisms as to its validity. Thus the search for
methods for early detection of pre-carcinogenic changes in the "normal"
animal appears as a more rational approach. One attractive idea is to try
to identify substances which are present in the circulation once a precar-
cinogenic event has taken place. This permits repetitive sampling over
the duration of a study and might require a reduced number of animals.
However, a brief examination of the status of tumour "markers" in human
medicine is not encouraging at first sight. Thus although substances
such as carcinoembryonic antigen, alpha-foetoprotein, chorionic gonadotro­
phin and sialic acid, have proved valuable in monitoring the success of
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cancer chemotherapy, they have not gained wide acceptance as early indi­
cators of neoplasia because they may also be disturbed in patients 
suffering from other non neoplastic conditions. Furthermore, markers have 
not yet been identified for some of the most important tumour types in 
man. Although there is not a vast amount of literature concerning circula­
ting markers for carcinogenesis in laboratory animals, the same criticism 
appears to apply to these species as well. For these reasons, it was 
decided to investigate the value of cytochemical examination of likely 
target organs for early precarcinogenic changes.
Choice of the target organ
The commonest target organs for chemical carcinogens in rodents are : 
liver, skin, lung, endocrine organs, bladder, mammary gland and kidney. 
Much of the experimental work in carcinogenesis has been performed with 
rat hepatocarcinoma as the model. The histologic development of tumours, 
the influence of carcinogen dosage and environmental factors on tumour 
induction, the many aspects of enzyme changes and the immunological 
factors produced by both tumours and hosts have all been studied more 
extensively in rat hepatocarcinogenesis than in any other tumour 
(Butler and Newberne, 1978). For these reasons the liver appeared as 
a suitable choice as the target organ to be studied initially.
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- Liver as a target organ for chemical carcinogenesis
Primary human liver cancer is a relatively rare disease in most parts 
of the world. Liver tumours occur in patients living in areas of high 
mycotoxin exposure (Hutt, 1971 ; Alpert and Davidson, 1969 ; Zimmerman,
1978), in workers exposed to agents such as vinyl chloride and occasionally 
in young women using oral contraceptives (Sherlock, 1975) and also in 
people receiving androgenic steroids (Farrell et al., 1975). Nevertheless, 
in most regions a large proportion (80 %) of liver cancers are associated 
with the presence of cirrhosis due to liver injury (Higginson, 1963 ; 
Shikata, 1976 ; Davies, 1973). This feature of human liver cancer, 
therefore is different from that in most laboratory animals in which 
cirrhosis is not a significant part of the process caused by hepatocarci- 
nogens. The mechanism through which cirrhosis predisposes to the develop­
ment of liver cancer is not well understood, but may have a counterpart 
in experimental carcinogenesis. Fibrosis and proliferation of hepatocytes 
to replace those lost by liver injury are the characteristic features of 
cirrhosis. Hepatocellular proliferation is thought to place the replica­
ting cells at greater risk of malignant conversion (Farber, 1976). It is 
well established that viral hepatitis plays an important role in the 
relationship of cirrhosis to liver cancer (Bergeret and Roulet, 1947 ;
Coady, 1976). The precise mechanism of action of the virus in the genesis 
of human liver cancer remains unresolved, but hepatitis B infection is a 
factor in many situations (Ohta, 1976). However, cirrhosis associated with 
alcohol intake is the liver condition preceding probably the largest 
number of liver cancers (Zimmerman, 1978). Very few carcinomas developing 
in the presence of alcoholic liver disease appear to be associated with 
viral antigens (Shikata, 1976 ; Otha, 1976).
Of all the genotoxic hepatocarcinogens known to man only aflatoxin and 
vinyl chloride have been associated with human liver cancer (Tomatis, 1976). 
However, other carcinogens implicated in liver cancer in rodents are 
associated with neoplasms in other human organs and tissues. Benzidine 
produces liver cancer in rats but is associated with bladder cancer
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in man. 2-naphthylamine induces both lung and liver cancer in rats but 
also only bladder cancer in man (Tomatis, 1976). Species differences 
in the organ selectivity of carcinogens are in many cases related to 
differences in metabolism or in the susceptibility of the organ as a 
function of its state. It therefore should not be expected that all 
carcinogens affecting the liver of experimental animals will necessarily 
affect the human liver. Thus, even though the incidence of human liver 
cancer is relatively low and the oncogenic mechanism implicated is not 
yet well defined, the major advantage of experimental hepatocarcinoge­
nesis as a model system is the large amount of background information 
available on the morphogenesis of hepatocellular carcinoma. Furthermore 
there is an even larger body of data available on the biochemistry and 
physiology of the liver of experimental animals. Thus, in studies aimed 
at dissecting and characterizing the distinct stages of hepatocarcino­
genesis , the investigator has as a base a wealth of information which 
can be applied to the understanding of each process as it is uncovered.
Importance of liver in experimental carcinogenesis
The liver is the major organ responsible for the metabolism of drugs 
and other anutrients within the mammalian body. Because of this and 
also due to the fact that the liver is the first major internal organ 
to receive a drug after administration, it often shows a diversity of 
adverse reactions to a drug, beside those which result in neoplasia.
The mammalian liver is a complex and heterogenous organ, both morpho­
logically and functionally. It is this functional heterogeneity that 
makes mammalian liver an ideal organ with which to study various bioche­
mical mechanisms of toxicity. These metabolic processes, including 
those concerned with the transformation of xenobiotics, can be studied 
at different levels of tissue organization : whole animal, isolated 
liver, isolated liver cells and isolated subcellular fractions.
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structure and circulation of the liver
The liver is divided into more or less well defined lobules, each 
lobule consisting of a central hepatic venule from which radiate plates 
of hepatocytes one cell thick. Around the periphery of the lobule are 
the portal tracts each of which contains several structures, a network 
of nerves, the terminal branches of the hepatic arterioles, the portal 
venules, the bile ductules and lymphatic vessels. The spaces between 
the plates of liver cells are known as sinusoids and are lined by 
endothelial cells, the kupffer cells and fat storing cells (Ito cells) 
(Schauer and Kunze, 1976 ; Elias, 1963).
Blood is brought to the liver by the portal vein and by the hepatic 
artery. The portal vein is formed by the union of the superior 
mesenteric vein with the splenic vein bringing blood from the small 
and large intestine, the spleen, pancreas and stomach. The hepatic . 
artery supplies the structures in the portal tracts including the bile 
ducts and anastomoses in a complicated fashion both with the sinusoids 
and with branches of the portal vein. Blood from the hepatic arterioles 
and portal venules perfuses the sinusoids and the hepatic venules and 
returns by the hepatic vein to the inferior vena cava (Gershbein and 
Elias, 1954).
The bile canaliculi form a lattice of communicating channels between 
the hepatocytes. Bile formed in the hepatocytes is discharged into 
the canaliculi which drain into the bile ductules in the portal tracts. 
The bile ductules open into the large bile ducts. There is no gall­
bladder in the rat (Schauer and Kunze, 1976).
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Functions of the liver
In addition to its well recognized role in intermediary metabolism, the 
liver has important excretory functions. Many hydrophobic substances are 
rendered watersoluble by hydroxylation by the microsomal cytochromes P-450 
system (Omura et al., 1965), by conjugation to form glucuronides, sulpha­
tes and glutathione conjugates (Boyland and Chasseaud, 1969) or by hydro­
xylation followed by conjugation. The water soluble derivatives are 
excreted in the urine or bile. Similar pathways are important in the 
excretion of endogenous substrates such as hormones. Many drugs and 
foreign substances (xenobiotics) are similarly excreted by the liver.
The liver also plays an essential role in the excretion of bilirubin 
from the breakdown of hemoglobin.
The continous administration of drugs metabolized by the hepatocytes 
often leads to an increased formation of the enzymes responsible for 
their metabolism. This process known as enzyme induction, is seldom 
specific and the administration of one drug may cause increased catabo-^ 
lism of another.
The principal form in which energy is stored in the liver is as glycogen. 
While much of the lipid found in normal liver is the structural lipid 
of the cells, some triglycerides are normally present as an energy store. 
Vitamin B12 and fat soluble vitamins A, E and K, together with iron 
and copper are also found in the liver.
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II - Why rats as an experimental model for neoplasia ?
Some of the most important advances in experimental oncology have resulted 
from animal experimentation ; and the laboratory rat has been the princi­
pal model. It has played an important role in the identification of many 
carcinogens and continues to be one of the most common laboratory animals 
used in experimental carcinogenesis today.
Although a perfect laboratory animal for cancer research does not exist, 
the rat appears to fit many of the criteria required for this purpose.
They are hardy, readily available and easy to breed. They have few 
serious diseases and the incidences of the spontaneous tumours are well 
documented in several strains. Also, rats are of convenient size, as well 
as economical to house and to maintain in large numbers. In addition, 
they are usually docile, genetically well defined and have a relatively 
short life span. Their sensitivity to many carcinogenic agents including 
known human carcinogens is well established (Tomatis, 1976). Finally a 
large volume of published information on their physiologic, pharmacologic 
and pathologic responses is available.
For all these reasons the rat appears to be the most suitable species 
for most aspects of oncologic research, including aetiology. Furthermore, 
rat and man often detoxify exogenous compounds in a similar manner, the 
differences which do exist being more quantitative than qualitative. In 
addition rats have a wide array of neoplasms, both spontaneous and induced, 
that are nearly all comparable with those of man in morphology and biolo­
gical behavior. Some tumours can also be demonstrated to undergo progres­
sion from hyperplasia to benign lesions and malignancy similar to the 
progression which occurs in man.
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F - PATHOLOGY OF RAT HEPATIC NEOPLASIA CAUSED BY CHEMICAL CARCINOGENS
The liver has received considerable attention as a target for chemical 
carcinogens since the discovery by Sasaki and Yoshida (1935) that liver 
cancer could be induced in the rat by administration of o-aminoazotoluene.
In their pioneering study,they detailed the morphology of the stepwise 
changes in the liver parenchyma of rats leading to the development of 
hepatic tumours. They described the sequential appearance of foci of 
hyperplasia, nodular adenomas and finally hepatomas. Although the nomencla­
ture for liver changes in the development of hepatocellular carcinomas 
has varied, the essential features of this process were confirmed in 
numerous subsequent studies in which a variety of chemical of diverse 
structure have been implicated in the genesis of experimental hepatic 
cancer (Orr, 1940 ; Opie, 1944 ; Firminger, 1955 ; Stewart and Snell, 1959 ; 
Farber and Ichinose, 1959 ; Popper et al., 1960 ; Bannasch, 1976).
64
I - Morphology 
Macroscopy
The number of tumours arising in the liver of rats depends to a high 
degree on the carcinogen. Highly potent carcinogenic agents given 
continuously induce multiple tumours in different parts of liver, 
whilst using weak carcinogens or after brief application of potent agents 
only isolated nodular masses are found. The main localization of the 
tumours in the liver lobules has been the subject of many contradictory 
reports. The size of the tumours varies greatly even in the same liver, 
ranging from a few millimeters up to several centimeters in diameter. 
Conglomerates of tumours can develop through the confluence of several 
nodular masses. Macroscopic differentiation between different types 
of tumours and large nodules is extremely difficult and in most cases 
impossible. The nodular masses bulge on the surface of the liver, some­
times pedunculated tumours connected to the liver by a thin stalk occur.
On cutting the smaller nodular masses look relatively uniform and 
homogeneous in structure. On progressive growth, necrosis, haemorrhage 
and cystic areas appear, rupture of the capsule occurs frequently in 
advance stages of hepatocellular carcinomas and vascular tumours.
Microscopy
Despite the wide experience of many investigators with rat hepatocarci^ 
noma, no general agreement exists on the histological criteria for 
evaluating the biological significance of the lesions that precede neoplasm, 
nor is there agreement as to the relationship between premalignant and 
malignant lesions. There has been extensive discussion of this question 
between different groups of pathologists at various workshops and meetings. 
Participants at the National Cancer Institute decided to designate the 
lesions anteceding the appearance of nodules as foci and areas of cellular 
alterations. This nomenclature has been accepted by other authors (Farber, 
1980 ; Pitot and Sirica, 1980 ; Williams, 1980 ; Newberne, 1976).
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Foci and areas of cellular alterations
Foci and areas of cellular alterations are small lesions of hepatocytes
that do not disrupt the parenchymal architecture. They are equivalent 
to the lesions described as foci of hyperplasia, hyperplastic areas, 
basophilic hyperplasia, enzyme deficient islands and glycogen-storage 
foci and areas. Current evidence indicates that areas are simply large
foci and that the choice of the term foci versus area depends upon the
judgement of the pathologist, therefore the two will be discussed 
together as foci.
Three distinctive types of foci may become manifest in the livers of rats 
exposed to carcinogens. These are : clear cell focus, basophilic focus 
and eosinophilic focus. All these lesions have certain features in common. 
Each are uniform in their cellular composition but may contain a few 
cells from either of the other two types. The cells in foci may be abnor­
mal in size and have a reduced level of binuclearity (Williams, 1980). 
Although there is no compression of the surrounding liver tissues the 
lesion is nonetheless sharply demarcated by the appearance and the 
staining reactions of the cells. The structure pattern within the foci 
is little altered from normal and the plates of the modified hepatocytes 
forming the foci are in continuity with those of the surrounding paren­
chyma (Williams, 1980).
Clear cell foci appear as group of more or less large pale cells when 
compared with the surrounding hepatic tissue, their cytoplasm look empty 
within a zone around the nucleus.
Eosinophilic cell foci stand out against the background of the liver 
parenchyma because of the intensity of the acidophilic staining and the 
ground glass aspect of the cell cytoplasm..The cells are enlarged although 
the ratio of cytoplasm to nucleus is unchanged.
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The distinguishing feature of basophilic focus is the diffuse cytoplasmic 
basophalia. The cells are reduced in size, mitotic figures are often 
observed and the plates of hepatocytes are frequently tortuous due to 
an increased cellularity (Squire and Levitt, 1975).
Foci of cellular alterations may occur as a single lesion or as multiple 
lesions and several different types may be present in the same liver. They 
are often not uniformly distributed throughout the liver lobules and they 
may coexist whith hyperplastic nodules and hepatocellular carcinomas.
Hyperplastic nodule
Hyperplastic nodules also designated as neoplastic nodules, liver nodules, 
adenomas and benign hepatomas are generally spherical lesions that 
usually occupy an area equivalent in size to that of several liver 
lobules. IVhen located near the surface of the liver they are generally 
elevated above the surface level. An important diagnostic feature of 
hyperplastic nodules is their peripheral demarcation and compression of 
the surrounding liver tissues. The normal liver architecture is modified 
within this lesion. The normal pattern of reticulum lining the sinusoid 
is absent, the sinusoidal may be compressed by enlarged hepatocytes and 
show varying degrees of dilatation and ectasia. Portal areas are rare 
inside the H. nodules. The liver cells forming the H. nodules are arranged 
in solid or irregular plates one or more cells thick which are not conti­
nuous with those of the unaffected cells, they often show mixtures of 
cytoplasmic alterations such as basophilia, eosinophilia, fatty change 
and clear cytoplasm. Their nuclei are frequently enlarged and their 
nucleoli are often prominent (Farber and Ichinose, 1959 ; Goldfarb and 
Zak, 1961 ; Williams, 1980).
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Primary hepatic malignant tumours
Primary malignant tumours of the rat liver may be single or multiple and 
are found in all lobes, often in the absence of nodular cirrhosis. Their 
siez varies from a few millimeters to several centimeters in diameter, they 
contain solid cystic, necrotic and hemorrhagic areas. Primary hepatic 
malignant tumoUrs frequently display the full behavior of malignant 
neoplasia e.g. invasiveness and metastasis.
Primary hepatic malignant tumours are divided into four groups :
Parenchymal cell tumour : Trabecular and glandular hepatocarcinomas,
II Tumours of bile duct origin : Cholangiocarcinoma.
Ill Anaplastic tumours.
IV Sarcomas : hemangiosarcomas• Kupffer cell sarcomas. Fibrosarcomas,
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I Parenchymal cell tumours
The histological characteristics of hepatocellular carcinomas have 
been extensively described in a number of publications (Squire and 
Levitt, 1975 ; Williams 1980 ; Schauer and Kunze, 1976 ; Jones and Butler,
1978).
Trabecular hepatocellular carcinomas are well differentiated tumours 
composed of cords of regular hepatocytes many cells thick, with sinusoids 
lined by normal endothelium. Their appearance may vary from being barely 
distinguishable from normal liver to one composed of large irregular 
abnormal cells that form irregular cords or sheets with corresponding 
distortion of the sinusoidal pattern. Neoplastic cells exhibit various 
degrees of cytological alterations. Eosinophilic cells with clear vesicu­
lar nuclei are characteristic of the well differentiated tumours. Some 
tumours are made up of small basophilic cells, other contain a variety 
of forms displaying variations in nuclear size, shape and cytoplasmic 
staining. Within the same tumour both basophilic and eosinophilic cells 
may be present. Reticulum and collagen fibres are usually sparse and 
mitotic figures are abundant. Tumours or areas within tumours showing 
fatty changes are often present with central necrosis and some degree 
of inflammation. Large papillary structures forming cystic spaces 
occur. Areas of infarction, hemorrhage and scarring are also charac­
teristic of the large lesions.
The main feature of glandular carcinomas is acinar formation. Its 
histology consists of half a dozen liver cells with a basement membrane 
arranged around a central lumen. A significant amount of stroma is obser­
ved in some areas.
Glandular structures and typically trabecular areas coexist with a 
predominance of one or the other cellular pattern. Cystic spaces lined 
by flattened epithelium containing amorphous material, necrotic hepato-
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cytes and inflammatory cells are found adjacent to the glandular and 
trabecular areas. There is a large variation among the hepatocytes 
forming the glandular structures. Some are typical eosinophilic liver 
cells with vesicular nuclei and prominent nucleoli. Other acini are 
composed of more basophilic cuboidal cells. Poorly differentiated lesions 
containing hyperchromatic cells, distorted glandular structures, abundant 
collagen and dense reticulum network also occur. In such cases, accurate 
differentiation with true cholangiocarcinomas by light microscopy is 
virtually impossible. The presence of mucus can be demonstrated in both 
glandular and trabecular carcinomas.
It is universally accepted that the glandular carcinomas develop from 
hepatocytes with the possible exception of a few animal tumours.
Some investigators believe that glandular carcinomas are formed by bile 
duct cells because they produce mucus and contain abundant collagen and 
reticulin fibres. Others disagree on whether bile ducts cells in rat 
give rise to cholangiocarcinoma (Stewart et al., 1980). The admixture 
of trabecular and glandular pattern which is frequently observed suggests 
a common origin from hepatocytes (Williams, 1980). Moreover, ultrastruc- 
tural studies tend to confirm that the majority of glandular carcinomas 
are of hepatocellular origin (Butler and Jones, 1978).
II Tumours of bile duct origin
Cholangiocarcinomas of liver are rare, and their morphology is similar 
to certain poorly differentiated hepatocellular carcinomas. The lesion 
consist of abundant stroma and glandular structures composed of basophi­
lic cells infiltrating the stroma and the adjacent hepatic tissue. The 
absence of hepatocytes within the tumour is characteristic. Cholangiocar­
cinomas have been reported in rats treated with aflatoxin (Jones and 
Butler, 1978).
70
III Anaplastic tumours
These tumours are composed of sheets of pleomorphic cells showing high 
mitotic rates, bizarre nuclei and large central areas of necrosis and 
hemorrhage . This pattern may totally dominate some tumours or may be 
confined to some areas of large tumours otherwise showing a recognizable 
structure (Jones and Butler, 1978 ; Squire and Levitt, 1975).
IV Sarcomas
Malignant neoplasm can develop from endothelial cells, kuppfer cells 
and fibrocytes.
Hemangiosarcomas have been reported after treatment with urethane, afla­
toxin (Newberne et__^., 1967) and nitrosomorpholine (Bannasch and Muller, 
1964). These are multiple tumours forming hemorrhagic cysts and solid 
areas with congested vascular channels. The blood filled spaces are 
sometimes lined by several layers of plump cells showing pale nuclei 
and with in some areas confluent sheets of poorly differentiated cells 
that invade the adjacent liver. Necrosis, thrombosis, foci of inflam­
mation, hemorrhage and blood, pigment are concurrent findings.
Mitotic figures are numerous, reticulum fibres are scarce in the cellular 
compact areas, but are not rare in the vascular areas where they occupy 
a basement membrane-like position in relation to the wall of the newly 
formed vessels.
Gillman and Hallowes (1972 a,b) reported pleomorphic mesenchymal sarcomas 
induced by trypan blue. They classified them as Kuppfer cell sarcomas. 
Sarcomas regularly arise from the wall of the cyst that encloses the 
parasite Cysticercus Fasciolaris the larva of the tape worm Taenia 
Grassicollis. The neoplasms are made of sheets of atypical spindle cells 
with abnormal nuclei containing many mitotic figures (Butler and Jones,
1978).
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II - Biological behavior
In all the groups of malignant tumours described, local invasion and 
distant métastasés are common. Lung métastasés from parenchymal cell 
tumours occur in a significant percent of rats. Invasion of adjacent 
liver tissue, vessels, liver capsule , and organs (e.g.', diaphragm, 
pancreas, and omentum) occurs. Cholangiocarcinomas metastasise as 
adenocarcinomas, but frequently the stromal component is lost. In 
addition, peritoneal spread with formation of ascites, lymphatic spread 
to abdominal nodes, and vascular dissemination to lungs, adrenal glands, 
and other organs are reported (Butler and Jones, 1978).
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Ill - Sequence of changes occurring in hepatocellular lesions
During the last twenty years the biochemical histochemical and functional 
hepatic changes induced by carcinogens have been widely investigated.
In most of these experiments the distinctive pattern of the enzymatic 
foci, nodules and carcinomas involved one or more biochemical, histoche­
mical and functional abnormalities.
Foci of altered cells
Foci of altered cells possess characteristic histochemical, biochemical 
and functional abnormalities that can be revealed by a variety of tests. 
In the early sixties, Gossner and Friedrich-Freksa (1964) showed a focal 
loss in the activity of the microsomal enzyme glucose-6-phosphatase in 
rats given diethylnitrosamine. The lesions, which develop long before 
the appearance of carcinomas, were characterized by small foci of cells 
devoid of histochemically demonstrable glucose-6-phosphatase activity.
The foci could only be distinguished from normal hepatocytes by the 
histochemical reaction and were found at all the dose levels given in 
this experiment.
During the same year Bannasch and Müller (1964) published their first 
results on rats receiving nitrosomorpholine. One of the early histopa- 
thological changes observed was an excessive focal storage of glycogen 
as shown by a positive PAS reaction. Later a close correlation was esta­
blished between the foci showing deficient glucose-6-phosphatase and the 
foci storing glycogen (Friedrich-Freksa et al., 1969a ; Friedrich-Freksa 
et al., 1969b ; Scherer and Emmelot, 1976). In continuity with these 
investigations, Rabes and coworkers (1972) observed within such glucose- 
6-phosphatase deficient foci, a marked loss in canalicular ATPase. 
Moreover, these investigators demonstrated that the number and the size 
of the foci induced by DENA and their label index were proportional to 
the length of the treatment. After 3 months of treatment, small foci of 
marked proliferation appeared in some enzyme deficient areas, simultane-
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ously some cells showing glucose-6-phosphatase activity were occasionally 
found within the same areas. These changes indicated changes in phenotypic 
expression in the altered liver cells associated to their progression.
Since then, various groups have reported that the foci of altered cells 
show a different spectrum of biochemical and functional changes even when 
induced by the same carcinogen (Scherer et aL, 1972 ; Scherer and Emmelot, 
1975 ; Scherer and Emmelot, 1976 ; Pitot et al., 1978 ; Sirica et al., 1978 ; 
Ogawa et al., 1980 ; Ogawa et al., 1979). It has not been so far clearly 
established whether these differences are important in the initiation and 
development of liver cancer or only reflected different experimental 
conditions. Scherer and Hoffman (1971) investigated the probable clonal 
origin of the foci of altered cells induced in rats by a single oral 
dose of DENA (10 mg/kg). H-methyl-thymidine was injected intraperitoneally 
at the same time. Six weeks later foci of altered cells were identified 
on the basis of their deficiency in glucose-6-phosphatase and ATPase.
On autoradiography the grain count within the foci was significant lower 
than in the surrounding parenchyma suggesting that each focus was formed 
by the division of a single precursor cell.
More recently, Schere and coworkers (1972) studied the focal enzymic and 
functional alterations occurring during the development of foci. The main 
changes observed were : depressed ATPase and glucose-6-phosphatase, 
glycogen retention and increased basophilia. All these modifications 
were induced by a single dose of DENA (10 mg/kg). The number of the foci 
was counted and their size measured. When partial hepatectomy was perfor­
med 24 hours before the feeding of the carcinogen, a month later the 
number of foci had increased by five to ten fold. Two months later, the 
foci had increased moderately in size though remaining constant in number. 
Most of the foci showed significant losses in the activity of both enzymes 
tested and retained glycogen. However, the basophilic foci, present in low 
number, did not show any modification in the activity of glucose-6-phospha­
tase and were unable to retain glycogen on fasting.
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One of the most interesting biochemical and histochemical markers for 
preneoplastic and neoplastic hepatic lesions in the rat is the enzyme 
y-glutamyl transferase (Pitot and Sirica, 1980). In foetal rats y-GT 
activity increases sharply just before birth and remains high for the 
first few days after (Fiala and Fiala, 1973). It then decreases rapidly 
to either non detectable or very low levels in normal adult rat liver.
This enzyme was first shown by Fiala and coworkers (1976) to be highly 
active in many rat hepatocellular carcinomas. Soon after the initial 
exposure to carcinogens foci of cells exhibiting moderate to high levels 
of y-GT appear. These are not recognizable on the basis of morphology 
in standard histological sections. The induction of increased y-GT 
activity in these foci persists long after the exposure to the carcinogen 
is discontinued, this in opposition to the transient rise in y-GT 
activity observed soon after partial hepatectomy, liver damage by toxic 
compounds, or enzyme induction (Fiala et al. , 1976 ; Roomi and Goldberg, 
1981 ; Satoh et al., 1980).
In rats exposed to carcinogens the frequency with which y-GT is associa­
ted with early changes suggests that the induction of y— GT positive foci 
is a valuable marker for carcinogenesis in short term in vivo tests. Based 
on this phenomenon, a wide range of experiments have been undertaken in 
order to investigate the promoting ability of compounds such as phénobar­
bital, in rats initiated with diethylnitrosamine (Shinozuka et al., 1982 ; 
Lans et al., 1983) or nitrosomorpholine (Moore et al., 1983). It has been 
used in rats initiated with diethylnitrosamine followed by partial hepa­
tectomy and acetylaminofluorene (Cameron et al., 1982 ; Ogawa et al, 1980). 
It has been also utilized by Moore and coworkers (1983) in rats initiated 
with nitrosomorpholine and subsequently subjected to the Solt-Farber selec­
tion system (1976), and by Enomoto and Farber (1982) in rats initiated 
with diethylnitrosamine and promoted only with hepatectomy. Tsuda (1980) 
has reported a marked y—GT activity in rat liver cells resistant to 
carbon tetrachloride previously induced with 2-acetylaminofluorene.
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Demi and Oesterle (1980) demonstrated by means of histochemical techniques 
the presence of reduced glutathione in foci and areas of altered cells.
In rats treated with either diethylnitrosamine or N-nitrosomorph61ine 
the foci deficient in ATPase showed an elevated concentration of reduced 
glutathione and a marked y-GT activity. The authors suggest that these 
observations may explain, at least partially the increased resistance of 
the modified cells to the toxic effects of the carcinogens.
Pugh and Goldfarb (1978) have developed combined histochemical and 
autoradiographic techniques with serial cryostat sections for determining 
the number, type and nuclear labeling indices of foci of altered cells, 
hyperplastic nodules and carcinomas. The rats were injected with a marker 
dose of labelled thymidine before sacrifice. The labeling indices were 
determined applying the following formula :
Nber of tagged nuclei in a focus (or area of a nodule or carcinoma)
X 100
Mean number of nuclei in comparable areas of non nodular liver
The foci of altered cells detected showed abnormalities in content of 
one, two or three different markers. 89 % of them were y-GT positive,
71 % showed a loss in ATPase and only in 35 % G6Pase was depressed.
The foci exhibiting modifications in the three enzymatic markers had the 
higher labeling index.
Recently extensive data has been published by Bannasch and his group on 
the histochemical, biochemical and immunocytochemical changes induced in 
the livers of rats treated with carcinogens. They studied the clear eosi­
nophilic and basophilic foci and also additional, intermediate lesions 
designated "foci of fat storage cells" and "mixed cell foci" (Bannasch 
et al., 1980). This group has established a distinction between clear cell 
areas and clear cell foci induced by nitrosomorpholine on the basis of 
the ability of the areas to reverse, at least partially, their characte­
ristic accumulation of glycogen after a short period of treatment. The 
foci, on withdrawal of the carcinogen, retained glycogen for months.
These clear cell areas and clear cell foci have been histochemically 
investigated by Hacker and associates (1982) and Moore et al., (1983).
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They tested a number of enzymes involved in the metabolism of carbo­
hydrates. The clear cell areas did not show any significant changes 
in the activity of any of the enzymes examined. The clear cell foci 
exhibited significant losses in glucose-6-phosphatase and glycogen phospho- 
rylase,marked increases in glucose-6-phosphatase dehydrogenase and Y— GT 
activities. Vacuolated cells accumulate large amounts of fat droplets 
in their cytoplasm. The majority of them were practically devoid of 
glycogen although cells containing glycogen and fat were not infrequently 
found.
The outstanding feature of the eosinophilic cells was the pronounced 
storage of glycogen (Bannasch et al., 1980). Eosinophilic foci, like 
clear cell foci, persisted for months on cessation of the treatment, even 
after a single injection of nitrosomorphiline. Their histochemical 
characteristics were the same as those observed for the clear cell foci 
(Hacker et al., 1982 ; Moore et al., 1983). The basophilic cell foci 
were always depleted of glycogen and fat. The enzymic pattern of the baso­
philic foci was similar to that observed in the clear and eosinophilic 
foci although more intense (Hacker et al., 1982 ; Moore et al., 1983). 
Bannasch and associates (1980) described mixed foci of altered cells 
composed of clear, eosinophilic and basophilic cells together with 
vacuolated cells containing fat.
The histochemistry of the mixed cell foci revealed the characteristic 
features of each of the different groups of cell composing it. Using a 
method of laser-microdissection and biochemical microanalysis, Klimek 
and coworkers (1982) showed that the hepatic foci storing glycogen 
contained 50-100 % more of this polysaccharide than the surrounding 
liver parenchyma or the liver of untreated, controls. This accumulation 
of glycogen was accompanied later by an increase in the activity of glu- 
cose-6-phosphate dehydrogenase.
Vacuolated foci are considered by many groups as degenerative forms of 
basophilic or eosinophilic cells (Newberne and Wogan, 1968 ; Newberne, 
1976 ; Kalengayi and Desmet, 1975).
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In addition to the widely documented changes in label index, glucose-6- 
phosphatase and ATPase of hepatic foci and areas induced by N-2-fluoreny- 
lacetamide, Kitagawa and Sugano (1973) found a marked deficiency in 
6-glucuronidase activity. Foci of altered cells possess specific functio­
nal abnormalities that can be detected by special techniques. Resistance 
to iron accumulation when the liver is rendered siderotic by iron overload 
through dietary administration (Williams, 1980) or subcutaneous injection 
(Hirota and Williams, 1979) is one of the characteristic changes. Serial 
liver sections of rats exposed to N-2-fluorenylacetamide when examined 
for iron and enzyme activities showed that every iron-resistant altered 
focus corresponded to one of those exhibiting a positive reactivity for 
Y-GT or bearing a reduction in ATPase or glucose-6-phosphatase. The foci 
were heterogeneous in their enzymatic reactions in that no focus was 
partially y-GT negative, however some residual activity was found in the 
deficient ATPase and glucose-6-phosphatase foci. Larger number of foci 
resistant to iron accumulation were observed than were detected by any 
one of the enzymatic markers. The phenotypic enzymatic changes varied 
significantly between foci, y-GT was found to be more reliable of the 
enzymatic markers for foci, although it failed to identified some basophi­
lic foci. The least reliable marker was glucose-6-phosphatase deficiency, 
this presumably relates to glycogen retention in foci. However, with 
discontinuation of the treatement, the iron deficient foci disappeared, 
thus indicating the transient nature of these foci. This is consistent 
with the biological behavior of many of the hyperplastic nodules in the 
rat following withdrawal of the carcinogenic stimulus. Another of the 
striking functional abnormalities of foci is their resistance to the 
cytotoxic effects of chemicals requiring enzymatic activation. Based on 
work indicating that neoplastic cells are relatively resistant to 
cytocidal and other toxic effects of carcinogenic polycyclic aromatic 
hydrocarbons, Haddow (1938) suggested that this resistance might play an 
important role during the carcinogenic process. This suggestion is in 
accordance with the following considerations ; many carcinogens are
78
inhibitors of cell proliferation and/or DNA synthesis (Farber, 1980), an 
independent growth seems to be a property acquired relatively late 
during the events leading to cancer (Farber, 1973 ; Reuber, 1965 ;
Williams et al., 1977 ; Laishes et al., 1978). Putative premalignant 
hepatocytes show a variety of properties that are indication of their 
resistance to cytotoxic agents ; high levels of DT-diaphorase and the 
persistance of initiated cells after treatment with hepatotoxic chemicals 
such as carbon tetrachloride are among their properties. DT-diaphorase 
has been used for the detection of foci of altered cells in the livers 
of rats by Schor and coworkers, 1978. DT-diaphorase positive cells 
were exclusively found in the foci under the experimental conditions 
employed. The authors concluded that DT-diaphorase was involved in the 
resistance of the "preneoplastic" cells to the lethal action of chemical 
carcinogens. This assumption was based on the relation of DT-diaphorase 
with the microsomal drug metabolizing enzyme system, specially with 
cytochrome P-448 reductase (Lind and Ernster, 1974 ; Hommes et al., 1979).
Hyperplastic nodules
Hyperplastic nodules share many of the biochemical and functional abnorma­
lities of foci. Their enzyme patterns vary greatly from one nodule to 
another and even within a single lesion regardless of the histology, the 
carcinogen employed and the moment at which the lesion is observed 
(Becker and Klein, 1971 ; Kalengayi and Desmet, 1975). Correlation has 
been reported between the type of cell forming the hyperplastic nodule 
and its histochemical reactions. The enzyme changes corresponded to 
those of the groups of clear, eosinophilic and basophilic cells present 
within the hyperplastic nodules (Hacker et al., 1982 ; Moore et al. , 
1983). An irregular distribution or absence of glycogen is a frequent 
feature of hyperplasia nodules (Bannasch and Muller, 1964 ; Bannasch, 
1968). Hacker and associates (1982) suggest a deviation from glycogen 
metabolism to glycolysis and to the pentose shunt occurring in the 
hyperplastic nodules as an explanation of this change. Reduced levels 
of G6Pase and increases in both glucose-6-phosphatase dehydrogenase and
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GADPH support this view. Although hyperplastic nodules, like foci, have 
elevated y-GT levels, in certain circumstances this enzyme is not 
increased and may even be absent (Hirota and Williams, 1979). This absence 
appears to be the rule in foci and hyperplastic nodules induced by hypo- 
lipidaemic drugs (Reddy et al., 1982).
Levels of cytochromes P-450 and P-448 drop significantly in microsomes 
isolated from hyperplastic nodules (Gravela et al., 1975 ; Cameron et al., 
1976 ; Eriksson et al., 1983). These changes persist on cessation of the 
treatment (Gravela et al., 1975). Other microsomal enzymes such as aryl- 
hydrocarbon hydroxylase and aminopyrine demethylase are also markedly 
depressed. On the other hand, epoxide hydrase, previously referred to as 
"preneoplastic antigen", increased markedly in the microsomal fractions of 
hyperplastic nodules (Okita et al., 1975 ; Liv et al., 1977). Cytosolic 
glutathione-S-transferase is many times more active whereas its microsomal 
activity appears unmodified. The composition of the individual phospholipids 
of the membranes are modified with a 2-fold increase in phosphatidylinosi- 
tol and a slight reduction in phosphatidylcholine. The total amount of 
endoplasmic reticulum is the same as in normal liver although the smooth 
surface component doubles (Eriksson et al., 1983).
A number of studies on the localization of a-fetoprotein in hyperplastic 
nodules induced by various carcinogens have revealed a total absence of 
reactivity to the specific antisera. By contrast, a large proportion of 
hepatocellular carcinomas give positive reactions (Sell, 1978 ; Tchipysheva 
et al., 1977 ; Kühlmann, 1981). Also hyperplastic nodules do not produce 
angiogenic factor : thus they display fewer encodevelopmental abnormalities 
than carcinomas (Becker, 1978). -
Protein synthesis is found to be generally suppressed in hyperplastic 
nodules ; a few proteins are produced in near normal quantities, but the 
production of most plasma proteins is reduced or absent (Becker et al., 
1972). This package of changes suggests the existence of a programme that 
is disturbed in the altered hepatocytes forming the hyperplastic nodules.
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Hyperplastic nodules retain many enzyme regulatory mechanisms that are 
lost in carcinomas. Their enzyme activity can be modified by dietary sti­
muli or fasting. Kitagawa and Pitot (1975) have found a marked increase in 
glucose-6-phosphatase and serine dehydratase in hyperplastic nodules of 
animals receiving a diet containing 90 % of protein. A gradual loss in 
hepatic glucose-6-phosphatase and its induction by starvation in both non 
nodular parenchyma and nodules has been reported by Teebor and Seidman 
(1970). Becker and associates (1972) observed a reduction in protein pro­
duction in early nodules examined soon after cessation of treatment.
Although nodules appear to arise from foci and display many of the same 
properties as foci they should be considered as distinct lesions. The 
discontinuity of the plates of the cells of the h^;perplastic nodules with 
those of the liver and the compression of the surrounding parenchyma indi­
cate a loss of intracellular association that is maintained in the foci.
This modification probably reflects the acquisition of greater growth 
potential and a degree of autonomy of the hyperplastic nodules. Furthermore, 
hyperplastic nodules, like foci, are unusually resistant to toxic effects 
of the inducing carcinogen and other toxic substances requiring metabolic 
activation (Williams, 1980). The reduced cytochrome P-450 and P-448 in 
nodules with increases in enzymes involved in phase II, mentioned elsewhere, 
are probably the basis of their increased resistance.
Hyperplastic nodules show a decrease in portal blood supply with a relative 
increase in arterial blood (Soit et al, 1977). Cell membranes of nodular 
hepatocytes are abnormally separated and have irregular bile canaliculi 
(Farber, 1980 ; Ogawa et al., 1979). Hyperplastic nodules exhibit elevated 
DNA synthesis and mitosis (Rabes et al., 1972 ; Kitagawa and Sugano, 1973, 
Pugh and Goldfarb, 1977) but in spite of this Daoust and Molnar (1954) 
have demonstrated déficiences in RNA.
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Hepatocellular carcinomas
Hepatocellular carcinomas share many of the functional abnormalities 
displayed by foci of altered cells and hyperplastic nodules. They are 
characterized by similar enzyme alterations (Farber, 1973 ; Bannasch, 1976 ; 
Pitot et al., 1978 ; Goldfarb and Zak, 1963 ; Kitagawa and Sugano, 1973 ;
Fiala et al., 1973 ; Pugh and Golfarb, 1977) and are resistant to iron
accumulation (Williams and Yamamoto, 1972). Nevertheless, they differ in 
several major ways from foci and hyperplastic nodules. They grow progres­
sively and when transplanted give rise to tumour masses (Schreiber et al., 
1966 ; Morris, 1965 ; Reid, 1970 ; Becker, 1978 ; Williams, 1980). 
Furthermore, hepatocellular carcinomas often display the full behavior 
of malignant tumours : they invade the adjacent tissues and. produce metas­
tasis. They also show prominent oncodevelopment abnormalities such as high 
production of foetal proteins. The production of a-fetoprotein during liver 
carcinogenesis has been the subject of many controversial studies.
However, it is now generally agreed that a -fetoprotein is produced in large 
quantities only by regenerating liver (oval cells) and by many hepatocel­
lular carcinomas (Kroes et al., 1972 ; Watabe, 1971 ; Kitagawa et al., 1972)
Angiogenic factor is another tumour-associated foetal protein found in
liver tumours. The developing embryo depends on this protein for the 
ingrowth of capillaries from the nearby blood vessels. This factor appears 
also essential for tumour growth (Folkman, 1974).
Similarities between neoplastic liver cells and foetal liver cells in 
terms of biological appearance and behavior and in terms of biochemical 
markers have been reported, (Coggin et al., 1980 ; Farber, 1980). Primary 
liver tumours induced by chemicals, as well as UA and WDA transplanted 
hepatomas assume a foetal enzyme pattern. UA and WDA are two transplanta­
ble hepatomas originally induced by ethionine (Reid, 1970). When passaged 
by subcutaneous implantation the first grows rapidly (3 weeks) whereas 
the second grows more slowly (4 weeks). However this stepwise retrodif- 
ferentiation is not specific to liver tumours as developing and regenera-
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ting liver show similar changes. In spite of this, it is possible to 
distinguish between neoplasia and regeneration on a quantitative rather 
than qualitative basis. The magnitude of the changes are many-fold 
greater in tumours than in regenerating liver (Curtin and Snell, 1983).
The development of highly sensitive methods of protein separation has 
allowed the identification of their chemical and kinetic properties. These 
multiple forms of enzymes termed isoenzymes, which are geared kinetically 
to fullfill specific adult hepatic functions are lost and replaced by 
isoenzymes with different kinetic properties, which are found normally 
only in foetal tissues. These changes presumably reflect the loss of host 
control over tumour growth that characterizes cancer. There is not only 
apparent reactivation of genes that were active during foetal stages and 
subsequently inactivated during normal development but also suppression 
of genes coding for adult isoenzymes (Weinhouse, 1982). Much of the 
knowledge of isoenzyme alterations in rat hepatocellular carcinomas is 
based on the Morris hepatoma model. These hepatomas are a spectrum of 
chemically induced transplantable rat liver tumours with a range of growth 
rate, degree of differentiation and loss of hepatic functions (Weinhouse, 
1982).
The levels of aldolase, hexokinase, pyruvate kinase and their respective 
isoenzymes investigated in these hepatomas gave results in accordance 
with the biological characteristics of the hepatoma transplanted, e.g. 
the less differentiated and fast growing tumours show the highest levels 
of foetal isoenzymes and the lowest levels and even absence of adult 
enzymes (Weinhouse, 1982). Chemically-induced liver tumours show similar 
enzyme modifications. Hepatocellular carcinomas induced by DENA, 2-AAF and 
3-Me-DAB have shown varying losses of several enzymes involved in glucose 
metabolism. The enzymes were gradually replaced by the non-hepatic foetal 
iso-enzyme. Ah exception to this was glucose-6-phosphate dehydrogenase 
which was constantly high regardless of the degree of cellular differentia­
tion of the tumours (Satoh et al, 1980). The magnitude of the alterations 
also correlated with the degree of tumour differentiation. Harvey and 
Lindhal (1982) have reported the appearance of an unique aldehyde dehydro­
genase phenotype in chemically-induced hepatocellular carcinomas. The 
phenotype characterized by a several-fold increase due to the appearance 
of several new cytosolic isoenzymes was not detected in normal liver.
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The presence of y-GT has been considered as a sign of activation of 
foetal genes in neoplastic cells (Tarnaguchi et al., 1975 ; Fiala et al.,
1979). However, in studies in which both a-fetoprotein and y-GT have 
been shown in the same liver section, the expression of a-fetoprotein 
does not occur in the same cells or at the same time as y-GT activity 
(Jalanko and Ruoslahti, 1979). Moreover, it does not appear that a special 
foetal type of y-GT is expressed in tumours. y-GT purified from a 
variety of neoplastic tissues (Jacken and Mason, 1978 ; Tsuchida et al.,
1979) appears to be associated with the same protein as in normal tissue, 
with only some minor differences in sialic acid content.
IV Pathogenesis of hepatocellular carcinomas
A variety of cellular alterations takes place in livers exposed to carci­
nogens. One of the best studied is the proliferation of a cell population 
designated by Farber as oval cells (1956). Although the suggestion that 
these cells differentiate into hepatocytes has received considerable 
support (Dempo et al., 1975) their contribution to the formation of foci 
of altered cells has not been established. The altered focus, which is 
not composed only of intoxicated cells is the earliest recognizable 
abnormal population of cells that appears in the liver after exposure to 
carcinogens. Foci develop from hepatocytes that have undergone persistent 
alteration, as indicated by the findings that they can persist following 
the discontinuation of the carcinogenic treatment (Williams and Yamamoto, 
1972 ; Reuber, 1965) and after a single dose of the carcinogen followed 
by promotion, even if that promotion is delayed up to 4 months (Peraino 
et al., 1977). According to Williams (1980), the only known mechanism 
producing a permanent change of this nature in a cell population is by 
altering the gene expression either by mutation or reprogramming.
However, foci, hyperplastic nodules and hepatocellular carcinomas occur 
in untreated rats. Furthermore, compounds which are not mutagenic such as 
hypolipidaemic agents (Reddy and Lalwani, 1983) phénobarbital
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(Rossi et al., 1977) and other "enzyme inducers" can generate the entire 
spectrum of liver changes leading to hepatic tumours. The abnormalities 
reported in foci by many groups such as the appearance of y-GT, increased 
G6PDH, loss of g-glucuronidase and others, could be considered as the 
expression of a blocked differentiation or oncogenity along the lines of 
the hypothesis of oncogenity developed by Potter (1978). The marked 
expression of foetal properties which includes a-fetoprotein production 
(Kroes et al., 1972 ; Khülmann, 1981 ; Watabe, 1971 ; Gutmann et al.,
1972) and extramedullary hematopoiesis (Rabes et al., 1972) early in the 
development of liver tumours is consistent with this concept. However 
other features of foci namely glycogen retention and ultrastructural 
abnormalities such as glycogen distribution, free ribosome ratio of SER/RER 
suggest that these are really abnormal cells, not just a cell population 
blocked during maturation. The lack of a constant association of the alte­
rations in foci, such as resistance to iron accumulation, loss of G-6-Pase 
etc. (Hirota and Williams, 1979 ; Scherer and Emmelot, 1975 ; Pugh and 
Goldfarb, 1978 ; Pitot et al., 1978 ; Hacker et al., 1982 ; Kalengayi 
and Desmet, 1975) may be the result of the occurence of multiple alteration 
in DNA during the exposure to carcinogen required to produce transforma­
tion (Hirota and Williams, 1979). This heterogeneity was interpreted by 
Scherer and Emmelot (1975) as "one-hit" kinetics, to indicate that the 
single hit which initiates subsequent formation of a focus may be in a 
DNA segment that controls many cell properties. However if this was the 
mechanism of initiation a constant association of properties should be 
expected which is not the case.
Foci of altered cells can undergo phenotypic reversion, can persist or 
can progress. On early cessation of exposure to carcinogenic agents, 
a large proportion of the foci disappear (Williams and Watanabe, 1978 ; 
Kitagawa, 1976). At the present time, the factors intervening in the 
initial stages of development of foci are still unknown. It has been 
proposed by several authors (Vassiliev and GUelstein, 1963 ; Emmelot, 1971 ; 
Farber, 1973-1980) that foci derived from mutant cells and that abnormal 
cell populations develop during liver carcinogenesis as a consequence
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of the ability of the initiated cells to resist the toxic action of carci­
nogens. This is clearly shown in experiments in which the number and size 
of the foci augment with increasing carcinogen administration. A limited 
number of foci even after a single or brief exposure to carcinogenic 
agents acquire the ability to progress to form liver nodules. When the 
administration of the carcinogen is continuous a larger number of foci 
progress to nodules. This process probably represents more than just 
enlargement of foci as indicated by the loss of continuity of the cells 
and reticulum network in the nodules. The persistence of these changes in 
the foci, represents an alteration in the organization and in the inter­
cellular communication of the nodular cells.
Hepatic nodules seem to appear only after the development of foci of 
altered cells (Williams, 1980). Sequential studies have documented the 
appearance of nodules following intervals of 2 to 4 weeks after additional 
carcinogen exposure to animals with livers containing only foci (Williams 
et al., 1976). These investigators concluded that these intervals were too 
short for the nodules to have developed ab initio and thus nodules arise 
from altered foci.
It is generally accepted that nodules occur in the livers of both carci­
nogen-treated and untreated rats and that morphologically they are identi­
cal. At this point opinions begin to differ. Working groups have defined 
them as neoplastic nodules (Squire and Levitt, 1975 ; Hirota and Williams, 
1979 ; Bannasch et al., 1982) postulated as being related to cancer deve­
lopment. A high incidence, however, has been reported in untreated aged 
germ-free Wistar rats (Pollard and Luckert, 1979). Nodules have also been 
induced by the simple surgical of portacaval anastomasis (Weinbren and 
Washington, 1976). Reuber (1965) has suggested that nodules seen in livers 
exposed to carcinogens result from regenerative activity in response to 
the death of normal hepatocytes. This concept is supported by the regres­
sion of many hepatic nodules after withdrawal of the carcinogen. However,
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there is evidence indicating that the cells of reversible nodules are 
different from normal and regenerative liver cells (Becker, 1978). This 
hypothesis is more applicable to necrogenic hepatocarcinogens than to 
those which are clearly less damaging. According to this concept the 
regenerative nodule is eventually replaced by cell division and results 
in a persistent nodule. In a sequential study of nodule development 
Hirota and Williams (1979) found that nodules persisted after removal of 
the carcinogen and continued to grow. These authors concluded that "nodu­
les are progressively growing lesions and must be considered neoplastic". 
Since these nodules showed no invasiveness and produced no métastasés 
they may be an end-stage of benign neoplasia. This would be in conformity 
with their original designation as adenomas by Sasaki and Yoshida (1935). 
Hirota and Williams (1979), however, found that many of the nodules per­
sisting after termination of treatment showed extensive changes indicating 
a degenerative or regressive alteration. End stage benign neoplasms of 
hepatocellular origin has not been identified with certainty in the rat 
liver. However, according to Grasso and Gray (1977), large solitary uni­
form nodules, in contrast to multiple and conglomerate nodules, could be 
regarded as true adenomas. It is currently admitted that in practice the 
border line between hyperplastic nodules and adenomas is extremely diffi­
cult to establish, unless clear persistence and autonomy of the nodules, 
on cessation of treatment, can be demonstrated. Recently accumulated evi­
dence suggests that a large percentage of nodules undergo a complex remo­
deling to normal-looking liver (Vesselinovitch, 1982 and Farber, 1976) and 
only a small minority persist to become, according to Farber (1982),
"sites for further steps in the evolution of cancer". Farber and coworkers 
(1959) were among the first to stress the importance of the hyperplastic 
nodules as possible preneoplastic precursors to hepatocellular carcinomas. 
Goldfarb and Zak (1961) further emphasized the relationship between hyper­
plastic nodules and hepatocellular carcinoma. Their study was based not 
only on morphology but also on a deficiency in glucose-6-phosphatase found 
in these nodules and in number of hepatocellular carcinomas. It does appear 
that in the liver there are a number of nodules which can be identified
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macroscopically, some of which are transient or unstable upon removal of 
the carcinogenic stimulus while other such lesions persist even when the 
stimulus is removed. At the present time it is impossible to distinguish 
between the stable and transient nodule in rat exclusively by the use of 
the light microscope and standard histopathological staining procedures 
(Pitot and Sirica, 1980). According to Farber (1980) hepatocytes from 
hyperplastic nodules do not show any proliferative capacity until a new 
population is seen in such lesions, "nodules within nodules", in which 
a growth capacity appears.
A significant contribution to the understanding of the nature of these 
hepatic nodules has been made by the work of Teebor and Becker (1971) 
who established that if the stimulus inducing the nodules was withdrawn 
they regressed under certain conditions. In this study, rats were given 
a diet containing 0.06 % of 2-acetylaminofluorene for three cycles of 
4 weeks each followed by a week of normal diet. After three cycles 
macroscopical nodules developed, but all these nodules disappeared with 
time and 14 months later only one rat had an hepatic tumour. If however 
the rats were treated for an additional 4 week cycle the nodules 
persisted and the majority of the animals had hepatocellular carcinomas 
after 14 months. According to Farber (1980) the route taken by the majo­
rity of the liver nodules in most of the different experimental models is 
disappearance or reversion to normal looking tissue. As the nodules 
undergo maturation or reverse to normal appearing liver, most of their 
characteristic enzymatic, chemical and biological markers slowly return 
to "normal" levels, with one exception : the nucleus. The nuclei are 
similar to the nuclei of proliferating hepatocytes, empty-looking with 
poorly-stained-chromatin and large single nucleoli. If, however, the cells 
are labelled with 3H-thymidine the vast majority of the nuclei appear to 
be in a resting phase, suggesting that the turn-off mechanism in cell 
proliferation is not operating normally in the cells of the nodules 
(Farber, 1980 ; Ogawa et al., 1979).
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The persisting nodules also retain many markers characteristic of the 
preneoplastic phase of liver carcinogenesis. Using epoxide hydrase 
as marker, Farber demonstrated that upon regression many hepatocytes 
of the nodules "remodelled" into the normal liver parenchyma but kept 
the ability to express the epoxide hydrase antigen. Hyperplastic 
nodules, as previously mentioned, are found in untreated aged rats 
usually in low incidence. In a more recent experiment Tatematsu and 
co-workers (1983) described the remodelling of hepatic nodules induced 
bu the "resistant hepatocyte model" (Soit and Farber, 1976) described 
elsewhere. They labelled with 3H-thymidine all the hepatocytes composing 
the nodules without any significant degree of labelling of the surroun­
ding liver cells. During remodelling many clear cut nodules disappeared 
as they blended, into the surrounding non-affected parenchyma. At this 
time the remodelling nodules could be only distinguished by the cellular 
reaction for Y— GT and the test for epoxide hydrase ; a third of these 
hepatocytes retained the labels. All these findings suggested that 
most, if not all, the hepatocytes taking part in the process of 
remodelling were not derived from liver cells outside the nodules but 
were present during development. Thus remodelling is essentially a 
redifferentiation process rather than regression.
Although the development of carcinoma has been widely held to be from 
hyperplastic nodules (Williams, 1980), this does not appear to be an 
essential prerequisite in the case of every carcinogen (Grasso and Gray, 
1977 ; Weisburger et al., 1972).
Williams (1976) reported the development of carcinomas without a signi­
ficant interval of preceding nodule appearance. In another study by 
this author on the behavior of the nodules, the numbers of carcinomas 
in relationship to the hyperplastic nodules was too great for carcinomas 
to have developed from hyperplastic nodules (Hirota and Williams, 1979). 
In experiments of hepatic changes preceding the appearance of liver 
tumours in rats with different compounds : 4'-fluoro-aminodiphenyl
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(Mathews and Walpole, 1958), dimethylnitrosamine (Cell et al., 1968), 
N-nitroso-morpholine (Bannasch, 1968), aflatoxin (Butler and Barnes, 
1968), cycasin (Zedeck et al., 1970), the authors did not find hyper­
plastic nodules prior to the development of hepatocellular carcinomas.
The first 3 compounds, however, have been reported to produce a variety 
of lesions, including hyperplastic nodules and carcinomas when adminis­
tered in larger doses or during longer periods (Bannasch, 1968 ;
Kalengayi et aL, 1975). Thus carcinomas can rise outside and/or 
within hyperplastic nodules. Nevertheless there is probably a greater 
risk for an hyperplastic nodule to undergo malignant change, probably 
as a consequence of their continuous proliferation but, so far, no 
quantitative data are available on the fraction of hyperplastic nodules 
that might progress to cancer or the fraction of cancers arising in 
hyperplastic nodules. But, there are strong presumptions suggesting 
that the nodule is not an obligate precursor of cancer and that cancers 
can develop directly from foci. The role of basophilic ("hyperbasophi- 
lic") foci may be especially important in this regard (Daoust and Molnar, 
1964 ; Karasaki, 1976 ; Bannasch et al, 1972 ; Bannasch, 1976 ; Hirota 
and Williams, 1979). However, like hyperplastic nodules, these 
"hyperbasophilic" foci have been reported to be transient (Taper and 
Bannasch, 1976). The process by which carcinomas develop from foci or 
hyperplastic nodules is poorly understood. It has been suggested 
that the replicating cells in foci and hyperplastic nodules are more 
susceptible to mutagenesis induced by carcinogens (Williams, 1980). 
Increases in the normal low level of proliferation of hepatocytes 
produced either by partial hepatectomy or liver damage leads to an 
enhanced susceptibility of the liver to carcinogens (Craddock, 1971 ; 
Hollander and Bertvelzen, 1968). The underlying mechanism of this 
process is not yet known. Two reasonable explanations are that the 
dividing cells either have an inadequate opportunity to repair DNA 
damage or they experience greater or more selective DNA damage during 
replication of DNA. Apparently cells in hyperplastic nodules do not 
have quantitatively reduced DNA repair capacity (Kitagawa et al., 1975)
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so that the enhanced susceptibility could be due to a consequence of 
proliferation itself. Recently, decreased fidelity of DNA polymerase 
activity has been reported in rats exposed to fluorenylacetamide (Chan 
and Becker, 1979), and it has been suggested that this could result in 
an accumulation of abnormalities in DNA resulting in development of 
liver cancer. However, the possibility that cells may express different 
degrees of susceptibility to selective biochemical injury at different 
times during the cell cycle must be considered.
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G - REASONS FOR USING QUANTITATIVE CYTOCHEMISTRY
Histochemical studies of the preneoplastic changes, nodular hyperplasia 
and hepatocellular carcinomas are abundantly found in the literature 
(Bannasch, 1976 ; Pitot et al., 1978 ; Cameron et al., 1978 ; Fiala 
et al., 1972 ; Schor et al., 1978 ; Pugh and Goldfarb, 1978 ; Kitagawa,
1971 ; Moore et al., 1983 ; Mayer et al., 1983 ; Friedrich-Freksa, 1969) . 
Ail the enzymatic changes occurring in the foci of altered cells, hyper­
plastic nodules and carcinomas were evaluated in a qualitative (presence 
or absence) or semi-quantitative manner (pluses and zeros). Histochemis­
try has developed as a branch of histopathology and tends to emphasise the 
subcellular localization of the stain. In the present study, cytochemical 
methods for assaying changes in cellular enzyme activity were adopted. 
Enzymes were chosen as likely representative markers of changes in dif­
ferent components of the cell.
One of the aims of quantitative cytochemistry is to extend conventional 
biochemistry to the level of the individual cell in a complex tissue. 
Cytochemistry is limited by the number of reaction products of enzymes 
which can be measured quantitatively. This is usually done with a microden­
sitometer, which is a spectrophotometer built around a microscope, allowing 
the biological cell to replace the cuvette. The difficulties with measuring 
reaction products within cells are fully discussed by Bitensky, 1980 ; 
Bitensky et al., 1973 and Chayen, 1978.
Liver cells are difficult to disrupt efficiently without causing damage 
to many of the cellular component. The conventional approach of determining 
cellular enzyme activity by breaking open the plasma membranes of the 
hepatic cells and separating the components by centrifugation prior 
to measurement is therefore by no means ideal. Moreover, such procedures 
may cause the redistribution of the xenobiotics or its metabolites.
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possibly resulting in additional artefactual damage (Bridges et al., 1979). 
In tissues containing a variety of functional cell types such as the liver, 
a priori it would seem more useful to study biochemical functions of 
a single cell, while preserving its normal structure and functional rela­
tionship with the other cells. Although the procedures used are similar 
to those used in biochemistry the main difference is that in cytochemistry 
the final coloured reaction is normally precipitated within active cells 
thus allowing one to relate the histological appearance to the biochemical 
activity of the cell. Functional heterogeneity of hep>atocytes exists in 
vivo with marked changes occurring in the. various lobular hepatic zones 
(Bridges et al., 1979). Preservation of the normal architecture of a tissue 
app)ears to be critically impx^rtant in relating differences in function to 
localization of cells within an organ. Cytochemical methods were therefore 
adopted for assaying changes in cellular enzyme activity. Enzymes were 
chosen as likely representative markers of changes occurring in the 
different cell components. The enzymes assayed were :
- Membrane bound enzymes : 5'-nucleotidase (5'-Nase) and y—glutamiltrans-
ferase ( y— GT).
- Cytoplasmic enzymes : glucose-6-phosphate dehydrogenase (G5PDH) and
a -glycerophosphate dehydrogenase NAD linked
ot-GPDH (NAD).
« Mitochondria : a -glyceropjhosphate dehydrogenase flavoprotein
linked (a -GPDH mitochondrial).
*
- Peroxisome : catalase and uricase.
- Lysosome : acid phosphatase (APase).
In addition the cytoplasmic concentration of reduced glutathione ( GSH ) 
was measured. Glycogen and neutral lipid content were assessed semi-quanti- 
tatively. The rational for this selection of enzymes and related cytolo- 
gical factors is discussed in chapter "Materials and Methods".
* These enzymes were assayed only in the clofibrate experiment.
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H - CHOICE OF TEST COMPOUNDS
A wide range of non-genotoxic compounds have been shown to increase the 
incidence of liver tumours in rodents. A large number of them have the 
ability to increase liver size and to induce hepatic enzymes. These 
compounds can be roughly divided in :
a) Classical liver enzyme inducers, such as phénobarbital, DDT and BHT.
b) Compounds which induce a transient increase in the activity of the 
mixed function oxidase system, for example. Ponceau MX and safrole.
c) Peroxisome proliferators, such as, clofibrate, diethylphthalate and 
tibric acid.
It has been suggested that peroxisome prolif erators constitute a novel 
class of chemical carcinogens for rodents (Reddy and Lalwani, 1983 ;
Reddy et al., 1980). For this reason, this class of compounds was particu­
larly favoured for assessment in a sequential bioassay for carcinogenesis. 
Among the various chemically unrelated peroxisome proliferators clofibrate 
was chosen because of the large amount of published data on its pharmaco­
logy, toxicology and carcinogenesis in various species including man 
(Cohen and Grasso, 1981 ; Reddy and Lalwani, 1983 ; EARC, 1980). The 
initial hepatic response elicited by clofibrate in rodents is characte­
rized by hepatomegaly, proliferation of the smooth endoplasmic reticulum, 
and a marked increase in the concentration of peroxisomes with changes in 
both the peroxisomal structure and their enzyme composition (Cohen and
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In many of them diethylnitrosamine was used, as initiator (Pitot et al., 
1978 ; Weisburger et al., 1975 ; Kitagawa and Sugano, 1978 ; Schulte- 
Hermann etal., 1983). Diethylnitrosamine is a N,N-dialkylnitrosamine 
that acts via generation of an alkylating species i.e. an alkyl 
carbonium ion :
Œ - . CH« CH.,CH« CH..CH+
\ \
N-N ______ — > N-N_________ > N-N + OH> \ft0
CH3 . CH2 CH3JCH CH3 . CHO
V
0 -H
DENA fullfills all the requirements for a genotoxic agent. DENA produces 
DNA modifications in several species (Magee and Lee, 1964 ; Montesano and 
Bartsch, 1976 ; Pegg, 1977 ; Swann and Magee, 1971) and is mutagenic 
in many mutagenicity and short term tests (Bartsch et al., 1975 ; Sugimura 
et al., 1976 ; Nakajima et al., 1974 ; Montesano and Bartsch, 1976). 
Diethylnitrosamine is carcinogenic in all animal species tested (lARC 
monographs, 1978). In rodents it induces benign and malignant tumours in a 
diversity of organs : liver, respiratory, upper digestive tract and kidneys 
(Schmahl et al., 1960 ; Lacassagne et al., 1967 ; Takayama et al., 1975 ;
Druckrey et al., 1963, 1964 ; Reuber, 1975). Phénobarbital has been widely
used as a promoting agent (Peraino et al., 1973 ; Pitot et al., 1978 ; Kita­
gawa and Sugano, 1978 ; Weisburger et al., 1975). It has been reported
to be mutagenic in Drosophila melanogaster (Filippova et al., 1975). 
Phénobarbital is considered to be carcinogenic in mice after its oral 
administration for lifetime (Thorpe and Walker, 1973 ; Peraino et al.,
1973 ; Ponomarkov et al., 1976), although according to Roe and Grant (1970)
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Grasso, 1981 ; Reddy and Lalwani, 1983). Clofibrate does not appear 
to be directly genotoxic as it is neither mutagenic in the Ames test nor 
does it bind covalently to DNA after in vivo administration. Despite 
this clofibrate induces liver tumours after prolonged administration of 
high doses. Reddy and Lalwani (1983) have proposed that liver tumour 
development is initiated by the leakage of from peroxisomes which
results in damage to DNA. In studies on clofibrate and other peroxisome 
proliferators, attention has been centered particularly on the initial 
liver response and to a certain extent on the carcinogenic end points 
(Cohen and Grasso, 1981). However, little regard has been paid to the 
sequential biochemical and pathological changes that take place during 
the development and progression of the liver lesions. For these reasons, 
the experimental work described in this thesis was designed with the 
intention to investigate the sequential changes leading to hepatic tumours 
in rats exposed to clofibrate. Special emphasis has been put on the le 
morphological and cytochemical changes occurring during the early stages 
in order to identify reliable markers for the anticipation of increases 
in tumour count and latency. In order to confirm the validity of these 
markers described in Part I, the progression and the biological behavior, 
of the early putative preneoplastic lesions was studied. Inherent to this 
project was the need to use known carcinogens as positive controls. The 
comparison of the liver lesions induced by a classical genotoxic carcino­
gen with those induced by clofibrate, both in morphological and cytoche­
mical grounds appeared of great importance. Recognizing the special safety 
problems involved in handling carcinogens, it was decided to use an 
initiation promotion system. This led to the choice of diethylnitrosamine 
(DENA) as initiator and phénobarbital as promoter. This system offers 
the double advantage of reducing the risk of contamination and inducing 
rapidly a large number of liver tumours. Since the first clear demonstra­
tion by Peraino and associates (1973) that hepatocarcinogenesis could be 
separated into stages, liver tumours and related preneoplastic lesions have 
been induced by a variety of two stage protocols (Farber et al., 1979 ; 
Pitot et al., 1979 ; Peraino et al., 1975 ; Schulte-Hermann et al., 1979).
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and Grasso and Crampton (1972) an increased incidence of liver tumours 
in mice constitutes insufficient evidence to classify a compound as car­
cinogenic. In rats treated orally with PB for their lifespan, hepatic 
nodules considered as benign neoplasms were reported by Rossi (Rossi 
et al., 1977). No evidence of a malignant or benign hepatocellular 
tumours was found in other published carcinogenicity studies (Peraino 
et al., 1975 ; Schmahl and Habs, 1976).
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P A R T  O N E
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1. MATERIALS AND METHODS
1.1 Animals
Male albino rats of the Crl : COBS-CD(SR)BR strain were received from 
Charles River breeding laboratory, Elboeuf, France, and acclimatised 
for 13 days in our laboratories. Their mean body weight on day 1 was
121.4 +12.7 grams (approximately 40-45 days of age).
1.1.1. Housing and diet
The animals were housed individually, on sterilized sawdust bedding 
(Litalabo, Société Parisienne des Sciures, France) in makrolon cages 
(42 X  27 X  15 cm). The temperature and relative humidity of the animal 
room were regulated at 22 + 2°C and 50 + 10 % respectively. The air 
was totally changed 15 times per hour and artificial lighting was 
provided from 0700 to 1900 hours.
The rats had free access to tap water and to a laboratory animal food 
(diet A04C obtained from Usine d 'Alimentation Rationnelle, Villemoisson- 
sur-Orge, France). From their arrival to the start of treatment with, 
phénobarbital or clofibrate, the animals were fed on a pelleted diet.
1.1.2. Randomisation and numbering
The animals were arbitrarily placed in sequentially numbered cages 
and identified individually with the number of the cage by means of
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a perforated code punched into the ear(s). Before the start of the trial, 
a computer-based random permutation generator was used to assign an indi­
vidual trial number and treatment group to each animal of each trial. 
Excess animals were discarded.
Observations
Clinical
The animals were observed daily in their cage for appearance of fur, 
secretions, consistency of stools, behaviour, posture as well as for any 
compound-induced effects. Once weekly during weighing, a more detailed 
examination was performed including a check for presence of palpable 
masses.
Body weight 
Recorded once weekly.
Food consumption
Measured, once a week during the initial 3 months of treatment, then once 
a month for the remaining of both experiments.
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1.2. Experimental design
1.2.1 Experiment n° I
Evolution of liver lesions occurring in rats treated with diethylnitrosamine 
followed by phénobarbital.
Duration of the study : 71 weeks.
Compounds
Diethylnitrosamine : N-Ethyl-N-nitroso-ethanamine - (DENA)
Sodium Phénobarbital : 5-ethyl-5-phenylbarbituric acid sodium salt -
(PB).
Preparation of the compounds 
Diethylnitrosamine (DENA)
The liquid was dissolved in the isopac with saline so as to obtain the 
desired dose level of 50 mg/kg body weight in a volume of 5 ml.
Sodium Phénobarbital (PB)
The compound was mechanically mixed with the ground diet at the concentra­
tion of 0.05 %.
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Treatment schedule
Group Treatment Animal Numbers Number of Animals
0 Unsupplemented diet 1 - 45 45
1 Phénobarbital in diet 101 - 130 30
2 DENA i.p. + phénobarbital 301 - 355 55
in diet
Total 130
A dose of 50 mg/kg body weight of diethylnitrosamine was administered 
by the intraperitoneal route once weekly to the animals of group 2 at 
days : 1, 8, 15 and 21. From week 4 onwards, a new diet containing 
0.05 of phénobarbital was prepared every week and placed in glass 
containers available continuously to the animals of groups 1 and 2.
Time schedule
The time schedule is shown in Fig. 1.1. Five rats having received 
once weekly intraperitoneal injection of 50 mg/kg bw. of DENA for four 
weeks and five untreated controls were sacrificed at week 4, end of the 
initation period. After 3 days of treatment with 0.05 % of PB, week 4.5, 
five rats pretreated with DENA, five rats having received only PB and 
the corresponding number of untreated controls were sacrificed. The 
same number of rats of each group were sacrificed at week : 6, 8, 17,
30, 45, 56 and 71. At weeks 17 and 30 four animals pretreated with DENA 
and exposed to PB, were withdrawn from treatment and sacrificed 17 to 18 
weeks later (weeks 45 and 56).
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Fig. 1.1
Time schedule of Experiment N® I - DENA followed by PB
Number of animals sacrificed at each time point
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1.2.2. Experiment N° II
Evolution of liver changes occurring in rats treated with clofibrate.
Duration of the study : 113 weeks
Compound
Clofibrate : ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
Preparation of the compound
Clofibrate was mechanically mixed with the ground diet at concentrations 
appropriate to provide dose levels of 400 mg/kg body weight day.
Treatment schedule
Group Treatment Animals Numbers Number of Animals
0 Unsupplemented diet 1 - 7 0  70
1 Clofibrate 101-200 200
Total 270
A diet containing 400 mg/kg of clofibrate was prepared every week and 
placed in glass containers available continuously to the animals of group I, 
The group of untreated controls received the same unsupplemented diet.
Time schedule
Five clofibrate treated rats and five untreated controls were sacrificed 
at each interval. From week 42 onwards, four animals from the clofibrate 
treated group were withdrawn from treatment and sacrificed sixteen to 
eighteen weeks later. The detailed time schedule is shown in Figure 1.2.
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Necropsy
Animals were killed by exposure to carbon dioxide gas in a transparent 
plastic airtight container. The animals were weighed, full necropsy was 
performed and any abnormality recorded. The liver was weighed.
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Fig. 1.2
Time schedule Clofibrate
Number of animals sacrificed at each time point
TIME D3 W2 W4 Wll W30 W42 W52 W59 W68 W77 W86 W95 W103 W113
CONTROL u u u u  u u u u u u u u u □
5 5 5 5 5 5 5 5 5 5 5 5 5 5
CLOFIBRATE
Reversibility 1st
2nd
4 th
5th
6 th
7th
This figure shows the programed number of animals to be sacrificed at 
each end point. The changes occurring due to incidental deaths 
are shown in Tables and Figures of Part 3.
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1.3 Histology and histochemistry
Sections were taken from the following tissues :
Lung : one section of each lobe.
Liver : one transverse section of each lobe.
All tissues were fixed for a minimum of 72 hours on 10 % formalin. They 
were then processed overnight in an autotechnicon and embedded in paraf­
fin wax. Sections 4-5 microns thick were cut and stained with haemalum 
(Mayer) and eosin.
Sections were also stained for lipofuscin according to the Schmorls' 
method.
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Periodic acid Schiff PAS (after Me Manus quoted by Bancroft and Stevens, 
1977)
Fresh unfixed frozen sections were hydrolyzed for 10 minutes with 1 % 
periodic acid in distilled water, at room temperature. The sections were 
rinsed for 3 minutes in tap water followed by 30 seconds of distilled 
water. Subsequently, the sections were treated for 15 minutes in Schiff's 
solution at room temperature. The sections were washed in tap water for 
15 minutes, rinsed with distilled water and mounted with glycerol.
Oil Red O (PRO after Lillie and Ashburn, 1943)
Reaction
Fresh unfixed frozen sections were treated with 60 % isopropylic alcohol 
for a few seconds, at room temperature. The sections were treated with an 
Oil Red 0 solution for 15 minutes, then washed rapidly in 60 % isopropylic 
alcohol, rinsed in distilled water and mounted in glycerol.
Solutions required for this procedure
Solution A - Concentred lysochrome solution :
0.5 g of Oil Red 0 dissolved in 100 ml of isopropylic alcohol,
Solution B - 6 ml of solution A in 4 ml of distilled water.
60 % isopropylic alcohol in distilled water prepared shortly 
before use.
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1.4. Electron microscopy
Standard technique
Small fragments of liver were fixed by immersion in 2.5 % glutaraldehyde
- 4 % paraformaldehyde mixture (modified Karnovsky fixative) for 1 Hr 30 
in O.IM phosphate buffer (pH 7.3) at 4° C. They were rinsed carefully in 
O.IM phosphate buffer, then postfixed in 2 % buffered osmium tetroxide 
for 2 Hr at 4° C (in darkness). After fixation, the tissues were washed 
in O.IM phosphate buffer (3 x 10 min.), followed by dehydration in 
graded alcohols : - ethanol 70° : 20 minutes
- ethanol 90° : 20 minutes
- ethanol 100° : 2 x 15 minutes,
- cleared in propylene oxide (3 x 15 min.)
- infiltrated in 1 : 1 mixture of Epon and propylene oxide 1 Hr at
room temperature
- followed by infiltration in Epon for 24 Hours at room temperature 
and embedded in Epon
- blocks were polymerized for 3 days at 58° C.
Ultrathin sections of about 800 A° were cut with an LKB ultramicrotome III 
and collected on nickel grids. They were stained automatically in an LKB 
ultrostainer (uranyl acetate solution and lead citrate) and observed 
using a ZEISS EM 109 electron microscope.
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1.5. Immunocytochemistry
Peroxidase-Antiperoxidase (PAP) Technique
Tissue sections were deparaffinized, washed in methanol and rehydrated.
The sections were incubated separately with two blocking reagents : 
firstly, hydrogen peroxide (100 vols in 120 ml of methanol) for 10 minutes, 
and secondly in 1 % normal serum in Tris saline for 30 minutes.
The tissues were then sequentially incubated with the following antibodies
1° - Overnight with one of the primary antibodies raised against a speci­
fic antigen and used to locate and bind to that antigen in tissue. These 
were :
antisheep cytochrome P-448 ( g -naphtoflavone induced form) ; 
antirabbit cytochrome P-450 (major phénobarbital induced form) and 
antisheep cytochrome P-452 (clofibrate induced form).
2° - 40 minutes with the linking antibody employed to bind to the primary 
antibodies, thus forming a bridge for the third (labeling) antibody.
Donkey antibody raised against the rabbit and sheep antibodies anti the 
three forms of cytochromes above mentioned were used.
3° - 40 minutes with the labeling antibody, a peroxidase-antiperoxidase 
immunoenzyme complex, antirabbit and antisheep antibodies, were employed 
to mark the localization of the antigen.
4° - The entire antibody complex was made visible by addition for 3 minu­
tes of a chromagenic solution, Diaminobenzidine (DAB).
5° - After washing for 10 minutes in running water, the sections were 
counterstained with Hematoxilin and mounted.
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1.6 Cytochemistry
1.6.1 Production of tissue sections
The left liver lobe, plus any hepatic lesion observed, at necropsy were 
sampled for cytochemistry. The tissues were cut in cubes of approxima-
3
tely 5 mm and frozen in cold hexane at about - 70° G. The samples were 
sectioned at 8 microns thick in a SLEE automatic cryostat. The ambient 
temperature in the cabinet was kept at - 30° C and the knife was cooled 
to - 70° C one hour before using. The sections were picked-up avoiding 
pressure of the glass slide onthe tissue (Chayen et al., 1973).
1.6.2. Microdensitometry
Enzyme activity was quantitated by means of a Vickers M85 scanning 
integrating microdensitometer. In this system, the specimen is examined 
by normal microscopy and the area to be measured is defined by an 
illuminated mask the area of which can be varied, over very wide limits, 
covering from a particular region of a cell to many cells. A small 
spot of monochromatic light scans the area to be measured and the 
individual extinctions at each spot are determined and integrated. The 
Vickers M85 records the relative integrated absorption of a chosen area. 
This is a function of the area scanned, and of the response characteristics 
of the photomultiplier tube which varies with different photomultipliers 
and depends on the voltage applied to the tube. In order to compare 
results obtained in different microdensitometers, uniform results can 
be achieved by measuring the relative absorption of a series of filters 
of known absolute absorbance. Thus, it is possible to express the 
relative absorption values in terms of the mean integrated extinction 
of■ the area, that is the mean absorbance of all the values recorded. Mean 
results from 3 x 12 measurements performed in the three hepatic lobular
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zones (e.g. periportal, midzonal and centrilobular) were obtained in 
arbitrary machine units. The arbitrary units of absorption recorded by 
the instrument were converted to absolute units of extinction. A calibra­
tion graph of absorption (as recorded by the microdensitometer) was 
plotted against absolute units of extinction , from neutral density 
filters (Bitensky et al., 1973 ; Butcher, 1972). The measurements were 
carried out with the appropriate magnification and wavelength for each of 
the tests. The suitable wavelength for measuring each reaction, with the 
exception of all the assays using néotétrazolium, is the one which gives 
the maximum absorption. This was calculated by measuring the blank field 
and the specimen at each of a number of wavelenghts, readjusting the instru­
ment for each wavelength and drawing a full absorption curve. For all 
the assays in which néotétrazolium was utilized the amount of formazan 
precipitated in individual cells was measured at the isobestic wavelength 
of 585 nm. At this wavelength the total concentration of both formazans 
produced, red and purple, by the reduction of néotétrazolium is fully 
estimate. For further details see Butcher (1972) and Butcher and Altman 
(1973).
All the dehydrogenases, catalase and uricase were measured at a magnifi­
cation of X  100 with a flying spot of 0.2 micron of diameter in the plane 
of the specimen. This to avoid errors inherent to the measurement of small 
chromophore particles (for full details see Bitensky et al., 1973).
Acid phosphatase glutathione and 5'-nucleotidase which all produce 
relatively diffuse precipitates were measured at a magnification of 
X  40, with a flying spot of 0.2 micron (Dr Chayen personal communication).
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1.6.3. Enzymes assayed
Glucose-6-phosphate dehydrogenase
Cytolsolic glucose-6-phosphate dehydrogenase (G6PDH) is the enzyme 
controlling the entrance of glucose-6-phosphate into the hexose-monophos- 
phate shunt, its natural substrate is glucose-6-phosphate (Mayes, 1981). 
This shunt also known as pentose-shunt, is an alternative pathway for 
oxidation of glucose. The role played by this pathway in cellular metabo­
lism is twofold. Firstly, it produces pentose sugars which are used 
to provide ribose and deoxyribose for the corresponding nucleic acids. 
Secondly this and other dehydrogenases (e.g., 6-phosphogluconate 
dehydrogenase) require NADP as co-enzyme and so are a major source of 
NADPH. Reducing equivalents from NADPH are of considerable importance 
in a number of essential metabolic reactions, such as synthesis of 
steroids (Mayes, 1981 ; Chayen et al., 1973) fatty acids (Mayes, 1981) 
and reduction of folic acid to tetrahydrofolic acid. They are also the 
source of reducing equivalents for the mixed function oxidations of drugs 
and steroids, involving cytochrome P-450 forms (Butcher, 1972 ; Chayen 
et al., 1973 ; Parke, 1974).
Rationale of this method
Hydrogen is removed from glucose-6-phosphate by G6PDH and passed to NADP,
the cofactor which is reduced to NADPH. Subsequently, the cofactor is
oxidated back to NADP at the expense of the tetrazole salt which is
reduced to formazan. The general rule ds that oxidizing systems have a more 
positive electrode potential than reducing systems which have more
negative electrode potentials (Chayen et al., 1973). Accordingly, the 
hydrogen passing down the hydrogen-transport chains, will bring about 
the reduction of an oxidation-reduction indicator if the acceptor 
system approximates to, but is still more negative than the electrode 
potential of the indicator. Thus, when dehydrogenase activity is demons­
trated cytochemically hydrogen is removed from the substrate by the 
enzyme and it is passed to one or more hydrogen acceptors until reaches 
an oxidation-reduction system with an electrode potential adequate
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for the reduction of tetrazole salts. It has been observed by Chayen 
and associates (1973) that not infrequently there is a considerable gap 
between the electrode potential at which the cofactor becomes reduced and 
that at which the tetrazole accepts hydrogen. This gap varies according 
the tétrazolium salt used (Altman, 1972 ; Chayen et al., 1973). This 
implies, firstly, that the localization as the formazan is that of the 
fraction of the hydrogen-transport chain from which it accepts the 
hydrogen ; secondly that the rate at which the dehydrogenase works may 
be considerably greater than the rate at which hydrogen is transported, 
consequently the levels of dehydrogenation detected will depend on the 
activity of the hydrogen-transport system and not on the activity of the
dehydrogenase. These problems can be overcome by including powerful hydro- 
gen-acceptors, such as menadione or phenazine metosulfate in the reaction 
medium, which rapidly and non-enzymatically take hydrogen from the reduced 
coenzyme of the dehydrogenase and transfers it to the tétrazolium salt. 
Biochemical and cytochemical evidence showed that G6PDH occurs in the 
soluble fraction of homogenates and that is very weakly bound in the cyto- 
lasm (Altman and Chayen, 1966). In order to avoid its lost from tissue 
sections into the incubation medium a suitable concentration of polyvinyl 
alcohol (PVA) was added to the reaction medium (Altman, 1972). The concen­
tration of the reactants was ajusted taking into account their slower 
diffusion through the PVA. In accordance with data previously reported 
(Chayen et al., 1973 ) increased concentrations of néotétrazolium did not 
inhibited the reaction. Oxygen has a marked inhibitory effect on the amounts 
of formazan (reduced tétrazolium) when néotétrazolium is used as hydrogen 
acceptor for G6PDH. This effect is probably due to competition between 
oxygen and néotétrazolium. Consequently when using néotétrazolium salts 
the reaction medium should be saturated with nitrogen. However, in many 
types of malignant neoplasms the inhibition of the néotétrazolium reaction 
by oxygen does not occur (Altman et al., 1970 ; Solomons and Daly, 1979 ; 
Heyden, 1974 ; Ibrahim et al., 1983), this property appears as an useful 
tool for detecting certain malignant changes. When phenazine methosulfate
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(PMS) is added to the reaction medium the amount of formazan produced 
may be up to several times that obtained without PMS, depending on the 
tissue tested. This is due to the fact that PMS transfers, rapidly and 
quantitatively, hydrogen directly from NADPH, as it is produced by 
G6PDH, to néotétrazolium salts. This reaction demonstrates the actual 
activity of G6PDH. In the absence of PMS, NADPH is used at a relatively 
positive electrode potential and the hydrogen equivalents are passed 
through the NADPH-diaphorase system to the néotétrazolium salt.
Based on these findings, it has been proposed by Chayen and associates
(1972) and Altman (1972) that two pathways of hydrogen equivalents 
exist each having its own biological significance. These are termed : 
G6PDH pathway I which represents the reducing equivalents, from NADPH, 
which are passed through the NADPH diaphorase system to the microsomal 
respiratory chain. This pathway provides an indication of the activity 
of the mixed function oxydase system. And G6PDH pathway II which is 
obtained by the subtraction of G6PDH pathway I values from the total 
production of NADPH by G6DPH incubated with PMS. G6PDH pathway II indi­
cates the fraction which remains at a very negative electrode potential 
and is used in cellular biosynthetic mechanisms.
Method (According to Altman, 1972)
Fresh cryostat sections of unfixed tissue were used. The reaction medium 
was incubated in glass rings in an atmosphere of nitrogen at 37° C with 
PMS for total G6PDH and without PMS for G6PDH pathway I. Additional 
sections of the same sample were simultaneously incubated with PMS in 
an atmosphere of oxygen. The optimal time of incubation was 15 minutes 
for the three types of G6PDH (total, pathway I and aerobic). This was 
established measuring serial sections incubated at different times and. 
plotting the arbitrary machine units obtained for each section against 
the scale of time. The reaction was shown to be linear for the three 
types of G6PDH, thus permitting in the case of very strong reactions, 
such as those observed in some tumours, the determination of the 
activity of G6PDH per unit of time (Butcher, 1972 ; Ibrahim, 1983).
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The reaction was stopped by rinsing the section with distilled water and 
mounted in Farrants' medium. Control sections were incubated as for the 
test but in which the substrate was omitted. In addition control sections 
with no NADP were also incubated.
Reaction medium
The reaction medium was obtained dissolving 5mM of néotétrazolium 
chloride in 100 ml of a 50 mM glycylglycine sodium hydroxide buffer at 
pH 8. A sufficient volume of w/v polyvinyl alcohol (G041/140 grade) 
was added to obtain a 30 % concentration. In addition 5 mM of glucose- 
6-phosphate and 3 mM of NADP were included in the medium. To test the 
total activity of G6PDH a concentration of 0.2 mg/ml MPS was added 
to the reaction medium, this was warmed at 37°C and nitrogen was bubbled 
for approximately 2 minutes before use. In order to detect the aerobic 
activity of G6PDH in tumours and suspected neoplastic lesions the 
nitrogen was replaced by oxygen.
Microdensitometry
The end reaction product was measured with a x 100 immersion oil objective, 
a spot size 1,0.20 microns in diameter, and a field size of 24 microns 
(mask B4). The wavelenght of the monochromatic light was 585 nm.
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g—  Glycerophosphate dehydrogenases
The natural susbtrate of intramitochondrial g-GPDH flavoprotein dependent 
is g-glycerophosphate. In addition to the intramitochondrial form, 
there is a soluble extramitochondrial NAD linked o-GPDH, the natural 
susbtrate of which is dihydroxyacetone-phosphate. Both enzymes cooperate 
in the glycerol-3-phosphate shuttle through which hydrogen is transported 
into the mitochondria. Intact mitochondrial membrane does not allow the 
penetration of reduced NAD, consequently cytoplasmic NADH is used to 
reduce dihydroxyacetone-phosphate to form g-glycerophosphate which 
passes readily the mitochondrial membrane. Once inside the organelle 
g-glycerophosphate is oxidized by the intramitochondrial g-GPDH which 
requires a flavoprotein as co-factor. A third form of g-GPDH NAD linked 
has been isolated from liver peroxisomes (Gee and Tolbert, 1982). This 
peroxisomal form differs biochemically from that found in the cytosol.
It has been suggested that peroxisomal g-GPDH has a role in a 
g-glycerophosphate shuttle between peroxisomes, cytoplasm and mitochon­
dria. It is presumed that this shuttle removes energy from the peroxi­
somes during g-oxidation, which reduces NAD. However, at present there 
is no cytochemical test to differentiate both NAD linked forms.
Rationale of this method.
Hydrogen is removed from the substrate by g-GPDH and passed directly to 
a flavoprotein for the mitochondrial form or to NAD for the extramito­
chondrial form, which are the hydrogen acceptors. Consequently, the subs­
trate is oxidised at the expense of the hydrogen acceptor, which is then 
reduced to either FPH or NADH. This, in turn is oxidised back to FP or 
NAD at the expense of the tetrazole salt which becomes reduced to 
formazan.
117
Method (according to methods suggested by Chayen and associates, 1973,
for NAD dependent dehydrogenases)
for g-Glycerophosphate dehydrogenase NAD dependent
Fresh unfixed frozen liver sections were used. The medium was incubated 
in glass rings for 20 minutes, rinsed with distilled water and mounted 
in Farrants' medium.
The reaction, as for other dehydrogenases, was shown to be linear, and 
20 minutes of incubation was considered as the optimum time.
Reaction medium
A 30 % PVA solution was prepared in 0.5 M glycylglycine buffer. A 0.3 % 
néotétrazolium chloride solution was subsequently prepared in the 
polyvinyl alcohol solution. The substrate was a 50 mM sodium dihyroxy- 
acetone phosphate solution in glycylglycine buffer. To 1 ml of the 
néotétrazolium solution were added : 0.1 ml of the substrate solution, 
0.1 ml of a 25/ml NAD solution in glycylglycine buffer, 0.1 ml of 
2 mg/ml potassium cyanide, 3 mg/ml phenazine methosulfate and 0.1 of 
glycylglycine. The pH was adjusted at 7.6.
Control
The same incubation medium was used with no substrate.
Microdensitometry
The end reaction product was measured with a x 100 immersion oil objec­
tive, a spot size 1,0.20 micron in diameter and a field size of 
10 microns (mask B9). The wavelenghth of the monochromatic light was 
585 nm.
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Method (according to Lodja, 1979)
for g-Glycerophosphate dehydrogenase flavoprotein dependent 
Fresh unfixed frozen liver sections were used. The medium was incubated 
in glass rings for 20 minutes, the sections were rinsed with distilled 
water and mounted in Farrants' medium.
Reaction medium
4 ml of Stock solution were added to 0.4 ml of IM sodium DL 
a-glycerophosphate solution (324 mg/ml, pH 7,2 - 7.4) plus 0.2 ml of a 
0.5 % menadione solution. The pH was adjusted to 7.6 and the medium was 
filtered before incubation. Stock solution for aqueous incubation media 
were prepared as follows : 10 ml of phosphate buffer O.IM, pH 7.2 were 
mixed with 10 ml of 0.4 % Nitro BT. (40 mg of Nitro BT dissolved in 
0.5 ml of N,N-dimethylformamide plus 9.5 ml of distilled water) ; to 
this it was added 4 ml of a solution of 0.065 % of potassium cyanide 
plus 4 ml of a 1 % magnesium chloride, and finally 8 ml of distilled 
water.
Control
The substrate was omitted from the incubation medium. The linearity of 
the reaction was confirmed by the same procedure used for the other 
enzymes tested.
Microdens i tometry
The maximum absorption was obtained with monochromatic light at wavelength 
of 520 nm. A x 100 immersion oil objective, a spot size 1,0.20 micron 
in diameter, and a mask B4, 24 microns in diameter, were used.
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Gamma glutamyltransferase ( y—GT) 
y-GT is a membrane bound enzyme which catalyzes three types of reactions:
a) Transpeptidation, y-Glu X + acceptor -^4 y-Glu-acceptor + HX;
b) Autotranspeptidation y-Glu X + y-Glu-X^ y-Glu-y-Glu X + HX;
c) and hydrolysis, y-Glu-X + H20 glutamate + HX (Barouki et al., 1983).
Gamma glutamyl donor include a variety of gamma glutamyl peptides in 
particular GSH ans its S-derivatives. A number of amino acids and dipep­
tides can serve as acceptors of the gamma glutamyl moiety (Tate, 1980).
In the liver y— GT is predominantly found in the cells of the bile ducts 
and in the adjacent hepatocytes. Its subcellular localization in these 
cells is in the cell membrane mainly in the bile canaliculus, its cata­
lytic site is on the extracellular side of the membrane (Pecker et al.,
1979 ; Novogrodsky et al., 1976 ; Tsao and Curtoys,, 1980). Meister
(1973) proposed the existence of a cyclic pathway for GSH metabolism in 
which transpeptidation catalyzed by y—GT plays a significant role in the 
uptake of certain amino acids. Another function of this enzyme may be to 
maintain intracellular levels of reduced glutathione. Inhibition of gamma 
glutamyl transferase in rats has been shown to induce glutathionuria and 
glutathionemia (Griffith and Meister, 1979). However, (Curthoys and 
Hughey, 1979 ; Me. Intyre and Curthoys, 1979) argue that the main func­
tion of y-GT is as one enzyme in the synthesis of mercapturic acids. 
Mercapturic acid biosynthesis has long been recognized as one of the 
mechanisms by which cells detoxify reactive electrophiles such as 
proximate carcinogens (Boyland and Chasseaud, 1969). The initial step is 
the conjugation of the activated carcinogen to GSH spontaneously or cata­
lyzed by several enzymes termed glutathione-S-transferases. Further 
metabolism involves the sequential cleavage of the glutamyl group by y-GT, 
and the glycine residue by cysteinyl-glycinase, followed by N-acetylation 
(Hughey et al., 1978 ; Chasseaud, 1976).
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Rationale of this method
In this method, y-L-glutamyl- a- -naphthylamide is used as substrate. A 
transpeptidation reaction is catalyzed by y'-GT as shown in the following 
scheme : 2 y-L-glutamyl— a— naphthylamide — ) g-napthylamine + y-L-gluta- 
myl- y-L-glutamyl-g— naphthylamide. The amount of g—naph thy lamine liberated, 
is coupled to Fast Garnet GBC salt, the amount of precipitated and reaction 
product indicates the enzyme activity. The optimum pH for y-GT is about 
8.8, at pH 6.7 the enzyme activity is reduced markedly. However, stimula­
tion of the enzymatic reactions performed at pH 6.7 is obtained by the
addition of glycylglycine. This substance serves as an acceptor for the
liberated y-L-glutamyl residues. The addition of glycylglycine is parti­
cularly recommended for the demonstration of y— GT in tissues with low 
y-GT activity such as normal adult rat liver.
Method (according to Albert and associates, 1961)
Fresh unfixed cryostat liver sections were used. The reaction medium 
was incubated in glass rings at 37° C for 20 minutes. The reaction medium 
was descarded and the sections were immersed in a O.IM copper sulfate 
solution for 2 minutes. The sections were rinsed with the sodium chloride
solution and mounted in Farrants' medium.
Reaction medium
5.4 mg of y-L-glutamyl— g— naphthylamide were dissolved in a mixture of 
4 ml O.IM phosphate buffer and 6 ml of a solution of 0.85 of sodium 
chloride at 37° C. To this solution 5 mg of Fast Garnet GBC salt and
26.4 mg of glycylglycine were added. The reaction medium was immediately 
used.
In control sections y-L-glutamyl— g—  naphthylamide was omitted from the 
reaction medium. The linearity of the reaction was confirmed measuring 
the activity of serial sections incubated at various time points. The 
enzyme-active sites are stained brown, the background of the sections 
yellow.
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Microdensitometry
The reaction was measured using the x 40 objective, a wavelenght of 
450 nm, a mask A5 (25 microns in diameter) and a spot I, 0.50 micron 
in size.
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Glutathione
Glutathione is present in all types of living cells (Meister, 1974).
The intracellular level of this tripeptide varies with growth, nutri­
tional state, and hormonal balance of the organism (Isaacs and Binkley, 
1977).
Reduced glutathione is particularly abundant in mammalian liver and 
forms covalent conjugates with many xenobiotics and their metabolites 
which are then excreted as mercapturic acids (Boyland and Chasseaud, 
1969). Glutathione also serves as substrate for glutathione peroxidase, 
which protects the cell from HgOg and organic hydroperoxides by reduc­
tion with concomitant oxidation of the reduced form of the tripeptide 
(Trush et al., 1982 ; Arrick and Nathan, 1984).
Rationale of this method
Loveridge and associates (1975) have demonstrated that in the presence
■[. I .{■
of a high concentration of F ions, ferricyanide is reduced more 
specifically by reduced glutathione than by other thiol substances or 
other reducing agents. This reaction produces the precipitation of 
the very insoluble dye ferric ferrocyanide (Prussian Blue), which can 
be quantitated by microdensitometry. At high concentration of the 
reactants, the reaction takes place in a matter of seconds.
Method (according to Loveridge et al., 1975)
Fresh frozen sections were immersed in the reaction medium for 20 
seconds at room temperature, then they were washed in water, air-dried 
and mounted in Farrants' medium.
Reaction medium
The reaction medium contained ferric and ferricyanide ions in a molar
ratio of 4.3,it was prepared mixing equal volumes of 33 % Fe C13 and
30 % K3Fe(CN) just before to use.
6
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Microdensitometry
The cytochemical reaction product was measured at a wavelength of 680 nm 
with a x  40 objective, a scanning spot 1, size 0.50 micron , and a 
filed size of 25 microns in diameter (mask A5).
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5'-Nucleotidase
5'-Nucleotidase is a phosphomonoesterase that hydrolyses all ribonucle- 
oside 5'-monophosphates (Song and Bodansky, 1966 ; Widnell, 1975 ;
Nakamura, 1976). There is also a soluble cytosolic form which constitutes 
only a small proportion of the total cell activity (Itoh, 1981 ; Newby, 
1980). Little activity towards 5'-deoxyribonucleotides was found in par­
tially purified enzyme preparations from rat liver (Widnell, 1975), the 
liver enzyme did not show any activity against phosphate esters on 
carbon-2 and 3 of 1 nucleotides (Song and Bodansky, 1966 ; Widnell, 1975). 
The 5'-Nucleotidases can be stimulated by manganese and magnesium ions, 
these latter according to Burstone (1962), would be stronger activators. 
Liver 5 '-Nucleotidase is an ectoenzyme predominantly located at the bile 
canalicular front of the hepatocyte. However, half of the total hepato- 
cyte content of 5'-Nucleotidase exists at intracellular sites on pathways 
of membrane circulation. Coated vesicles containing 5'-Nucleotidase act 
as a shuttle between their external and internal pools, transferring the 
enzyme and some other cell surface proteins as well as molecules present 
in the medium surrounding the cells (Stanley et al., 1980). The function 
of 5 ' -Nucleotidase remains obscur. Its ubiquitous distribution as an ecto­
enzyme had led to suggestions of involvement in nutrition, nucleotidase 
scavenging or adenosine production (Stanley et al., 1982). It has been 
proposed that 5 '-Nucleotidase plays a role in a substrate cycle between 
AMP and adenosine to permit a rapid increase in the concentration of this 
latter which can be transported into the extracellular medium to act as 
local hormone (Arch and Newssholme, 1978). However, Sasaki and associates, 
(1983) have presented evidence against this view, moreover the cellular 
orientation of 5'-Nucleotidase and its inhibition by intracellular nucleo­
tidase concentrations argue against its involvement in such a cycle. 
Another hypothetical function of 5'-Nucleotidase is a participation in 
the control of cell growth and differentiation (Hardonk, 1968 ; Lelievre 
et al., 1971 ; Sivak et al., 1972 ; Graham, 1979).
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Rationale of this method
This is a phosphatase reaction in which the liberated phosphate has to 
be trapped to give the cytochemical assessment of the activity of the 
enzyme. In order to diminish considerably the activity of non specific 
alkaline phosphatase which otherwise will also hydrolyse the carbon-5 
of the nucleoside at pH 8.3 the reaction is done at pH 6.5. At this pH 
the 5 '-Nucleotidases with alkaline pH optima are highly active whereas 
the activity of the non specific alkaline phosphatase is markedly 
reduced (Gomori, 1952). Nickel and zinc inhibit almost completly 5'-Nu- 
cleotisase leaving the non specific alkaline phosphatase relatively 
unaffected. The reaction for acidic and neutral 5'-Nucleotidases is done 
at pH 6.5 or 7, however at these pH lead has to be used as trapping 
agent since calcium phosphate is not insoluble.
Method (lead method for 5'-Nucleotidase, according to Naidoo and Pratt, 
1954 ; Wachstein and Meisel, 1952, 1957).
Unfixed fresh cryostat sections were incubated as described elsewhere 
in the prepared medium for 20 minutes. At the end of the incubation 
time, the sections were washed in running tap water, rinsed in distilled 
water and immersed in a 0.5 % solution of ammonium sulphide for 1 minute, 
Then rinsed again in distilled water and mounted in Farrants' medium.
The sites of enzyme activity are shown by a brown precipitate of lead 
sulphide. In control sections adenosine 5'-monophosphate was replaced 
by 25 mg of sodium— 3—glycerophosphate.
Reaction medium
31 mg of adenosine-5'-monophosphate were dissolved in 40 ml of O.IM 
sodium acetate buffer at pH 6.5, to this solution 1 ml of O.lM lead 
nitrate was added.
Control
—3The adenosine-5'-monophosphate was replaced with 25 mg (2 x 10 M) 
sodium- 3-glycerophosphate.
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Microdensitometry
A X  40 objective a scanning spot 1 (0.50 micron in diameter) and a 
mask A5 (25 microns) were employed. The wavelength of the monochromatic 
light was 450 nm.
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Acid phosphatase
From the full and detailed work of de Duve (1969) it now seems clear 
that the acid phosphatase of most tissues occurs inside lysosomes. It 
is now also appreciated that the term lysosome covers an array structures 
which form the "intracellular vacuolar system" of mammalian cells 
(de Duve, 1969). This term includes the primary lysosomes, secondary 
lysosomes which have fused with an endocyte vacuole, autophagic vacuoles 
and residual bodies. Autophagosomes are found under normal functional 
conditions as a morphological indication of constantly occurring destruc­
tion of cytoplasmic components especially when markedly proliferated. 
Cytological injury, on the other hand, is reflected by loss of the 
normal pericanalicular lysosomal distribution and the presence of large 
autophagosomes randomly distributed within the cytoplasm (Crampton et al., 
1977 b).
Rationale of this method
Azo-dye methods involve the use of phosphoorganic esters as substrates 
the organic moiety of which, after hydrolysis by enzyme, is usually 
coupled to aromatic amines or these derivative forming insoluble azo- 
dyes. It is important that the diazonium salt used for coupling is 
soluble at the pH reaction under study and does not unduly inhibit 
enzyme activity ; at the same time it must combine rapidly with the 
reaction product. One of the problems with the azo-dye coupling methods 
for acid phosphatase is that at acid pH certain adverse changes are 
enforced. The efficient coupling of most diazonium salts requires an 
alkaline pH (Barka and Anderson, 1963). It was shown that of pararosa- 
niline is diazotized shortly before is used., the resultant hexazonium 
pararosaniline will couple with a-naphthol at pH 5.5 but its rate of 
hydrolysis at this pH is greater than its rate of coupling. Accordingly, 
a compromise is reached by doing the whole reaction at pH 6.5. However, 
there is little evidence concerning, firstly, the speed of coupling at 
this pH,secondly, how the rate of enzymic liberation of the naphthol 
from the naphthol phosphate is affected and thirdly, the insolubility
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of the naphthol diazotized pararosaniline complex (precipitation rate). 
Moreover, at pH 6.5 the acid phosphatase loses about 50 % of its activity 
and in addition the hexazonium pararosaniline itself causes a substantial 
inhibition of the enzyme, thus the association of both these factors 
allows only the assessment of only approximately 30 % of the real activity 
of acid phosphatase (Barka and Anderson, 1963). The use of naphthol AS 
derivatives such as naphthol ASTR en naphthol ASBI phosphates at a pH of 
5.0 has been widely recommanded (Barka and Anderson, 1963 ; Lojda et al., 
1964 . Benes, 1961 . Lojda et al., 1967). However, is not clear how this 
overcomes the objections expressed by Barka and Anderson (1963) concerning 
the use of hexazonium pararosaniline at this pH. The advantage of the 
azo-dye technique, besides being widely used and recommended by many 
experts, is that it does not involve inhibitory metal ions for its reac­
tion and provides a bright red coloured and product more suitable for 
microdensitometry (maximum absorption wavelength).
Method (According to Lojda, 1962 and Lojda et al., 1967 ; Barka and 
Anderson, 1963).
Frozen sections were mounted on slides and dried (for 60 minutes at 
room temperature) and incubated at 37° C for 30 minutes. At the end of 
the incubation time, the sections were rinsed in distilled water and 
mounted in Farrants' medium.
Reaction medium
25 mg of naphthol AS-BI phosphate were dissolved in one ml of dimethyl- 
formamide. To this 49 ml of sodium acetate (O.IM) was added. After 
stirring, 4 ml of the solution of pararosaniline plus sodium nitrite 
was added and the pH was adjusted at 5.0 with sodium hydroxide. The 
pararosaniline solution was prepared as follows : 400 mg of pararosani­
line hydrochloride were dissolved in 8 ml of distilled water, 2 ml of 
2 N hydrochloridric acid were added. One volume of this solution was mixed 
with one volume of 4 % sodium nitrite solution. The medium was filtered 
before incubation.
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Microdens i tometry
The bright and coloured reaction product was measured at a wavelength 
of 520 nm (maximum absorption wavelength) using a x 40 objective, a 
scanning spot of 0.50 micron in diameter in the plane of the specimen 
and a field size of 25 microns (mask A5). In order to determine the 
optimal incubation time serial sections were incubated at various times, 
after a lag of 5 minutes the reaction appeared linear.
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Catalase
Catalase is a hemeprotein containing 4 heme groups. In addition to
possessing peroxidase activity, it is able to use one molecule of
HLOu as a substrate electron donor and onother molecule of HLOu as z z z z
oxidant or electron acceptor. Under most conditions in vivo, the peroxi­
dase activity of catalase seems to be favored, — » catalase — )
2HL0 + 0-. Catalase is found in blood and liver. Its function is 2 2
assumed to be the destruction of hydrogen peroxide formed by the action 
of aerobic dehydrogenases. Peroxisomes present in liver are rich in 
aerobic dehydrogenases and in catalase, this suggests that there may be 
a biological advantage in grouping the enzymes which produce H2 O 2  with 
the enzyme which destroys it (de Duve and Baudhuin, 1966). In addition 
to the peroxisomal enzymes, mitochondrial and microsomal electron 
transport systems must be considered as sources of 0^ 0*2 (Boveris et al., 
1972).
Rationale of this method
This reaction depends on the oxidation of diaminobenzidine by the 
peroxidase-catalase system.
Method (after Novikoff et al., 1972)
Fresh cryostat liver sections were fixed in cold 2.5 % glutaraldehyde 
for 10 minutes, then they were washed in cacodylate buffer for 5 minutes, 
The reaction medium was incubated for 10 minutes at 37° C. At the end 
of the incubation time, the sections were rinsed with distilled water, 
air-dried and mounted with glycerol. The incubation time was determined 
as for the other cytochemical assays.
Reaction medium
20 mg of 3.3'diaminobenzidine-tetrahydrochloride were dissolved in
9.3 ml of 0.5M propanediol buffer. The pH was adjusted at 9.7 with NaOH. 
0.2 ml of a 2.5 % solution of 8^ 0*2 and 0.5 ml of a second O.IM solution 
of H2 Ü2 and 0.5 ml of a second O.IM solution of KCN were added. The reac­
tion medium was filtered before use.
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Control
The reaction was inhibited by the addition of 3-amino-l,2,4 triazole 
at the final concentration of O.IM.
Microdensitometry
The concentration of catalase positive particles was measured with mono­
chromatic light of 460 nm, and a x 100 immersion oil objective. The size 
of the scanning spot was 0.20 micron and the field size 24 microns (B4).
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Uricase
Uricase catalyzes the oxidation of urate by 0^ yielding allantoin, CO^ 
and H2 O2  (Batelli and Stern, 1909, quoted by Graham and Karnovsky, 1965 ; 
Keilin and Hartree, 1936). The enzyme is found in all mammals except man 
and other primates (Keilin, 1959). In mammals significant amounts of 
uricase have been found only in the liver, the kidney, or both, depending 
upon the species (Graham and Karnovsky, 1965).The cell fractionation 
studies of de Duve and associates (1960) have provided evidence that in 
the rat liver uricase is associated with peroxisomes. Based on the 
absence of uricase activity in rat kidney homogenates and the lack of 
the characteristic crystalloid observed normally in rat liver cells 
Hruban and Swift (1964) concluded that the crystalloid represented 
crystalline uricase.
Rationale of this method
In this technique, horseradish peroxidase catalyzes the oxidation of 
3-amino-9-ethylcarbazole by H2 O 2  generated at the site of uricase 
activity. The 3-amino-9-ethylcarbazole is oxidized, to an insoluble red 
compound.
Method (after Graham and Karnovsky, 1965)
Fresh frozen sections were fixed for 10 minutes in cooled acetone (4° C) 
and rinsed in 0.15 NaCl before being placed in the incubation medium.
The sections were incubated for 60 minutes at 37° C. When sections were 
incubated aerobically at different time points, no difference in the 
reaction rate was detected between 30 to 90 minutes. After incubation 
the sections were washed in 0.15M NaCl and fixed for one hour in 10 % 
formaldehyde. Then they were washed in 0.15 NaCl and mounted in glycerol 
(medium recommended by Graham and Karnovsky).
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Reaction medium
3 mg of 3-amino-9-ethylcarbazole was dissolved in ml of dimethylformamide, 
and 10 ml 0.05M tris HCl buffer pH 8.0 was added. The mixture was shaken 
throughly, allowed to stand for 2 or 3 minutes, and filtered. The following 
were then added : sodium urate, 3 mg ; ethylenediamine tetra acetic 
acid (EDTA), 5 mg ; and horseradish peroxidase, 3 mg ; then the mixture 
was vigorously shaken.
Control
2,6,8-trichloropurine was used as a competitive inhibitor of uricase 
(Mahler, 1963). Sections were incubated in a buffered solution (tris-HCl) 
at a concentration of 2 x 10 ^M for 15 minutes, and a similar concentra­
tion of the inhibitor was added to the standard incubating medium. The 
reaction for uricase activity in the rat liver was completely inhibited 
by 2,6,8-trichloropurine employed in the above manner.
Microdensitometry
Measurements were carried out at a wavelength of 500 nm. A x 100 immer­
sion oil objective, a spot 1, size of 0.20 micron in diameter, and a 
mask of 24 microns (B4) were used.
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1.7 Stastistical method
Cytochemical data from the test groups and reversibility groups of 
the two experiments (DENA + PB and clofibrate) were compared with their 
respective controls at each time point. Differences between the mean 
values of all the cytochemical parameters assayed were tested for 
significance using the Student's t-test.
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1.8 Materials and Chemicals
1.8.1. Materials
Filters Kodak Wratten n° 96 of neutral density were provided by Kodak.
The optical density ranged from 0.1 to 2 units in steps of 0.1 unit. 
Mounting medium :
Farrants'medium was obtained from Hopkin and Williams.
1.8.2 Compounds and chemicals used for treatment
Diethylnitrosamine was purchased from Sigma in 100 ml serum bottle with 
butyl rubber stopper (isopac).
Sodium phénobarbital was obtained from Cooperative Pharmaceutique Fran­
çaise.
Clofibrate was supplied by Société Sibert.
1.8.3 Chemicals 
Cytochemistry -
Dehydrogenases
Néotétrazolium chloride was obtained from Serva and purified before uti­
lization with chloroform.
Glucose-6-phosphate, a -^glycerophosphate, dihydroxyacetone phosphate, 
phenazine methosulfate, menadione, Nitro Blue tétrazolium, NAD, NADP, 
and glycylglycine were purchased from Sigma. The polyvinyl alcohol 
GO^/140 grade was from Wacker-Chemie. -
Gamma glutamyltransferase 
Fast Garnet G.B.C. salt, y -L-glutamyl- a -nag±ithylamide and glycylglycine 
were obtained from Sigma, copper sulfate from Prolabo.
Glutathione
Potassium ferricyanide and ferric chloride were purchased from Prolabo. 
Acid phosphatase
Naphthol AS-BI phosphate and pararosaniline hydrochloride were bought from 
Sigma. Sodium acetate, sodium nitrite, and dimethylformamide from Prolabo.
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5'-Nucleotidase
Lead nitrate adenosin 5'monophosphate and sodium 3-glycerophosphate 
were obtained from Sigma.
Catalase
Glutaraldehyde, sodium cacodylate, diaminobenzidine, propanediol were 
purchased from Sigma. Potassium cyanide and hydrogen peroxide were 
obtained from Polabo.
Uricase
Tris-(hydroxymethyl) aminomethane, 3-eimino-9-ethylcarbazole, sodium 
urate, ethylenediaminetetraacetic acid (EDTA) and horseradish peroxida­
se were supplied by Sigma.
Histology and Histochemistry -
All the reactives used were obtained from Merck.
Electron microscopy -
Propylene oxide, osmium tetroxide, glutaraldehyde, and paraformaldehyde 
were bought from Sigma.
Epon 812 was obtained from Touzart Matignon.
1.8.4. Immunocytochemistry
The immunocytochemical techniques were performed at the Robens Institute, 
University of Surrey, U.K., using antisera of their own production.
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Address of suppliers :
Kodak, Paris, France
Hopkin and Williams, Romford, Essex, U.K.
Sigma-Chemie Gmbh, Taufkirchen, FRG
Cooperative Pharmaceutique Française, Paris, France
Société Sibert, Lyon, France
Serva, TEBU, Houdan, Yvelines, France
Wacker-Chemie, München, FRG
Prolabo, Paris, France
Merck, Darmstadt, FRG
Touzart Matignon, Vitry-sur-Seine, France
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2. EFFECT OF DIETHYLNITROSAMINE TREATMENT (DENA) FOLLOWED BY 
PHENOBARBITAL (PB) IN THE LIVER OF RATS
Introduction
There is now substantial experimental evidence to support hepatocarcinoge- 
nesis in the rat as being a multistep process involving at least two well 
defined stages in its natural history, namely those of initiation and 
promotion in a manner analagous to that first described by Boutwell, for 
skin carcinogenesis. Characteristic of this process is the relative early 
and sequential development in the livers of rats exposed to carcinogens, 
of focal and nodular hyperplastic lesions of atypical hepatocytes, followed 
later by the frank development of hepatocellular carcinomas. In this regard, 
the persistent hyperplastic liver foci and nodules are generally believed 
to represent putative preneoplastic precursor lesions for the evolution 
of liver neoplasm. When the administration of the carcinogen is followed 
by exposure to a promoter, the number of the presumed preneoplastic lesions 
and hepatocellular carcinomas increases and their latency diminish. Promo­
ters do not have the ability to induce tumours per se. The focal and 
nodular hepatic lesions have been shown mostly by histochemical or immuno- 
histochemical methods to share with malignant hepatocellular neoplasms 
a define number of phenotypically diverse pattern of biochemical and enzy­
matic alterations. However, it has only been possible with this method to 
obtain qualitative or semi-qualitative measurements of the effects of 
hepatic tumour promoting agents, such as phénobarbital, on specific bioche­
mical or enzyme marker alterations shown by the putative preneoplastic 
liver lesions. Thus, in the present experiment the changes induced in the 
livers of rats initiated with diethylnitrosamine (DENA) and promoted with 
phénobarbital (PB) were examined by means of quantitative cytochemical, 
histological and ultrastruetural procedures. Also the hepatic changes occur­
ring in rats exposed to phénobarbital alone were studied.
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Materials and methods
Materials and methods are described in Part I,
2.1. Results
2.1.1. Body and liver weights
Mean body weights decreased markedly from week 45 onwards in the group 
of rats initiated with DENA and promoted with PB and also in the groups 
in which PB treatment was withdrawn. A significant increase in both 
absolute and relative liver weights (32%) was first noted in all treated 
animals at week 6, two weeks after commencement of exposure to PB. At 
weeek 17, the relative and absolute liver weights of the group treated 
with PB alone remained at 32 % above control ; in the rats pretreated 
with DENA followed by PB similar values were obtained but a progressive 
increase in liver weights was found at all subsequent intervals in the 
later group. The onset of advanced nodular lesions and tumours probably 
accounted for this additional increased in liver weight. On cessation 
of PB treatment, the relative and absolute liver weights of the rats 
pretreated with DENA, declined susbtantially. However, these values 
still remained significantly above those of control animals. These 
changes probably reflect both reversibility of the cytomegaly and enzyme 
induction and the persistence of the hyperplastic and neoplastic lesions. 
The values for body and liver weights are presented in Tables' 2.1. and 2.2,
2.1.2. Early hepatic changes
Gross
Grossly liver enlargement was seen in all treated animals throughout the 
experiment. The livers were sometimes slightly pale, occasionally dark 
and frequently mottled.
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Histology
Enlargement of centrilobular hepatocytes was first observed at week 
4 1/2. The cytoplasm of these cells was granular and moderatly eosi­
nophilic. Single cell necrosis distributed throughout the liver was 
frequently found. These changes were seen in all treated animals 
throughout the experiment. In addition, at week 4 1/2 and week 6 high 
mitotic rates were observed in all the rats exposed to PB.
2.1.3. Later hepatic changes
Gross
In all rats pretreated with DENA and fed PB, macroscopic masses first 
appeared at week 17. These lesions were small, nodular, and were 
situated deep in the liver parenchyma. From week 30 onwards large 
multinodular masses were found, sometimes confined to a single lobe, 
sometimes distributed in different lobes. The masses were either pale 
or slightly darker than the rest of the liver, both at their outer and 
cut surface. Areas of necrosis of variable size, were not infrequently 
observed. In addition occasional adherence to the diaphragm was seen.
No gross lesions were found in untreated controls or in rats treated 
with PB alone.
Histology
Foci of cellular alteration
The first foci of cellular alteration were detected at week 8. At this 
time, two rats of the DENA treated group showed both basophilic and. 
clear cell foci. Increasing numbers of animals with foci were seen at 
all subsequent periods of test. The numbers of foci per section also 
augmented as the experiment progressed. Beyond week 17 basophilic, 
clear, and eosinophilic foci were present in similar numbers. Some focal
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lesions were composed of both basophilic and eosinophilic hepatocytes 
and a few of all three types of cells. Cystic foci were also seen. The 
two groups in which treated was stopped (reversibility groups) showed 
an incidence of foci similar to that of the initiated group treated 
chronically with PB alone. By week 45 two rats of the group receiving 
PB alone had developed clear cell foci. Towards the end of the study 
one untreated rat also had numerous clear cell foci. The number of rats 
with foci are shown in Table 2.3. The summary of the main histological 
type of foci is presented in Table 2.4.
Hyperplastic nodule (Fig. 2.32)
Histologically the masses varied considerably in structure. The smaller 
ones were composed of nodules showing regular cords of hepatocytes, 
similar to those of the liver parenchyma, but without the normal rela­
tionship of central veins and portal tracts. A certain degree of cellu­
lar pleomorphism was frequently present. Kiipffer cells and sinusoidal 
spaces could be readily recognized. Portal tracts were occasionally 
seen within the nodules. Compression of the surrounding host tissue was 
always observed. Little fibrosis, bile duct hyperplasia or fatty change 
were seen in these nodules. As in normal liver, the liver cell cords 
were usually one cell thick, but sometimes the cords were two cells 
thick. These lesions were on histological grounds considered hyper­
plastic in nature and diagnosed as hyperplastic nodules. Frequency 
of hyperplastic nodules is shown in Table 2.3.
Hepatocellular carcinoma (Fig. 2.41)
The larger hepatic lesions were complex in structure. They were com­
posed typically of multiple masses separated from one another by thick 
bands of fibrous tissue. Other masses were separated by a compressed 
zone of hepatic tissue, while others merely merged together. Bile duct 
hyperplasia was often observed at the periphery of the masses, and not 
infrequently was also seen within the fibrous septae. Large numbers of 
oval cells were found in some areas. The cells were seen radiating out
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from portal spaces, quite often penetrating into the multinodular struc­
tures. The masses showed a variety of cytological changes. In some, 
cell enlargement was a prominent finding. The cells were frequently twice 
normal size and sometimes larger, the staining characteristics of 
the cells were variable. Tumours composed of eosinophilic cells with 
pale vesicular nuclei and prominent nucleoli, coexisted with clumps of 
small basophilic cells. Others disclosed a variety of forms with 
variations in nuclear size, shape and cytoplasmic staining. Within the 
same lesion , both basophilic and eosinophilic cells were sometimes 
present. In some poorly differentiated areas multiple cells with abnormal 
nuclei, a high mitotic rate and abnormal mitoses were observed.
Cell vacuolation was seen in many masses, this varied from scanty 
collections of small vacuoles to numerous ones filling the entire cell. 
Frequently vacuoles were single and large, distending the cell and 
pushing the nucleus to one side. In frozen sections stained with Oil- 
Red-0, both the large and small vacuoles gave a strong positive 
reaction indicating the presence of neutral fat.
Associated with the trabecular tumours there were areas displaying an 
obvious glandular pattern. These areas showed a characteristic acinar 
formation. Typically five to ten cells with a basement membrane, 
were arranged, around a central lumen. Sometimes a significant amount of 
stroma was present between the glandular elements. Cystic spaces lined 
by flattened epithelium were frequently found. The presence of necrotic 
debris and occasional inflammatory cells was observed adjacent to glandu­
lar structures and typical trabecular areas. The cells forming the glan­
dular structures varied considerably in shape and staining affinities. 
Some were eosinophilic cells with vesicular nuclei and prominent nucleoli. 
Other acini were composed of more basophilic cuboidal cells. Some poorly 
differentiated lesions had foci of hyperchromatic cells with distorted 
glandular structures and abundant fibrous tissue. Pulmonary metastasis 
and peritoneal invasion was found in two cases (Fig. 2.43.).
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These lesions were considered of unequivocal neoplastic nature and 
diagnosed as hepatocellular carcinomas. Hepatocellular carcinomas 
always coexisted with focal lesions of various types and very often with 
the hyperplastic nodular lesions previously described. The number of 
animals bearing hepatocellular carcinomas is presented in Table 2.3.
2.1.4. Early cytochemical changes
At the end of the initiation period, week 4, in which the rats had 
received four injections of DENA, a significant increase in the activity 
of both total G6PDH (Fig. 2.1 ; Table 2.5) and G6PDH pathway I was noted 
(Fig. 2.4 ; Table 2.6). However, G6PDH pathway II (Fig. 2.7 ; Table 2.7) 
was only slightly augmented. The changes were most prominent in the 
centrilobular hepatic region. Y-GT was markedly enhanced attaining a 
50 % increase (Fig. 2.10 ; Table 2.8) and a 28 % rise in the activity of 
the plasma membrane 5'-Nase was also found (Fig. 2.19 and Table 2.11).
No changes were observed in the other parameters investigated.
At week 4 1/2, after three days of exposure to PB, the group initiated 
with DENA and the control group receiving PB alone showed similar enzyme 
changes. In both groups total G6PDH and G6PDH patway I were induced to 
a similar extent in all regions of the hepatic lobule while G6PDH path­
way II was augmented only in the centrilobular region. These findings 
were paralleled by a severe centrilobular GSH depletion. All these 
changes were statistically significant (Fig. 2.1, 2.3, 2.7 and 2.8 ; 
Tables 2.5, 2.6 and 2.7). In contrast the activity of y-GT, acid 
phosphatase and 5'Nase did not differ significantly from control values 
(shown in Figs. 2.10, 2.12, 2.19 and 2.21 ; Tables 2.8 and 2.11).
In all treated rats, 6 weeks after the beginning of the study, all types 
of anaerobic G6PDH were greatly increased, throughout the liver lobule 
(Figs. 2.1, 2.3, 2.4, 2.6, 2.7 and 2.9 ; Tables 2.5, 2.6 and 2.7).
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These changes were accompanied by a substantial rise in the activity of 
Y-GT (Figs. 2.10 and 2.12 ; Table 2.8). The modifications observed in 
the activity of the other parameters examined were not significant except 
for the confirmation of the marked loss in GSH seen earlier, this GSH 
depletion was found at all subsequent time points.
By week 8, although the levels of total G6PDH had declined from those of 
week 6, they were still slightly above basal values (Fig. 2.1 and 2.3 ; 
Table 2.5). While the activity of G6PDH pathway I was again significantly 
increased, G6PDH pathway II fell markedly to a third of the mean control 
values (Fig. 2.4, 2.6, 2.7 and 2.9 ; Tables 2.6 and 2.7). At this time 
the rats initiated with DENA showed a two fold rise in y-GT whereas in 
the group receiving PB alone the increase was only of 46 % over basal 
levels (Fig. 2.10 and 2.12 ; Table 2.8). PB also induced 5'-Nase activity 
in both treated groups, however the increases were greater in the DENA 
initiated group (Fig. 2.19 and 2.21 ; Table 2.11).
At week 17, all rats exposed to PB regained activity of both total and 
type II G6PDH (Fig. 2.1, 2.3, 2.7 and 2.9 ; Tables 2.5 and 2.7) whereas 
G6PDH pathway I showed a moderate but nonetheless, significant further 
increase in activity ( Fig. 2.4 and 2.6 ; Table 2.6) . The levels of y-GT 
fell to approximately control values in the rats given PB alone. In this 
group although the intensity of the reaction for y-GT per cell 
diminished, the number of positive cells increased and extended to the 
midzonal regions (Fig. 2.12 ; Table 2.8). In contrast y-GT remained 
significantly augmented in the DENA initiated group (Fig. 2.10 ; Table
2.8). The activity of y-GT was significantly increased in all rats 
exposed to PB at all subsequent intervals. (Fig. 2.10 and 2.12 ; Table
2.8). Cell membrane enzyme 5'-Nase showed an increase of activity in both 
treated groups, the increase being greatest in the DENA pretreated rats. 
At later time points 5'-Nase declined to 50 % of the control values
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(week 45) returning to near normal values subsequently (Fig. 2.19 and 
2.21 ; Table 2.11). From week 17 onwards the values for total G6PDH 
were constantly significantly increased. The changes observed with 
G6PDH pathways I and II were in conformity with those reported for total
G6PDH. However the fluctuations seen were greater and although the
increases observed in the centrilobular region were always significant 
this was not the case for the values measured in the other lobular 
regions (Fig. 2.1, 2.3, 2.4, 2.6, 2.7 and 2.9 ; Tables 2.5, 2.6 and 
2.7).
There were no statistically significant changes in the activities of 
acid phosphatase or a-GPDH at any of the various periods of test 
(Fig. 2.22, 2.24, 2.16 and 2.18 ; Tables 2.12 and 2.10)
In sections of liver stained with PAS from rats initiated with DENA and
fed PB or from rats exposed to PB alone, there was a focal loss of 
glycogen. Initially, small groups of cells, principally from centrilobular 
areas, were affected. By week 8, all treated animals showed a substantial 
centrilobular loss of glycogen. This was a constant finding at all 
subsequent intervals. (Fig. 2.25).
Frozen sections of livers from rats treated with DENA and PB, as well as 
from those receiving PB alone, showed a mild periportal accumulation of 
lipid when stained with ORO. Increased numbers of small droplets of 
lipids around the central vein and in the intermedian lobular region was 
the main feature observed during the early phase of the experiment 
(Fig. 2.26). The size of the lipid-laden zone increased with time 
and in later samples liver cells containing large droplets of fats 
were frequently seen, randomly distributed (Fig. 2.27).
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2.1.5. Later cytochemical changes
During the early stages of the experiment (4, 4 1/2, 6, and 8 weeks) 
focal liver lesions developed in the group of rats initiated with DENA 
and subsequently exposed to PB, most of which were only detectable by 
their cytochemical reactions. The majority of these lesions were intensely 
positive for aerobic G6PDH (Fig. 2.28 and Table 2.13). Some of these 
foci acquired y-GT activity and all of them retained GSH (Fig. 2.29,
2.30 ; Tables 2.17, 2.18). Only a few foci stored glycogen (Fig. 2.31).
At week 17, hyperplastic nodules were observed in the DENA initiated 
group (Table 2.3). These nodules were however only found after fixation 
and trimming of the liver and consequently were not suitable for cyto­
chemical assays. Foci of cellular alteration were also found in this 
group (Table 2.3). Similar numbers of basophilic and clear cell foci 
were present. A few foci showed mixtures of both types of cells. The 
enzymic patterns of the foci did not correlate strictly with their 
histological appearance. y-GT activity was found in all types of foci 
and additionally in groups of altered cells not seen histologically 
(Fig. 2.29 ; Table 2.17). All basophilic foci and some of the other 
types of foci had acquired aerobic G6PDH activity (Fig. 2.28 ; Table 
2.13) . As expected, many foci of cellular alteration had accumulated 
glycogen.
At week 30, an increasing number of foci of cellular alteration were 
detected in the DENA initiated rats. The foci, as reported previously, 
showed a variable enzymic pattern, regardless of their histology. One 
animal simultaneously developed a multifocal hepatocellular carcinoma 
(Fig. 2.33) and an hyperplastic nodule (Fig.2.32). Two other animals 
showed hyperplastic nodules.
The rat with the malignant tumour also had. a small hyperplastic nodule 
detected only histologically. The malignant liver tumour had intense
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total G6PDH activity (Fig. 2.36 ; Table 2.14), and both Type I (Fig. 2.34 ; 
Table 2.15) and Type II pathways (Table 2.16) were markedly stimulated, 
in addition it had acquired aerobic G6PDH (Fig. 2.35 ; Table 2.13). In 
contrast the hyperplastic nodules found in the other two rats reacted 
differently, two showed intense total G6PDH activity and augmented Type I 
and Type II pathways, while only one showed the acquisition of aerobic 
G6PDH. The third hyperplastic nodule did not show significant changes for 
any type of G6PDH. As before, some of the foci of cellular alteration 
showed intense aerobic G6PDH and both anaerobic G6PDH patways I and II 
activities. All the nodular and neoplastic lesions were practically 
devoid of glycogen (Fig. 2.42).
At 30 weeks, one rat treated with PB alone exhibited y-GT positive foci. 
These lesions were not detected histologically however almost all the 
lesions observed in the group initiated with DENA and fed PB were 
intensely y-GT positive (Fig. 2.29, 2.37 ; Table 2.17). However, the 
hyperplastic nodule devoid of all types of G6PDH, did not react for 
y-GT. The hyperplastic nodules retained GSH, in contrast, the neoplastic 
lesion did not (Fig. 2.38). In the rat with the neoplasm and cytochemical- 
ly active nodular lesions, acid phosphatase and a-GPDH were considerably 
reduced. These enzymes were unaltered in the third unreactive nodule.
In focal lesions, only acid phosphatase was detected and was markedly 
depressed when compared to the surrounding host tissue or the mean control 
values (Table 2.19 and 2.21). The intensity of the acid phosphatase reac­
tion within the neoplastic cells varied from substantial increases, 
which corresponded to varying losses of activity of all types of G6PDH, 
to evident reductions, which correlated with increases in the activity 
of all types of G6PDH. Low levels of 5 '-Nase were always found in the 
hyperplastic nodules (Fig. 2.39), whereas the hepatocellular carcinoma 
showed marked variations in the activity of this membrane bound 
enzyme (Fig. 2.40 ; Table 2.20).
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By week 45 all the animals of the group treated with PB alone had foci 
positive for y-GT. Some of which retained GSH (Tables 2.17 and 2.18).
Half of the focal lesions yjere not seen histologically. Those found, 
were all of the clear cell-type. At 45 weeks, two rats of the DENA 
pretreated group, developed hepatocellular carcinomas and hyperplastic 
nodules. A third rat had an hyperplastic nodule. The numerous foci of 
cellular alteration displayed essentially the same cytochemical and 
morphological changes seen at 30 weeks. Although the activities of all 
types of G6PDH were markedly enhanced in the hepatocellular carcinomas, 
they varied considerably throughout the lesion. No traces of aerobic 
G6PDH were found in any of the hyperplastic nodules, whereas total an­
aerobic G6PDH and both Type I and II pathways were substantially increased, 
One hepatocellular carcinoma and all the nodular lesions had high levels 
of y-GT. The other hepatocellular carcinoma was devoid of y-GT. The 
malignant tumours as previously observed had a low GSH content, whereas 
the hyperplastic nodules retained GSH.
The activity of 5 '-Nase was generally depressed in the focal and nodular 
lesions. In the hepatocellular carcinomas it was either similar to or 
less than the activity observed in the surrounding host tissue, and 
greater than that seen in the hyperplastic nodules, however, occasional 
increases were observed (Fig. 2.39 and 2.40 ; Table 2.20).
Abnormal acid phosphatase reactions were observed in each of the hepato­
cellular carcinomas. Small acid phosphatase positive granules were 
dispersed throughout the cytoplasm of the neoplastic cells but the 
number per cell varied widely. Large acid phosphatase positive vacuoles 
were present in small numbers within single cells or groups of cells.
The intensity of the reaction varied from moderate increases to slight 
reductions (Table 2.21). The latter corresponding to the areas rich in 
all types of G5PDH, and the former to those in which all the enzymes 
investigated showed varying losses.
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At week 56, two untreated control rats had some clear cell foci, none 
were found in the corresponding frozen sections. Focal lesions positive 
for anaerobic G6PDH were observed in two other animals of this group 
(Table 2.13). In the DENApretreated group, all the rats had developed 
hepatocellular carcinomas. Two of the rats had two distinctive multi­
focal malignant tumours. These neoplasms were situated in different 
hepatic lobes. Numerous focal lesions of variable morphology and some 
hyperplastic nodules coexisted with the malignant tumours. All the 
neoplastic, nodular, and. focal lesions displayed the same enzyme abnor­
malities described at earlier time points. Immunocytochemical techniques 
were performed on some controls and treated rats. Antibodies directed 
against cytochromes P-450 (the phénobarbital induced form) and P-448 
(g - naphtoflavone induced, form) were used. Positive results were 
observed in non nodular control tissue (Fig. 2.44) and in the hyperplastic 
nodules and hepatocellular carcinomas tested. P-450 was the most 
intensely staining isoenzyme in the nodular and neoplastic lesions but 
was restricted, in the hepatocellular carcinomas, to areas of cells 
showing a higher degree of differentiation (Fig. 2.45). These areas 
corresponded to those staining strongly for various forms of G6PDH, 
specially pathway I. The more anaplastic areas which showed a positive 
although variable ditribution of G6PDH patway I did not react for 
cytochrome P-450 (Fig. 2.46). Staining for the P-448 form was generally 
weaker than in controls and also very heterogenous in all the liver 
lesions examined (Fig. 2.47). At the final interval (week 71) 3 untreated 
control rats bearing foci of cellular alteration were seen. All the focal 
lesions were of the clear cell type and randomly distributed throughout 
the liver parenchyma. Their number varied from ten or twenty to over 
40 per section. These foci stored glycogen and a single focus showed a 
strong anaerobic G6PDH reaction and was acid phosphatase positive. Only 
two animals out of five DENA pretreated rats survived till the end of the 
experiment. At autopsy both had advanced liver lesions. Microscopically 
one had an hepatocellular carcinoma and the second a large hyperplastic 
nodule. Both showed numerous focal lesions of various types. The 
enzyme patterns of all these lesions were essentially similar to that 
described previously.
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2.1.6. Ultrastructure of early liver changes
Proliferation of the SER mainly within the centrilobular liver cells was 
evident after pretreatment with DENA. Examination of the livers of all 
the rats receiving PB showed similar early features. The increased SER 
appeared mainly as a tightly meshed network of smooth-surfaced, tubules 
and vesicles. In addition, areas characterized by the presence of 
regular vacuoles od SER were also seen. Further treatment with PB 
produce little further increase in the amount of SER. No evidence of 
changes in either the nature or the amount of RER was observed at any 
time (Fig. 2.48).
From week 8 onwards, the presence of multilaminated structures was seen 
(Fig. 2.49). These consisted of SER manbranes, sometimes involving 
mitochondria, other times fat droplets. Myelin figures although present 
were not abundant. There were no nuclear or mitochondrial abnormalities.
On cessation of treatment the above changes reversed. Typically no 
difference was detectable between the non nodular tissue of these rats 
and the comparable control group (Fig. 2.50).
2.1.7. Ultrastructure of later liver changes
The ultrastructural aspect of the liver cells varied considerably both 
between and within the individual hepatocellular lesions. In the hyper­
plastic nodules and in the well differentiated trabecular carcinomas, 
single cell plates of liver cells with well organized rough endoplasmic 
reticulum were a common feature (Fig. 2.51).
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Adjacent cell sometimes had a sparse network of rough endoplasmic reti­
culum cisternae and widely dispersed free ribosomes. In these cells, 
the cisternae often encircled mitochondria. The amount of smooth 
endoplasmic reticulum was in general increased. Some cells contained 
large areas of regular vesicles of smooth endoplasmic reticulum, others 
had a tightly meshed netwoork of smooth surfaced tubules and vesicles. 
Packed myelin structures made up of smooth membrane and looser whorls 
of rough endoplasmic reticulum, enclosing fat droplets and mitochondria, 
were often present. In addition, there was some variation in the number 
of Golgi complexes : in some cells they were larger and more abundant 
than in normal hepatocytes (Fig. 2.52). Annulate lamellae were not infre­
quent. The cells of the poorly differentiated hepatocellular carcinomas 
contained little well organized rough endoplasmic reticulum cisternae or 
areas of smooth endoplasmic reticulum. The presence of vacuoles containing 
disintegrating organelles was commonly seen (Fig. 2.53).
The mitochondria showed considerable variation : in many cells they were 
abundant and had a normal structure ; in others they were variable in 
size, quantity and form. Peroxisomes were rarely seen. Many cells 
contained cytoplasmic glycogen ; the amount varied greatly however.
Lipid droplets were found in all the hepatic lesions examined. The bile 
canaliculi were sometimes small, with multiple microvilli lying between 
two cells or at the junction of three or more cells. Desmosomes were 
present at the point of opposition of the plasma membranes. In other 
cases, the canalicular spaces were dilated, had sparse microvilli and 
were lined by four or more hepatocytes. The nuclei of these hepatocellular 
lesions were mostly regular with fine interspersed chromatin and large 
nucleoli. The glandular hepatocellular areas were composed of irregular 
acini lined by columnar and cuboidal cells. Each acinus was bounded by 
basement membrane, which frequently was multiple. No canalicular 
structures were seen in the border of the cells abutting the basement 
membrane. In all the cells the organelles were sparse. Rough endoplasmic
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reticulum was usually present in normal amounts although normally accom­
panied by many dispersed ribosomes. Smooth endoplasmic reticulum was 
always seen, often as regular vesicles. Golgi complexes were observed 
in some cells. Mitochondria, present in slightly increased number, were 
not infrequently swollen, with no cristae. Microbodies were rarely 
seen. The nuclei were either large and regular in size and shape or 
irregular and markedly indented. The nucleoli, often two, were prominent 
and marginated, as seen in the trabecular carcinomas (changes shown in 
Fig. 2.52 and 2.53).
2.1.8. Study of possible reversibility of the liver lesions
At weeks 17 and 30 respectively, one group of four rats each pretreated 
with DENA, were withdrawn from PB exposure. The animals received basal 
diet for six month and were killed at weeks 45 and 56. The host liver 
tissue of all these animals, showed no morphologic or cytochemical 
differences when compared with the untreated controls of the same age 
(Tables 2.5 to 2.12). Focal and advanced liver lesions were found in 
both groups. As expected, a larger number of malignant neoplasms was 
seen in the group exposed for a longer period to PB. Grossly, histolo­
gically and ultrastructurally the liver lesions observed did not differ 
from those found in the groups initiated with DENA receiving continuously 
PB, killed at the same intervals. Cytochemically, all the hepatic 
lesions displayed essentially the same enzyme abnormalities seen in 
lesions of similar nature arising in the groups promoted continuously 
with PB (Fig. 2.2, 2.5, 2.8, 2.11, 2.14, 2.17, 2.20, 2.23.
Tables 2.3 and from 2.13 to 2.21).
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2.2. Discussion
2.2.1 Non nodular liver
Severals experiments with carcinogenic agents such as thioacetamide 
(Barker and Smuckler, 1972), 2-acetylamino-fluorene (Trams et al.,
1961),dimethylnitrosamine (Norred et al., 1975) and aflatoxin 
(Mgbodile et al., 1975) have shown an early depression of the activity 
of the drug-metabolizing enzymes. Such a depression is considered as 
reflection of damage to microsomal membranes. In contrast, the livers 
of rats receiving injections of DENA once weekly for four weeks are 
presumed to have contained elevated levels of drug metabolizing enzymes 
as reflected by a marked rise in total G6PDH, and principally in G6PDH 
pathway I, which is consistent with an increased metabolism of glucose 
via the pentose-phosphate pathway in response to greater requirements 
for NADPH to sustain the induced levels of drug metabolizing enzymes 
(Chayen et al., 1973). Support for this explanation is provided by the 
observations that the enhanced activity of G6PDH pathway I is mainly 
localized in the centrilobular cells showing glycogen depletion and, 
ultrastructural examination revealed a significant proliferation of the 
smooth endoplasmic reticulum. This view is also reinforced by the 
absence of any cytochemical or ultrastructural lysosomal change charac­
teristic of cell injury, for example high levels of acid phosphatase and 
large autophagosomic vacuoles (Crampton et al., 1977).
The observation of high levels of y—GT with no changes in GSH content 
agrees with the findings reported by Fiala and coworkers (1976) on early 
effects of carcinogens on the liver of rodents. It has been suggested 
by these investigators that in the absence of cytotoxic effects, diffe­
rentiated cells have the ability to maintain high levels of both y-GT 
and GSH, in spite of a rapid turnover of the latter. The rats initiated
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with DENA and fed PB for three days, and those receiving PB alone for 
the same period of time, showed changes consistent with a marked induction 
of the MFO enzymes similar to that observed when DENA alone was given 
for four weeks. There were however some noteworthy differences. The 
elevated activity of total G6PDH and G6PDH patway I was paralleled by a 
significant increase in G6PDH patway II. These effects, in agreement 
with those reported by Butcher (1971) and Altman (1971), are not only 
compatible with an augmented production of NADPH to meet increased microso­
mal enzyme requirements, but in addition indicate an enhanced supply of 
reducing equivalents and ribose for biosynthetic processes (Chayen et al.,
1973). The high mitotic rates observed at this stage, in spite of the 
absence of significant increases in liver weights, suggest a transient 
hyperplastic phase, preceding a second stage, considered by many authors 
as a hypertrophic adaptative liver enlargement (Crampton et al., 1977 ; 
Schulte-Hermann, 1974). The stimulatory effects of PB on total G6PDH 
and pathway I were maintained throughout the continued PB dietary adminis­
tration. These features were paralleled by a sustained increase of 
the activity of G6PDH pathway II with, one exception, a significant 
depression at week 8.
Schulte-Hermann and coworkers (1982) reported an initial short-lived 
increase in DNA synthesis induced by PB. These authors suggested that acti­
vation of the same feed-back mechanism involved in the limited DNA 
synthesis occurring at later stages is also responsible for this early 
change. The above mentioned fall in G6PDH activity may have reflected the 
initiation of this feed-back process. Thus, the subsequent increase in 
G6PDH patway II activity would result from stimulation of the synthesis of 
other substances such as phospholipids, RNA, MFO enzymes and other proteins.
Changes compatible with the stimulation of conjugative processes were 
also seen. However, the significant increase in y-GT was paralleled by 
a marked centrilobular reduction of the GSH concentration, y— GT may
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function as one enzyme in the synthesis of mercapturic acids 
(N-acetylated-cysteine conjugates). The initial step following xenobiotic 
metabolism by microsomal, enzymes is the conjugation of the intermediate 
metabolite(s) to various endogenous substances including GSH. The reaction 
with GSH may occur spontaneously or may be mediated by one or more 
enzymes termed GSH-S-transferases. These are a group of enzymes that 
although showing specificity for the thiol of GSH have a rather broad 
and overlapping afinity for chemically reactive metabolites (Boyland and 
Chasseaud, 1969). PB has been reported to increase the activity of liver 
G-S-Transferases (Clifton and Kaplowitz, 1978 ; Hales and Neims, 1977 ; 
Pickett et al., 1981 ; Gillette, 1978).
Alternative interpretation could be given to these GSH and y—GT changes. 
Meister (1973 and 1981) and Tate and Meister (1981) proposed the existence 
of a cyclic pathway for GSH metabolism and suggest transpeptidation as a 
significant step in the uptake of certain aminoacids. Hydrolysis is consi­
dered by these investigators as a secondary function. On the other hand, 
Curthoys ans associates (1979) and Me Intyre and Curthoys (1979) argue 
that the main role of y—GT is the hydrolysis of gamma-glutamyl compounds. 
Both groups agree that glutathione is a requisite part of the substrate 
for y-GT in vivo. There is also evidence to suggest that y— GT is involved 
in the metabolism of leukotrienes and other endogenous substances (Barouki 
et al., 1983). It has been proposed that a cooperation exists between the 
liver and the kidneys for the synthesis of mercapturic acids. The presence 
of large quantities of GSH ans GSH-S-transferase activities in the hepato­
cytes , and y-GT in the bile ducts and renal cells supports this hypothesis 
(Chasseaud, 1979 ; Me Intyre and Curthoys, 1979). This provides an expla­
nation for the periportal increases in y—GT activity and the concomitent 
centrilobular GSH depletion observed throughout the experiment.
Mention should be made of the changes occurring in 5 '-Nase activity.
The cause of the marked rise of 5'-Nase in the DENA plus phénobarbital 
group observed at week 8, with a peak at week 17 and a subsequent depres­
sion is unknown. This biphasic pattern is unlikely to be due to the onset 
of focal and neoplastic lesions for the group treated with PB alone, 
in which only minor lesions developed, showed essentially the same
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although less marked enzymic changes. Studies on regeneration of rat liver 
demonstrated that the 5 '-Nase activity showed cyclic variations which 
were inversely related to growth rate (Fritzon, 1967). However, in the 
present experiment, there was no evidence of any relationship between 
growth rate and variations in 5'-Nase activity. Indeed the most striking 
changes in the activity of 5 '-Nase occurred at a stage in which PB 
was not inducing cell growth. Moreover, no modification in the activity 
of 5 '-Nase was observed during the early phases of the study in which cell 
growth was evident.
In agrément with previously published date (Crampton et al., 1977) PB 
did not produce any significant modification in the activity of acid 
phosphatase. a-GPDH, like acid phosphatase, showed no change in any of 
treated groups throughout the experiment.
Apart the hepatocellular lesions and tumours, no significant differences 
were seen in the host liver tissue of the animals pretreated with DENA 
and. exposed to PB and in the livers of those receiving PB alone.
However, although the changes observed in y-GI were qualitatively 
similar in both treated groups, the changes were quantitatively greater 
in the DENA-PB group. Essentially, the same cytochemical, histological 
and ultrastructural changes were induced by PB in both groups. Centri­
lobular cell enlargement has been observed previously following adminis­
tration of PB (Crampton et al., 1977) as well as many other compounds 
which stimulate the xenobiotic metabolising enzymes (Schulte-Hermann,
1974) (Schulte-Hermann et al, 1971) (Schulte-Hermann, 1979). The 
association of cell enlargement with induction of the drug-metabolising 
enzymes and proliferation of SER has been regarded as a reflection:df 
the increased functional capacity of the liver and thus a physiological 
rather than a pathological response (Crampton et al., 1977 ; 
Schulte-Hermann, 1979). The reversibility of these changes on termination 
of treatment, also observed by Crampton and coworkers (1977) is 
consistent with this view.
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2.2.2 Hepatic lesions
The presence of foci of hepatic cellular alteration in aged untreated 
Sprague-Dawley rats have been reported by many investigators (Greaves 
and Faccini, 1984 ; Ward, 1981 ; Burek, 1978 ; Pollard and Luckert,
1979). The factors involved in the genesis of these changes are not 
clear. It has been suggested that they may result from small amounts of 
carcinogens often present in laboratory animal diets (Schulte-Hermann,
1983 ; Williams, 1980 ; Pitot and Sirica, 1980). The histological 
description of the foci observed varies considerably between the different 
studies published. In the present study, however, they were clear, PAS 
positive foci, occasionally these were rich in y-GT and rarely in 
anaerobic G6PDH. In rats treated, with DENA, foci positive for aerobic 
G6PDH were observed as early as week 4, even before the onset of treatment 
with PB.
Several investigators (Weber 1977 a and b, Bannasch et al., 1982) consi­
der G6PDH as a key enzyme in cancer cell metabolism. The activity of 
this enzyme appears augmented in many cancers and. the increase occurs at 
an early stage in the development of a neoplastic cell from a normal 
one. Others, however, have reported either absence or decreased activity 
of G5PDH in cancer cells. Cytochemically dehydrogenase reactions, as 
described elsewhere, are usually performed in an anaerobic atmosphere 
since the production of néotétrazolium formazans is inhibited by oxygen 
(Altman, 1969). However when sections of experimentally induced rat 
liver carcinomas were incubated in an atmosphere saturated, with oxygen 
only slight inhibition occurred (Altman, 1970).
Ibrahim and associates (1983) compared the activities in oxygen of 
sections of potentially malignant and established malignant human 
gastro-intestinal lesions with clinically healthy tissues and benign 
lesions. In almost all of the first group there was a positive reaction, 
in contrast all the control tissues were negative. Thus it appears that
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the dehydrogenases in neoplastic cells differ from those of normal
cells. Studies on the mechanism of tumour development have shown that 
many genotoxic carcinogens have not only the capacity to initiate cells 
but also to promote their development when given repeatedly (Farber, 1976) 
Thus, it can be reasonably assumed that the acquisition of this aberrant 
G6PDH by single cells and foci is the probable expression of mutational 
changes which have occurred in certain hepacotytes of rats exposed to 
DENA, and has been favoured, or accelerated, by its subsequent adminis­
tration.
After three days of exposure to PB following DENA single liver cells and 
a few foci displaying enzyme abnormalities were found in the rats pre­
treated with DENA. These altered hepatocytes had also acquired aerobic 
G6PDH, were y-GT positive and some of them retained GSH. An increasing 
number of foci of altered cells was observed as the experiment progressed. 
In addition to the acquisition of y-GT and aerobic G6PDH activities, 
many foci showed a sustained anaerobic G6PDH activity. Total G6PDH and 
both I and IIpathways were markedly enhanced. This reflected respec­
tively a stimulated microsomal activity and an increased production of 
NADPH and ribose for synthetic processes (Chayen et al., 1973). In 
conformity with published observations (Bannasch, 1968 ; Epstein et al., 
1967 ; Bannasch et al., 1979) many foci accumulated glycogen.
The y—GT positive foci induced in small numbers after exposure to PB 
alone, were always of the clear cell type and sometimes retained glycogen. 
Their low incidence and relative long latency were in agreement with 
previous publications (Williams et al., 1984 ; Pugh and Goldfarb, 1978 ; 
Pereira et al., 1984). Similar and additional enzyme modifications were 
observed in the more advanced liver lesions, hyperplastic nodules and 
hepatocellular carcinomas.
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The mechanism by which PB favours and accelerates the development of 
Y potential neoplastic cells is not yet understood. Must interest has 
been centered on the effects of promoters on cell membranes (Boyland,
1980 ; O'Brien, 1976 ; Boutwell, 1974 ; Yotti et al., 1979 ; Murray 
and Fitzgerald, 1979). Results of these investigations have shown the 
ability of tumour promoters to inhibit intercellular communications, 
particularly in fibroblast cell cultures. Similar effects have also 
been confirmed in liver cell cultures exposed to PB (Williams, 1980) 
and DDT (Williams et al., 1981). These "in vitro" results could indicate 
a possible mechanism for the "in vivo" promotion of initiated cells.
It has been shown in both mouse and rat liver tumours that PB affects 
the activity of several membrane associated enzymes namely y— GT, ATPase 
(Williams et al., 1980 ; Ward, 1981) and 5 '-Nase (Butler and Hempsall, 
1981). The changes observed in the two membrane-related enzymes, tested 
in the present experiment, 5'-Nase and y-GT appear in conformity 
with this pattern.
As described elsewhere 5'-Nase activity was substantially depressed in 
most focal and nodular lesions. In contrast, the hepatocellular 
carcinomas exhibited sometimes slight increases, or marked losses in 
5'-Nase. These changes occurred either in different tumours or within 
the same tumour. .
5'-Nase has been demonstrated to be involved in the recycling of cell 
membranes (Stanley et al., 1980). As much as 50 % of the total 5'-Nase is 
found inside the cell. The intracellular pool of 5 '-Nase is contained in 
vesicles and is membrane bound (Houslay and Stanley, 1982). A large body 
of evidence from a variety of studies support the notion that biological 
membranes are in a highly dynamic state. The most frequently described 
movement is between cell surface and lysosomes, endoplasmic reticulum 
and Golgi apparatus. It seems likely that in many cases the principal 
means of membrane uptake is via coated vesicles, whether this occurs at 
the cell surface during receptor mediated endpcytosis or at endoplasmic
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reticulum during the transport of newly synthesized secretory protein.
This scheme of membrane movement is of prime importance in the export 
and import of proteins. Thus, the well documented depression in 5'-Nase 
activity, observed in some areas of hepatocellular tumours and related 
lesions, might reflect an abnormal functioning of this process.
The true function of 5'-Nase remains obscure. Its distribution and its 
cellular localization as an ectoenzyme has led to suggestions of invol­
vement in nutrition, nucleotide scavenging or adenosine production 
(Stanley et al., 1982). However in liver cells there is evidence against 
its involvement in the production of adenosine (Sasaki et al, 1983).
Its cellular orientation, a membrane protein whose catalytic site is 
located at the external face of the plasma membrane, its substrate Km 
and inhibition by intracellular nucleotide concentrations argue against 
its participation in a cycle between AMP and adenosine which rapidly 
increases the concentration of adenosine extracellularly to act as local 
hormone. A further hypothetical function is an involvement in the 
control of cell growth and differentiation. Fluctuations in 5 '-Nase 
content have been observed in different stages of the cell cycle and 
during cell maturation in various cell types (Sivak et al., 1972 ;
Rodan et al., 1977 ; Graham, 1979 ; Bastian et al., 1984). It has been 
observed that in rat liver plasma membrane, 5'-Nase can act in concert 
with other membrane enzymes to degrade RNA (Yannarell and Aronson,
1977). The suggestion that exogenous nucleic acid can control diffe­
rentiation was proposed by Niu and coworkers (1974). If this is the 
case then the reduced levels of 5'-Nase and related, enzymes in neoplastic 
cells would allow them to be more susceptible to environmental influences 
which stimulate their growth and proliferation.
Reports in the literature on y-GT in experimental rat liver cancer are 
abundant (Pugh and Goldfarb, 1978 ; Cameron et al., 1978 ; Fiala et al., 
1976 ; Pitot et al., 1978 ; Farber et al., 1979). In the overwhelming
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majority of these studies, islands of cells considered as potentially 
neoplastic, developed soon after exposure to carcinogens. These are not 
recognizable on the basis of morphology on histologic sections alone but 
are clearly distinguishable when stained for y-GT. However, many adult 
tissues such as kidney (Albert et al. , 1970), intestine (Adjarov et al., 
1979 ; Marathe et al., 1979), pancreas (Albert et al., 1969, 1970), 
mammary gland (Dawson et al.,1979) and endothelial cells of brain 
capillaries (Albert et al., 1966) contain highly active y—GT, thus it 
cannot be implied that y-GT activity is unique to neoplastic tissue. 
Furthermore, evidence is available indicating that potential tumour cells 
lacking y-GT give rise to some hepatocellular tumours (Pitot 
et al., 1978). On the other hand, the frequency of y-GT positive 
phenotypes of the presumed preneoplastic lesions and unequivocal tumours, 
resulting from widely differing protocols is very high, and this fact, 
suggests an important role, if not a strict requirement for this enzyme 
in liver tumour development during chemical carcinogenesis (Fiala et al., 
1976 ; Pugh and Goldfarb, 1978 ; Salt et al., 1980 ; Hirota and Williams, 
1979 ; Enomoto and Farber, 1982 ; Goldsworthy et al., 1984).
Enhanced y-GT is assumed to be one of the key factors for the growth 
advantage of neoplastic cells (Farber, 1980 ; Laishes et al., 1978).
Normal hepatocytes contain high GSH-S-transferases and cysteinyl-glycinase 
levels (Phares and Vanderlaan, 1979) but lack y-GT. In HTC cells, a 
cultured hepatoma cell line, all three enzymes are present, suggesting 
that these cells may be more competent than normal hepatocytes to 
detoxify carcinogens (Vanderlaan and Phares, 1981). Further support for 
this idea comes from Demi and Oes ter le study (1980) in which both, y— GT 
and GSH levels were shown to be increase in the same foci of cellular 
alteration.
It has been proposed that the various steps of GSH conjugation occur in 
different zones of the hepatic lobule (Hughey et al., 1978 ; Chasseaud,
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1976 ; Chasseaud, 1979). Hepatocytes having constitutive y-GT, might be 
freed from the suggested need for tissue cooperation (Vanderlaan and 
Phares, 1981). Moreover, at least one form of the GSH-S-transferases, 
GSH-S-transferase A, is inhibited by the conjugated GSH product (Pabst 
et al., 1974). Thus, the rapid break-down of GS-con jugate by y-GT would 
facilitate the continuation of the initial conjugation reaction. While 
most of the hyperplastic nodules retained GSH, the malignant tumours 
always showed low levels of this tripeptide. Two processes are probably 
responsible for the substantial depletion of GSH in the malignant tumours. 
First, a highly active GSH conjugation pathway which is related to the 
enhanced metabolism of neoplastic tissue. Evidence for this is provided by 
the observation of significant increases in the activities of y—GT and all 
types of G6PDH paralleled by low GSH concentration. And second, deficiencies 
in GSH synthesis as a consequence of an impaired blood supply. The large 
areas of necrosis found within the malignant tumours support this idea.
The interaction of abnormal vascular structures and absence of portal 
triads (Farber, 1980 ; Pitot and Sirica, 1980) and the fast growth 
capacity of tumour cells are probably responsible for this impaired 
blood flow.
Ultrastructural changes consistent with many of the cytochemical modi­
fications described above were found in the hepatocellular carcinomas 
examined. The most important of these changes was the presence of 
abundant smooth endoplasmic reticulum, together with irregular strands 
of rough endoplasmic reticulum and dispersed ribosomes. These morpho­
logical alterations have been consistently reported, in hepatocellular 
tumours induced by many carcinogens (Butler and Jones, 1978 ; Svoboda,
1964 ; Merkow et al., 1969 and 1972) and in spontaneous human liver 
tumours (Ghadially and Parry, 1966 ; Ma and Blackburn, 1973 ; O'Connor 
et al., 1972). These cytoplasmic changes were associated with the 
presence of prominent clear nuclei, exhibiting large nucleoli
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sometimes marginated and apparently in continuity with the nuclear 
envelope. Nucleolar margination is a sign of increased protein synthesis 
and is commonly found in a variety of tumours (Ghadially, 1982).
Cell resistance is a property that appears to be particularly important 
in the development of altered cells. Changes in cell membranes are 
thought to be involved in this phenomenon. Hyperplastic nodules show 
deficient uptake of 2-acetylamino-fluorene (Farber et al., 1976) and 
iron (Williams, 1980).
According to Astrom and associates (1983) a further factor involved in 
cell resistance seems to be ergastoplasmic membrane alterations. Studies 
in which the activity of xenobiotic metabolizing enzymes was determined, 
in both nodular and neoplastic tissue revealed considerable decrease in 
the concentration of microsomal cytochromes accompanied by a depressed 
activity of many enzymes related to the MFO system. Diminished ability 
of genetically altered cells to metabolise xenobiotics and hence to 
generate potentially toxic metabolites, has been claimed as an essential 
prerequisite for selection and ultimately proliferation of initiated 
cells (Cameron et al., 1976 ; Farber, 1980 ; Williams, 1980 ; Gravela 
et al., 1975 ; Astrom et al., 1983 ; Kaneko et al. 1980). In contrast 
with this data, the majority of the hepatic lesions induced by DENA and 
promoted by PB showed a considerably increased activity of G6PDH pathway I, 
Anaerobic incubation of G6PDH without the intermediate hydrogen acceptor 
phenazine methosulphate (PMS), pathway I, generates reducing equivalents 
at a redox potential accessible to the NADPH diaphorase system. This 
system (described in more details elsewhere) is related to the group 
of cytochromes P-450 and P-448. Furthermore, when immunocytochemical 
techniques were performed using antibodies directed against both cyto­
chromes, positive results were observed in some of the hyperplastic 
nodules and hepatocellular carcinomas. P-450 (phénobarbital inducible 
form) was the most intensely staining isoenzyme but was restricted, in
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the hepatocellular carcinomas, to areas of cells showing a higher degree 
of differentiation. These areas also stained strongly for various forms 
of G6PDH, specially pathway I. The more anaplastic areas which showed a 
positive although variable distribution of G5PDH pathway I did not react 
for cytochrome P-450. Staining for the P-448 form was generally weaker 
than in controls and also very heterogenous in all the liver lesions 
examined.
There is evidence to suggest that foci of cellular alteration, hyper­
plastic nodules and hepatocellular carcinomas respond to PB treatment.
The intensity of the response varies according to the timing, dose level 
and length of the exposure. Feo and associates (1978) demonstrated the 
ability of PB to stimulate microsomal enzymes of hyperplastic nodules 
and hepatocellular tumours induced by DL-ethionine. After a single PB 
injection, cytochrome P-450 concentrations and aminopyrine-N-demethylase 
activity increased significantly. However, the levels attained, especially 
in the malignant tumours, were below those of the PB treated controls 
and the surrounding non nodular tissue. These results were confirmed 
both by Kaneko and coworkers (1980) in hyperplastic nodules and hepato­
cellular carcinomas previously induced by 3'-methyl 4-dimethylaminoazo- 
benzene, and more recently by Sirica ans associates (1984), using DENA as 
carcinogen.
Schulte-Hermann and coworkers (1984) reported the presence of cytochro­
mes P-450 in nodular and neoplastic lesions induced by the combination 
of pretreatment with different carcinogens and subsequent exposure to 
PB. By means of immunocytochemical and biochemical techniques, these 
authors showed that hyperplastic nodules stained strongly and uniformly 
for cytochrome P-450. Furthermore, the cytochrome P-450 present 
was shown to be active as indicated by its capacity to demethylate 
benzphetamine and ethylmorphine. They also reported that 4 weeks after 
cessation of PB treatment, the hyperplastic nodules and tumours were 
devoid of cytochrome P-450 and any related enzyme activity. In disagre­
ement with these observations, in the present study, the enzymic changes
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related to the microsomal cytochromes persisted in the liver lesions up 
to twenty six weeks after withdrawal of the PB treatment. This finding was 
unexpected, as was the persistence of a sustained changes compatible 
with increased Phase II metabolism in the liver lesions of the same 
groups of rats. A widely accepted hypothesis is that as result of the 
promotion phase the initiated hepatocytes remain trapped in a foetal 
state (Curtin and Snell, 1983). However, it is well known that foetal 
cells are unable to detoxicate many xenobiotics effectively, yet in our 
study the majority of the neoplastic cells forming the hepatocellular 
lesions showed evidence of active detoxicating processes. A characte­
ristic feature of neoplasms is varying degrees of differentiation, 
neoplastic cells not only proliferate but differentiate ; neoplastic 
cells often retain the ability to be transformed into reasonably 
differentiated cells (Farber, 1973).
In our study, there is good evidence that a large population of the 
initiated cells, when promoted with PB not only acquired the ability to 
proliferate but also develop many of the characteristics of normal cells 
exposed, to enzyme inducers. However, the cytochemical changes elicited 
in the hepatocellular lesions after DENA, although similar to those 
observed in the normal cells are of greater magnitude and irreversible. 
Induction of a different form of microsomal cytochrome may be one aspect 
of this process. Another may be that neoplastic cells do not possess 
the feed-back mechanism present in normal cells, which allows enzyme 
levels to turn to basal activity, once the PB stimulus has been withdrawn. 
These characteristics are difficult to consider as normal differentiation, 
and must be regarded as aberrant. In addition, these altered and tumoral 
cells showed features of an obviously less interpretable form of dif­
ferentiation such as acquisition of aerobic G6PDH and ability to invade 
adjacent tissues and to produce métastasés.
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Heterogeneity of acid phosphatase activity has been observed by different 
groups in nodules and liver tumours (Butler and Hempsall, 1981 ; Basso 
et al., 1982 ; Tret'iakov et al., 1982 ; Fiszer-Szafarz and Szafarz,
1983). In the large liver lesions, examined in this study, this 
lysosomal enzyme was markedly reduced, irregularly distributed and 
occasionally contained in large autophagic vacuoles. There was no 
evidence of increased secretion of lytic enzymes by the neoplastic 
cells. This has been proposed as one of the mechanisms by which 
neoplastic cells act on neighbouring cells or tissue matrix, in order to 
invade local or distant tissues (Sylven and Malmgren, 1957 ; Willighagen 
and Planteijdt, 1959).
The implication of the reduction of acid phosphatase activity observed 
in our study is obscure. It might be related to a mixed population of 
cells which have attained varying degrees of differentiation (Butler and 
Hempsall, 1981), or to the existence of several molecular form which 
hydrolyze different substrates (Tret'iakov et al., 1982).
An irregular distribution or absence of glycogen is a common feature of 
hyperplastic nodules and hepatocellular carcinomas (Bannasch and Muller, 
1964 ; Bannasch, 1968). Hacker and associates (1982) suggested a 
deviation from glycogen metabolism to glycolysis and to the pentose 
shunt occurring in the hyperplastic nodules as an explanation of this 
change. Increases in both forms G6PDH support this view.
Low levels of a-GPDH activity was a constant feature of all the 
hepatocellular lesions examined. In the absence of any sign of toxicity 
the decrease a-GPDH activity might be interpreted as resulting from a 
general genetic reprogramming which would advantage those enzymes 
pathways involved in metabolic processes specific to neoplastic cells.
It is well established that during carcinogenesis many of the increasing 
enzymes are the foetal type (dedifferentiation) whereas the adult enzymes 
such as a-GPDH usually decrease in these circumstances (Curtin and 
Snell, 1983 ; Farber, 1976 ; Enomoto et al., 1978).
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2.2.3. Conclusion
The DENA-PB treatment schedule produced most of the sequence of changes 
recorded in the literature for liver carcinogenesis. Histologically 
foci of altered cells were first seen after 4 1/2 weeks of PB treatment, 
thereafter their incidence increased rapidly. Subsequently, nodules and 
hepatocellular carcinomas quickly developed, at a time when similar 
lesions are not prone to occur in untreated rats. Also the quantitative 
and qualitative cytochemical heterogeneity of foci hyperplastic nodules 
and carcinomas observed by many investigators (Scherer et al., 1972 ; 
Scherer and Emmelot, 1975 ; Scherer and Emmelot, 1976 ; Pitot, 1977 ;
Pitot et al., 1978 ; Sirica et al., 1978 ; Ogawa et al., 1980 ; Ogawa 
et al., 1979 ; Pugh and Goldfarb, 1978) was confirmed. There was no 
evidence of remodelling of nodular and focal lesions, as described in 
rats exposed to genotoxic compounds (Tatematsu et al., 1983 ; Farber, 1980) 
In addition many of these nodules, although clearly demarcated from the 
surrounding liver, showed a certain degree of pleomorphism. These 
findings strongly suggest that such hepatocellular lesions are already 
neoplastic. The persistence of enzyme abnormalities in foci and nodules 
on cessation of treatment and the acquisition of aberrant G6PDH support 
this view. In this context the results for y—GT and aerobic G6PDH 
are very relevant. -y-GT was detected in foci arising in controls at the 
same time that the foci of altered cells were seen in histological 
sections. A slightly higher incidence and a shorter latency of y-GT 
positive foci was observed in the group receiving PB only. On the other 
hand, most of the foci, hyperplastic nodules and carcinomas, induced 
by DENA followed by PB, were positive for y-GT, although exceptions 
were not uncommon. These observations are in keeping with reports in the 
literature for such agents (Williams and Furuya, 1984 ; Fiala et al.,
1972 • Pugh and Goldfarb, 1978 ; Peraino et al., 1984 ; Pereira et al.,
1984). However, no positive foci for aerobic G6PDH were seen in the 
untreated, control or in the groups treated with PB alone, while they
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were numerous in the DENA pretreated rats promoted with PB. Moreover,
they acquired aberrant G6PDH before the PB treatment began, also some 
hyperplastic nodules showed aberrant G6PDH and all the carcinomas did 
so. In view of these results aerobic G6PDH appears to be a useful marker 
for putative preneoplastic hepatocytes, at least for experiments in 
which genotoxic compounds are utilised. The intrinsic nature of aerobic 
G6PDH appears worth of further investigation, for example : in this 
phenomenon the result of enzymic retrodifferentiation, and therefore, 
aberrant G6PDH the expression of foetal isoenzymes?
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Table 2.5
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic total
glucose-6-phosphate dehydrogenase
CONTtOL DENA
PP MZ CL PP -- kZ CL PP MZ CL
WEEK 4 22.07*1.21 18.07*1.07 15.51*0.33 - - -
X
27.3410.95
X X
24.97*1.16
X X
23.80*0.65
CONTROL PHeNORARlITAL DENA * PB
PP MZ CL PP HZ CL PP MZ CL
WEEK 4 1/2 30.87*1.64 26.33*1.49 21.68*1.48 35.74*1.88 31.96*1.41
XX
30.76*2.36
X
36.98*1.17
X
32.18*9.95
. X X
30.15*1.18
WEEK 6 33.91*2.35 26.39*1.51 21.16*0.75
X X
47.71*2.42
X X
38.05*1.51
XX
32.42*0.72
X X
51.68*4.32
X X
38.35*1.32
X X
33.42*1.34
WEEK 8 33.05*2.19 26.78*1.91 22.18*0.84 37.00*0.52 29.81*1.18 23.47*1.81 35.57*2.37 29.54*1.91
X
26.79*1.76
WEEK 17 26.50*1.28 21.77*0.90 19.04*0.42
X X
36.82*0.75
X X
31.94*0.70
X X
27.42*0.28
X X
36.9310.61
X X
31.77*2.38
XX
27.7310.34
WEEK 30 27.12*1.01 21.12*1.14 17.70*0.73
X
32.64*0.95
X X
28.5710.88
X X
24.6810.58
X
34.0110.77
X X
28.78*0.88
X X
25.36*1.12
WEEK 45 44.08*3.56 34.12*1.64 26.86±2.02
X X
60.6712.49
X X
19.8413.99
X X
42.0414.60
X X
61.62*2.39
X X
48.4114.68
X X
41.6113.50
WEEK 56 38.74*1.93 30.86*1.27 21.16*1.61 - - - 49.28*3.76 39.76*2.88
X X
34.67*2.00
WEEK 71 39.18*3.69 31.98*1.36 25.98*2.23 - - -
•
55.67
•
44.03
•
34.45
X X X REVERSIBILITY
WEEK 45 54-.22t7.03 38.7415.83 31.15*2.59
WEEK 56 37.28*2.11 32.53*1.41 22.89*1.55
X significantly different from control at 51 
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values standard deviation of 3 x 12 measurements carried out in three 
hepatic lobular zones (PP: periportal, MZ; midzonal, and CL: centrilobular) of all rats of each group,
expressed in mean integrated extinction units x ICO.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Table 2,6
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic
glucose-6-phosphate dehydrogenase pathway I of liver cells
CONTROL DENA
PP HZ CL PP HZ CL PP HZ CL
WEEK 4 8.44t0.23 9.86*0.80 11.46*0.57 - - -
X X
12.33+0.77 14.76+2.18
XX
19.05+0.76
CONTROL PHENOBARBITAL DENA + PB
PP HZ CL PP HZ CL PP HZ CL
WEEK 4 1/2 8.42+0.62 9.03+0.48 11.20+0.66
X X
11.23+0.68
X X
13.40+0.35
X X
16.35+1.25
X X
II. 12+0.73
X X
13.31+0.42
X X
15.64+1.01
WEEK 6 8.68+0.30 10.12+0.44 11.67+0.55
X X
14.57+0.74
X X
16.26+0.81
X X
18.98+1.32
X X
14.51+0.66
X X
16.58+0.28
XX
19.43+0.48
WEEK 8 7.91+0.32 9.65+0.85 II.95+0.61
X X
13.90+1.07
X X
17.68+1.50
X X
21.07+1.79
X X
13.97+1.24
X X
17.66+2.28
X X
22.31+1.84
WEEK 17 8.34+0.31 II.00+0.17 13.01+0.53 9.65*0.53
X
13.45*0.44
X X
17.25*0.53
X
10.42*0.65
X
14.04*0.36
XX
18.44*0.87
WEEK 30 8.15+0.48 10.94+0.45 12.43+0.63
X
9.59+0.64 12.35+0.32
X X
18.59+0.56
X
10.34+0.85 12.86+0.68
X X
18.37+1.32
WEEK 45 9.92+0.71 II.29+1.13 13.75+0.85
X
12.79*0.65
X X
14.76*0.84
X X
18.59*0.76 10.91*0.65 13.71*1.42 17.66*1.44
WEEK 56 7.06+0.47 8.64+0.62 10.80+0.54 - - 13.35*1.16
X X
15.62*1.37
X X
19.32*1.35
WEEK 71 10.26+0.59 11.72+0.78 13.86*1.15 - - -
a
13.77
•
15.74
■
18.45
X X X REVERSIBILITY
WEEK 45 I0.64t0.50 11.98*0.78 14.71*1.74
WEEK 56 7.25+0.36 8.79*0.94 11.90*0.31
X Significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values + standard deviation of 3 x 12 measurements carried out in thre 
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group,
expressed in mean integrated extinction units x 100.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Table 2.7
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic
glucose—6—phosphate dehydrogenase pathway II of liver cells
CONTROL DENA
PP HZ CL PP MZ CL PP MZ CL
WEEK 4 13.63+1.23 8.85+1.20 4.06*0.25 - - - 15.01*1.03 10.94*1.65 4.75*0.24
CONTROL PHENOBARBITAL DENA + PB
PP MZ CL PP HZ CL PP HZ CL
WEEK 4 1/2 22.62+1.32 17.29+1.41 10.47+0.99 24.51+1.39 18.55*1.17
XX
14.44+0.49 26.24+1.37 18.88+0.78
XX
14.51+0.62
WEEK 6 25.24+2.33 16.52+1.45 9.48+0.49
XX
33.14+2.53
XX
21.79*1.99
X X
13.44+1.3
XX
37.17+2.7
X X
21.77*1.8
X X
13.99+1.1
WEEK 8 25.14+2.24 16.87+1.60 11.04+1.18 23.10+2.23
X
12.76*1.00
X
6.21*1.37 21.60*2.24 11.87+2.47
XX
4.41+0.69
WEEK 17 18.16+0.47 10.67+0.83 6.03+0.55
X X
27.16*0.85
XX
18.50*0.51
X X
10.16*0.80
X X
26.51+0.93
X X
17.73+1.46
X X
9.30+1.11
WEEK 30 18.97+1.34 10.17+0.80 5.27+0.35 23.06*1.16
XX
16.21*0.76 6.03*0.73
X
23.67*1.30
X X
15.92*1.11
X
6.99*0.26
WEEK 45 34.15+3.35 22.81+0.98 13.11+1.46
XX
47.90+2.75
XX
35.00*3.76
X X
23.46*4.25
XX
50.35*2.12
X X
34.73+3.32
X X
23.56+1.81
WEEK 56 31,71+2.00 22.27+1.65 10.35+0.99 - - - 35.92+3.30 24.15+2.55
X X
15.35+1.84
WEEK 71 27.48+1 .20 19.85+0.90 11.42+1.36 - - 41.89
s
28,29
■
16.00
X X X REVERSIBILITY
WEEK 45 43.57+6.90 26.76*6.41 16.43*3,60
WEEK 56 30.03+1.81 23.73*1.65 10.99*1.43
X Significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of A rats (unless otherwise 
stated). The figures represent mean values _+ standard deviation of 3 x 12 measurements carried out in three 
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group,
expressed in mean integrated extinction units x 100.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Table 2.8
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic
gamma-glutamyltransferase
CONTROL DENA
PP MZ CL PP MZ CL PP HZ CL
WEEK 4 68.20* 5.34 - - - - -
XX
106.9 * 7.40 - -
CONTROL PHENOBARBITAL DENA ♦ PB
PP MZ CL PP M Z CL PP HZ CL
WEEK 4 1/2 87.73* 2.00 - - 94.56*6.00 - - 85.55*16.30 - -
WEEK 6 54.47* 5.72 - -
X X
92.56*6.01 - -
X X
99.27* 3.84 - -
WEEK 8 58.97* 5.70 - -
XX
53.05*8.84 -
X X
106.45*20.50 - -
WEEK 17 68.47* 5.35 - - 73.50*7.54 - -
XX
10.50* 7.43 - —
WEEK 30 67.60* 4.80 - - 77.25*9.67 - . -
X X
91.07* 7.92 - -
WEEK 45 86.27* 4.82 - -
X
99.80*9.0 - - -
XX
115.5 * 9.79 - . -
WEEK 56 57.17* 6.27 - - - -
X X
89.45*12.54 - -
WEEK 71 69.79*14.65 - - - . - -
a
84.85 - -
BO C REVEISIBILITT
WEEK 45 98.80* 8.82 - -
WEEK 56 70.11* 7.15 • -
X Significantly different from control at 5%
XX Significantly different from control at 1%
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values + standard deviation of 12 measurements carried out in the
periportal hepatic lobular zone of all rats of each group, expressed in mean integrated extinction units
X 100.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
178
Table 2.9
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic glutathione
concentration of liver cells
CONTROL
PP HZ CL PP MZ CL PP MZ CL
VKEX 4 131.0 + 8.44 134.8 + 1.67 101.85+ 8.83 - - - 132.69+12.35 134.46+ 9.90 99.99+ 8.10
CONTROL PHENOBARBITAL DENA + PB
PP CL PP MZ CL PP HZ CL
WEEK 4 1/2 73.88+ 2.55 80.75+ 8.77 57.00+ 2.79 68.61+ 2.62 73.88+ 3.46
XX
29.02+16.12 66.50+ 4.74 70.72+ 2.63 27.97+ 3.18
WEEK 6 64.92+ 2.21 71.25+ 7.11 54.88+ 2.96 61.22+ 5.80 63.33+ 5.30 26.38+ 3.66 58.05+10.83 60.66+ 9.77 23.26+ 5.27
WEEK 8 64.40+ 3.29 63.55+4.51 62.50+ 2.39 59.70+13.50 38.55+
XX
3.00 23.52+
XX
1.39 61.38+ 6.12 41.83+ 5.36 18.25+23.44
WEEK 17 76.35+ 2.90 73.33+ 6.33 49.00+ 4.37 64.38+ 8.00 44.05+ 8.66 34.33+
X X
6.39 70.63+ 6.85 54.77+ 6.31 32.43+ 3.17
WEEK 30 62.18+ 4.35 64.53+ 1.33 40.88+ 5.94 59.33+ 9.58 57.38+ 7.16 13.50+
XX
5.00 59.20+17.85 53.55+12.23 18.16+ 7.22
WEEK 45 79.69+ 3.87 80.50+ 4.69 59.60+ 3.35 60.83+ 2.83 63.83+ 4.19 21.93+
X X
2.68 52.67+ 8.77
X X
56.66+ 6.33 20.86+ 3.02
WEEK 56 72.17+ 2.22 73.83+ 6.60 53.83+ 5.18 - - -
X X
48.52+ 5.19
X X
51.20+ 9.05 21.33+ 4.30
WEEK 71 70.72+ 5.50 76.03+ 4.96 51.40+ 4.70 - - -
■
37.38
•
46.55 17.55
W M K  45 72.25+11.42 71.66+13.53 42.10+ 6.30
W m  56 63.20+ 8.22 65.86* 7.77 42.40+ 3.99
X Significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values + standard deviation of 3 x 12 measurements carried out in three 
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group,
expressed in mean integrated extinction units x 100.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover 
for 27 weeks.
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Table 2.10
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB); and phénobarbital alone (PB) on the activity of hepatic
alpha-glycerophosphate dehydrogenase NAD dependent of liver cells
CONTROL DENA
PP MZ CL PP MZ CL PP HZ CL
WEEK 4 - - - - - - - - -
CONTROL PHENOBARBITAL DENA + PB
PP MZ CL PP MZ CL PP MZ CL
WEEK 4 1/2 31.90+2.44 27.00+8.48 21.60+1.21 31.63*1.95 26.60*0.97 21.57*1.13 31.30*2.50 26.30+2.22 21.63*0.99
WEEK 6 30.90+1.00 27.26+2.24 21.65+1.33 32.18+1.30 26.31+0.87 21.64+1.30 32.12*0.99 26.77+1.51 22.61+1.56
WEEK 8 28.46+3.31 26.24+3.03 29.72+1.00 32.35*1.44 28.43*1.27 22.25*2.53 30.83*2.81 27.70+2.09 20.98*0.97
WEEK 17 30.74*2.00 26.45*1.44 21.8 *1.37 31.99*1.08 27.20+2.59 21.63*1.33 31.44+1.67 26.78+0.61 20.46+1.04
WEEK 30 28.10*1.88 24.76*1.21 20.13*1.47 28.1 *1.13 24.21*1.17 18.82*0.45 27.48*0.88 23.85+1.01 17.82*0.79
WEEK 45 45.55+4.10 36.72+4.75 31/24+1.91 47.23*2.63 34.25+1.37 29.22*2.40 45.32*2.20 34.50+1.25 31.33*0.61
WEEK 56 38.24+3.00 30.80+2.01 23.98+2.21 - - - 35.97+1.03 29.78+2:87 23.08+1.88
WEEK 71 35.15+4.95 30.40+2.11 25.41+3.00 - - , - 32.35
•
29.13
s
28.89
X X X REVERSIBILITY
WEEK 45 52.12*6.66 35.58*2.10 31.35*1.17
WEEK 56 37.-90*2.95 30.16*1.84 24.0 *1.53
X significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values + standard deviation of 3 x 12 measurements carried out in thre 
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group,
expressed in mean integrated extinction units x 100.
XXX Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Table 2.11
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic
5’-nucleotidase of liver cells
CONTROL DENA
PP MZ CL PP HZ CL PP MZ CL
WEEK 4 43.92+3.43 48.20+4.31 54.85+3.09 - - - 52.98+9.70 58.71+4.56 70.32* 6.26
CONTROL PHENOBARBITAL DENA + PB
PP HZ CL PP HZ CL PP HZ CL
WEEK 4 1/2 36.71+3.24 42.81+3.63 53.20+3.45 33.38+1.56 41.98+3.01 49.22*1.41 36.57*2.67 44.61*4.64 52.53* 2.36
WEEK 6 37.63+1.69 43.84+0.62 53.53+1.49 39.83*2.06 47.65*2.50 58.09*4.43 40.36*1.70 50.35*2.13 59.07* 3.69
WEEK 8 35.22+3.78 39.61+4.51 51.38+5.76 40.95+2.7! 51.64+3.59
X X
64.02*4.12 38.16*2.21 56.07*5.30 74.41* 7.33
WEEK 17 32.91+0.65 37.70+0.99 46.34+1.11 39.5 +1.15 47.33+1.22 55.24*3.05 42.67+3.55 55.35+8.30
XX
78.73+13.95
WEEK 30 27.85+1.18 32.32+1.87 39.11+2.40 28.49+1.76 31.93+1.41 42.21+2.21 29.03+1.68 33.53+0.76 45.45+ 2.02
WEEK 45 33.43+1.26 37.29+1.32 46.30+1.90 30.76+0.87
X
24.10+3.51 25.80*6.44 32.03*1.89
X
23.84+5.46
XX
23.05* 5.30
WEEK 56 33.37+2.47 38.86+2.96 48.50*2.96 - - - 31.72*2.99 37.15*2.86 46.06* 3.28
WEEK 71 34.80*3.62 43.52+2.82 50.26+3.30 - - -
s
35.87
•
42.59
•
50.12
xzz REVERSIBILITY
WEEK 45 30.93*1.44 36.15*1.14 45.63*0.96
WEEK 56 31.89*1.11 37.53*3.63 48.21*1.89
X Significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values +_ standard deviation of 3 x 12 measurements carried out in three 
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group,»
expressed in mean integrated extinction units x 100.
X X X  Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Table 2.12
Effect of diethylnitrosamine (DENA) treatment followed by phénobarbital
(PB), and phénobarbital alone (PB) on the activity of hepatic acid
phosphatase of liver cells
CONTROL DENA
PP HZ CL PP HZ CL PP HZ CL
WEEK 4 55.53+4.9 58.24*3.7 58.44*2.20 - - - 56.11+3.3 56.18*1.6 56.06*2.0
CONTROL PHENOBARBITAL DENA + PB
PP HZ CL PP HZ CL PP HZ CL
WEEK 4 1/2 58.87*5.14 58.79*3.99 57.37*4.73 58.48*4.55 57.79*2.97 56.89* 1.91 62.20*3.00 54.6 *3.05 60.20*4.31
WEEK 6 56.19+2.37 56.18+4.60 53.37+2.43 67.97+7.75 66.73+3.25 62.0 ♦ 3.24 69.14+1.52 67.11+1.7 63.86*7.1
WEEK 8 70.6 +6.63 69.0 +6.17 68.0 +7.08 72.24*3.00 71.50*2.05 70.06* 3.93 71.0 *2.22 74.93*4.35 79.95*6.36
WEEK 17 60.3 +2.67 61.11+2.75 60.0 +3.03 68.82+6.00 68.85+4.04 72.61+ 1.53 71.7 +2.01 72.43*2.3 72.67*5.63
WEEK 30 59.1 +3.44 60.46+3.57 59.88+4.71 60.06+1.95 60.44+2.18 59.58+ 2.00 60.24+3.80 62.27+1.50
X
92.44+3.99
WEEK 45 80.4 +4.7 71.92+8.35 68.26+2.1 82.59+5.66 68.6 +5.37 54.09*17.83 84.82*3.50 74.27+4.07 66.06+8.89
WEEK 56 74.14+5.44 72.82+4.8 74.41+4.5 - - - 76.96+8.4 77.26+5.70 95.0 +7.11
WEEK 71 76.41+5.41 73.93+3.26 75.6 +4.37 - - -
s
77.26
s
77.31
#
61.17
XXT REVERSIBILITI
WEEK 45 84.44*2.54 72.89*3.3 71.86*4.0
WEEK 56 77.17*4.53 75.72*4.66 77.58*3.50
X Significantly different from control at 5%
XX Significantly different from control at 1% 
s Only two rats
Each control and treated groups consisted of 5 rats ; each reversibility group of 4 rats (unless otherwise 
stated). The figures represent mean values standard deviation of 3 x 12 measurements carried out in three
hepatic lobular zones (PP: periportal, MZ: midzonal, and CL: centrilobular) of all rats of each group, 
expressed in mean integrated extinction units x 100.
X X X  Animals initiated with DNA were treated with PB for 13 and 26 weeks respectively and allowed to recover
for 27 weeks.
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Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA) 
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding 
for 71 weeks, on the activity of hepatic total glucose-6-phosphate 
dehydrogenase.
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#  Rmc# created only with diechylnicroaamine.
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained In Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
$  *  Only two rats
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Fig. 2.2
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic total glucose-6-phosphate dehydrogenase,
of rats initiated with diethylnitrosamine (DENA)
hh k s H .SHK5 EMCS S6WKS 7IHKSBWKS I7WK5
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control rats * standard deviation.
Animals initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.3
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
the activity of hepatic total glucose-6-phosphate dehydrogenase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.4
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA) 
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding 
for 71 weeks, on the activity of hepatic glucose—6—phosphate dehydrogenase 
pathway I
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#  Rati treated only with diethylnitroiaaine.
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
$ *  Only two rats
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Fig. 2.5
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic glucose-6-phosphate dehydrogenase
pathway I, of rats initiated with diethylnitrosamine (DENA)
.. 1/1
SGHK.5I7M <5 3(&*S
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained In Integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control rats *  standard deviation.
Animals Initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.6
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on 
the activity of hepatic glucose-6-phosphate dehydrogenase pathway I
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained In Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.7
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA) 
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding 
for 71 weeks, on the activity of hepatic glucose-6-phosphate dehydrogenase 
pathway II
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♦  Râts treated only with diethylnitrosamine.
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats ^ standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
$  $  Only two rats
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Fig. 2.8
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic glucose-6-phosphate dehydrogenase
pathway II, of rats initiated with diethylnitrosamine (DENA)
.. N
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7 U * 5BWKS
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control rats * standard deviation.
Animals initiated with DENA were treated with FB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.9
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on 
the activity of hepatic glucose-6-phosphate dehydrogenase pathway II
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.10
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA)
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding
for 71 weeks, on the activity of hepatic gamma-glutamyltransferase
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$  Ract created only wich diechylnicroaamine.
Average results from 12 measurements carried out in the periportal hepatic lobular zone of 
five treated rats. The measurements obtained in integrated extinction units xlOO, are 
expressed as percentage of 12 mean periportal readings of five control rats * standard 
deviation.
♦  $  Only two rats
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Fig/ 2.11
Effect of stopping oral administration of continuous 0,05% phénobarbital (PB)
feeding on the activity of hepatic gamma-glutamyltransferase, of rats
initiated with diethylnitrosamine (DENA)
SEHKS 7IHK5H.SHK5 GM(5
Average results from 12 measurements carried out in the periportal hepatic lobular zone of 
four treated rats (unless otherwise stated). The measurements obtained in integrated 
extinction units x 100 are expressed as percentage of 12 mean periportal readings of five 
control rats * standard deviation.
Animals initiated with DENA were treated with PB for 13 and 26 weeks respectively and 
allowed to recover for 26 to 28 weeks.
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Fig. 2.12
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
the activity of hepatic gamma-glutamyltransferase
I7WK5
Average results from 12 measurements carried out in the periportal hepatic lobular zone of 
five treated rats. The measurements obtained in integrated extinction units xlOO, are 
expressed as percentage of 12 mean periportal readings of five control rats * standard 
deviation.
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Fig. 2.13
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA)
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding
for 71 weeks, on hepatic glutathione concentration
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$  Rats treated only with diethylnitrosamine.
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
♦  *  Only two rats
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Fig. 2.14
Effect of stopping oral administration of continuous 0,05% phénobarbital (PB)
feeding on hepatic glutathione concentration, of rats initiated with
diethylnitrosamine (DENA)
.. 1/1
yWKS H.SWtS 7IWK5
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control <*ats * standard deviation.
Animals initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.15
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
hepatic glutathione concentration
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Average resulcs from 3x12 ■easurcaencs carried out In three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig" 2-16
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA) 
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding 
for 71 weeks, on the activity of hepatic alpha-glycerophosphate 
dehydrogenase NAD dependent
» «
a
S.SMCS EMCS 7IHKS
Average results fro* 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents fro* left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
>  *  Only two rats
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Fig. 2.17
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic alpha-glycerophosphate dehydrogenase
NAD dependent, of rats initiated with diethylnitrosamine (DENA)
. .  1/1
I7WK5
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control rats * standard deviation.
Animals initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
217
Fig. 2.18
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
the activity of hepatic alpha-glycerophosphate dehydrogenase NAD dependent
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrllobular) readings of five control rats ^ standard deviation.
Each group of histograms represents from left to right the three liver lobular zones : peri­
portal, midzonal and centrllobular.
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Fig. 2.19
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA)
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding
for 71 weeks, on the activity of hepatic 5'-nucleotidase
.. 1/1
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*  Rats treated only with diethylnitrosamine.
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained In Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
♦  *  Only two rats
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Fig. 2.20
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic 5'-nucleotidase, of rats initiated with
diethylnitrosamine (DENA)
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained In Integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, mldzonal and centrllobular) readings of five control rats * standard deviation.
Animals Initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right the three liver lobular zones : peri­
portal, mldzonal and centrllobular.
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Fig. 2.21
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
the activity of hepatic 5'-nucleotidase
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Average results from 3x12 maasuremaats carried out la three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained In Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
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Fig. 2.22
Effect of once weekly injection of 50 mg/kg of diethylnitrosamine (DENA)
for 4 weeks, followed by continuous 0.05% phénobarbital (PB) feeding
for 71 weeks, on the activity of hepatic acid phosphatase
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#  Rats treated only with diethylnitrosamine.
Average resulcs from 3x12 oeasureaenCs carried out la three hepatic lobular zones (periportal, 
mldzonal and centrllobular) of five treated rats. The measurements obtained In Integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, mldzonal and 
centrllobular) readings of five control.rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, mldzonal and centrllobular.
*  *Only two rats
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Fig. 2 . 2 3
Effect of stopping oral administration of continuous 0.05% phénobarbital (PB)
feeding on the activity of hepatic acid phosphatase, of rats initiated
with diethylnitrosamine (DENA)
N
7IHKSSEHKS
Average resulcs from 3x12 measurements carried out In three hepatic lobular zones (periportal, 
midzonal and centrllobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrllobular) readings of five control rats *  standard deviation.
Animals initiated with DENA were treated with PB for 13 and 26 weeks respectively and allowed 
to recover for 26 to 28 weeks.
Each group of histograms represents from left to right Che three liver lobular zones: peri­
portal, midzonal and centrllobular.
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Fig. 2.24
Effect of continuous 0.05% phénobarbital (PB) feeding for 45 weeks on
the activity of hepatic acid phosphatase
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Average resulcs from 3x12 stemsuremeocs carried cue in three hepatic lobular zones (periportal, 
midzonal and centrllobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrllobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrllobular.
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Fig. 2*25 Photographs of frozen liver section stained with PAS (x 125),
a) Section taken from the liver of a control rat.
b) Section taken from a rat pretreated with DENA and subsequently with 
PB for four weeks# In this section there is a midzonal—centrilobular 
loss of glycogen#
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Pig. 2.26 Frozen liver section stained with ORO (x 125). Mild centri- 
lobular loss of lipid, with a tendency for lipid to accumulate 
midzonal to periportal. Rat initiated with RENA and treated with 
PB for two weeks.
226
&Fig. 2 . 2 7  Frozen liver section stained with ORO 270). Rat 
pretreated with DENA and exposed to PB for thirteen weeks. There is 
a diffuse distribution of lipid throughout the lobule.
227
Pig. 2.28 Frozen liver section of a rat pretreated with D M A  and 
subsequently fed PB for three days. Focus of cellular alteration 
staining for aerobic G6PDH (z 270).
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Fig. 2 . 2 9  Frozen liver section showing a focus of cellular alteration 
staining for y-GT. Rat pretreated with RENA followed by PB feeding
(z 2 7 0).
229
kFig. 2 . 3 0  Focus of cellular alteration showing retention of GSH. 
Frozen liver section of a rat pretreated with RENA and subsequently 
fed PB for four weeks (z 12$).
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Fig. 2 . 3 1  Foci of cellular alteration showing accumulation of 
glycogen. Frozen liver section stained with PAS of a rat pretreated 
with RENA and having received PB continuously for thirteen weeks
(% 3 2 5 ).
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Pig. 2 . 3 2  H and E stained section of a hyperplastic nodule from a 
rat initiated with DENA and promoted with PB for thirteen weeks
(z 1 2 5 ).
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Fig. 2.33 Acinar formations of tumour cells about a central lumen 
characteristic of glandular hepatocellular carcinoma. Hat pretreated 
with DENA and subsequently erposed continuously to PB for twenty sir 
weeks (H and E^  z 270).
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Fig. 2 . 3 4  Frozen section of a glandular hepatocellular carcinoma 
stained for G6PDH pathway I. A positive reaction is observed in 
the neoplastic cells (r 2 7 0 ).
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Fig# 2*35 Frozen section of an hepatocellular carcinoma. The 
tumour shows a marked aerobic G6PDH reaction (r 270).
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Pig. 2 . 3 6 Frozen section of a glandular hepatocellular carcinoma, 
A marked total G6PDH activity is noted in the neoplastic tissue
(i 2 7 0 ).
236
Fig* 2*37 Frozen section of a glandular hepatocellular carcinoma 
showing a marked y— GT activity (r 270).
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Fig. 2 . 3 8  Frozen section taken from same malignant tumour as Fig. 2.37 
showing a substantial depletion of GSH (r 270).
238
► "•: , -»• * £ \ \ V
Fig. 2 . 3 9  Frozen section of a hyperplastic nodule stained for 5'-Nase. 
Variable losses in the activity of 5’~Nase are seen in different 
areas of the nodular lesion (r 2J0),
239
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Fig. 2 , 4 0  Distribution of 5'-Nase in a trabecular hepatocellular 
carcinoma. Zones showing marked losses adjacent to zones of high
activity are seen (r 1 2 5 ).
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Fig. 2 . 4 1  Histological appearance of well-differentiated trabecular 
hepatocellular carcinoma with multicellular cords and sinusoids 
lined by normal endothelium (H and E, x 370).
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Fig. 2 , 4 2  Patchy distribution of glycogen in a glandular hepato­
cellular carcinoma. Frozen section stained with PAS (r I 2 5 ).
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Fig» 2 . 4 3  Pulmonary metastasis of hepatocellular carcinoma 
(H and E, x 270).
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Fig. 2 . 4 4  Centrilobular distribution of cytochrome P-450 (major 
phénobarbital induced form) (PAP, r 125).
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Fig. 2 . 4 5  Trabecular hepatocellular carcinoma showing well
differentiated cells reacting positively for cytochrome P-450 
(PAP, r 2 7 0 ).
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Pig. 2.46 A more anaplastic area of hepatocellular carcinoma showing 
absence of reactivity for cytochrome P-450 (PAP, x I25).
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Fig. 2.47 Distribution pattern of cytochrome P- 4 4 8  in a trabecular 
hepatocellular carcinoma. The staining is weaker than for cytochrome 
P-4 5 0 (PAP, % 270).
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Fig, 2 , 4 8  Electron microphotograph of a centrilobular hepatocyte 
from a rat pretreated with DENA and promoted with PB. Hypertrophy 
and dilatation of the SEE is evident also a slight dilatation of 
the REE can be observed (% I8 OOO),
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Fig. 2 . 4 9  Centrilobular bepatocyte from a rat initiated with DENA 
and promoted with PB. Smooth-membraned concentric bodies are seen 
enclosing portions of cytoplasm containing disintegrated organelles 
(probably mitochondria) and fat droplets (% I 8 OOO).
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Fig. 2 . 5 0  Electron microphotograph of the liver of a rat treated 
with DENA followed by PB for twenty six weeks and subsequently 
withdrawn from treatment for twenty seven weeks. The morphology 
and the quantity of the SER appear within normal limits (z I 8 OOO).
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Figé 2 . 5 1  Electron microphotograph of a cell from a hyperplastic 
nodule. The nucleus shows condensed chromatin. The nucleolus 
appears marginated. In the cytoplasm there are numerous mitochondria 
and both the SER and the HER are hypertrophic (z I 8 OOO),
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Fig. 2 . 5 2  Electron microphotograph from an hepatocellular carcinoma 
showing a large nucleus with a prominent marginated nucleolus. Sparse 
free ribosomes, and Golgi complexes are present in the cytoplasm
(x 1 8 0 0 0 ).
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Fig. 2 . 5 3  Electron microphotograph from an hepatocellular carcinoma 
showing rather abundant HER and the presence of vacuoles adjacent 
to the nucleus containing disintegrated membranes (x I8 OOO).
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3. EFFECT OF CLOFIBRATE TREATMENT IN THE LIVER OF RATS
Introduction
A wide range of compounds including plasticizers (long chain dialkylph- 
talates), phenoxyacetic and herbicides and other chemicals produce 
liver enlargement and hepatic peroxisome proliferation in rodents (Reddy 
and Lalwani, 1983). A number of these peroxisome proliférâtors have also 
been shown to increase the incidence of liver tumours in rodents (Reddy 
and Lalwani, 1983; Kluwe et al., 1982,1983). Similar hepatic changes 
are found in animals treated with other drugs, most notably with hypo- 
lipidaemic drugs typified by clofibrate (Svoboda et al., 1967; Svoboda 
and Azarnoff, 1979; Reddy and Lalwani, 1983). Clofibrate as, most of 
these agents, give negative results in mutagenicity tests, (Cohen and 
Grasso, 1981). Reddy and Lalwani, (1983) have suggested that there is a 
distinct class of chemical hepatocarcinogens which may be identified by 
their potential to cause peroxisome proliferation in the livers of 
rodents. In studies on clofibrate and other peroxisome proliferators 
attention has been centered particularly in the initial liver response 
and to certain extent on the carcinogenic and points (Cohen and Grasso, 
1981). However, little regard has been paid to the sequential biochemical 
and pathological changes that take place during the development and 
progression of the liver lesions. For these reasons, the experimental 
work described in this thesis was design with the intention to invest­
igate the sequential changes leading to hepatic tumours in rats exposed 
to clofibrate. Special emphasis was put on the morphological and cyto- 
chemical changes occurring during the early stages in order to identify 
reliable markers for the anticipation of increases in tumour count and 
latency. In order to confirm the validity of these markers described in 
Part I, the progression and the biological behavior of the early putative 
preneoplastic lesions was studied.
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Materials and Methods
Materials and methods are described in Part II.
3.1 Findings
3.1.1 Body and liver weights
Body weights were moderatly lower in the treated groups during the 
initial phase of the experiment. From week 59 onwards a marked fall in 
body weights was constantly found. Liver weights, both absolute and 
relative to body weight, were higher than those of the controls throughout 
the study, except at three days. From week 68 onwards the liver weight 
both absolute and relative of the treated animals was further increased 
by the presence of large hepatic masses. Withdrawal of the treatment for 
16 to 18 weeks led to the liver weights returning to values near those of 
the controls (All these changes are shown in Table 3.1).
3.1.2 Early liver changes
Gross
The livers of all treated rats were increased in size, frequently pale, 
occasionally dark and always friable.
Histology
After 3 days of treatment all the treated rats examined showed an in­
creased number of mitotic figures diffusely distributed throughout 
the liver parenchyma. In addition, the liver cells looked larger, 
granular and more eosinophilic than those of the controls. The presence 
of some picnotic hepatocytes was observed. At two weeks, the numbers of
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mitotic figures decreased to control values and did not show further 
modification at later times. A slight centrilobular hypertrophy accom­
panied by dilated sinusoids and single cell necrosis was found at this 
and at all the following periods of assessment. Towards the middle of 
the experiment (week 52) the presence of lipofuscin randomly distributed, 
was observed in the livers of all treated rats. Lipofuscin pigment 
accumulated progressively at later examination periods in both rat 
continually administered clofibrate and reversibility groups (Fig. 3.23).
3.1.3 Later liver changes
Gross
The first macroscopically detectable masses were seen at week 68.
These lesions were moderate in size, dark nodular and bulging on the 
surface of the liver parenchyma. From this interval onwards increasing 
number of larger coalescing masses were observed in the rats exposed to 
clofibrate. With the exception of one small nodule detected at week 86, 
no gross lesions were seen in any of the animals withdrawn from treatment 
This nodule was found in a rat treated for 86 weeks and removed from 
treatment only 11 days previously.
Histology
Foci of cellular alteration
In controls rats the first foci of altered cells were observed in H.E. 
stained sections at week 59 and were found at all subsequent examination 
periods. The liver of one of the eight control rats found dead or 
moribund also contained foci. Histologically, a preponderance of clear 
cell foci were found (Table 3.3). The numbers of foci per animal varied 
from one to a dozen per square centimeter.
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In clofibrate treated rats foci of cellular alteration were observed 
earlier than in controls, at week 42. These were mainly clear cell 
foci although a substantial proportion were eosinophilic in type and 
a few were basophilic. The number of animals with foci of various 
types was proportional to the length of the treatment (Table 3.2).
The number of foci per section also increased as the experiment 
progressed. A large number of focal hepatocellular lesions persisted 
in all the groups withdrawn from treatment. The majority of the foci 
observed in these groups were clear cell in type.
Occasionally basophilic and eosinophilic foci of cellular alteration 
were detected; in addition, areas of cystic degeneration were not 
infrequently found.
Hyperplastic nodules
No hyperplastic nodules were found in any of the control rats. Between 
week 68 and week 95 a total of eighteen rats exposed continuously 
to clofibrate developed liver nodules (Table 3.2). Five of these were 
found among the fourteen incidental deaths. These five all occurred 
among the six animals of this group which died between week 68 and 
week 96. The liver nodules induced by clofibrate were characterized 
by multifocal growths composed of regular trabeculae of hepatocytes not 
very different from normal liver tissue. Liver cords formed by more 
than one cell were sometimes observed. Portal tracts were only seen 
at the periphery of the nodules. The nodules were intersected by fibrous 
tissue bands, in which some pigment was included. These lesions 
compressed but did not infiltrate the surrounding liver tissue. The 
cells composing these lesions were large, granular with abundant dense 
eosinophilic cytoplasm. Their nuclei were large, round with prominent 
nuclear membranes and large dense nucleoli. Mitoses were scarce.
(Fig. 3.24 and 3.25).
Hepatocellular carcinomas
Two hepatocellular carcinomas were found in animals moribund or found 
dead at or after week 100 in the groups treated continuously (Table 3.3)
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These tumours were well differentiated although areas showing glandu­
lar structure were present (Fig. 3.26). Most of the cells composing the 
tumours, were large, granular and eosinophilic. In addition to the zones 
of glandular structure, already mentioned, areas of pleomorphic basophilic 
hepatocytes were observed. Next to these, necrotic areas of variable 
size were sometimes present. The neoplastic cells infiltrated the 
normal liver parenchyma and produced pulmonary métastasés in one case. 
These malignant neoplasms coexisted with hyperplastic nodules and foci 
of cellular alteration of various types.
In sections of livers stained with oil red 0, the normal distribution 
of fat in the hepatic lobules was altered. After three days of treat­
ment the fat was located predominantly in the periportal zone instead 
of around the central vein as it was in untreated controls. As the 
study progressed the number of liver cells containing lipid droplets 
increased and extended into the midzonal region. Variable number of 
hepatocytes showing large vacuoles of neutral fat were apparent.
During the later examination periods livers exhibiting marked diffuse 
fatty vacuolation were often found (Fig. 3.27 and 3.28).
In rats exposed continuously to clofibrate, PAS staining revealed 
focal loss of glycogen involving groups of centrilobular cells. This
change was found throughout the experiment (Fig. 3.29).
3.1.4 Early cytochemical detectable liver changes
The cytochemical changes in total G6PDH and pathways I and II from 
day 3 to completion of the experiment are presented in Fig. 3.1, 3.2 and 
3.3 and in Tables 3.4, 3.5 and 3.6. After 3 days of exposure to clofi­
brate, the treated rats showed a moderate although significant increase 
in the activity of total G6PDH and G6PDH pathway II. The levels of G6PDH 
pathway I were substantially higher than those of the control group.
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At week 2, the activity of all types of G6PDH was significantly enhanced 
in the treated group. The activity of total G6PDH was only moderatly 
increased at week 4, whereas the activity of G6PDH pathway I was markedly 
augmented in all hepatic lobular regions. In contrast, G6PDH type II had 
declined to basal levels in the periportal and midzonal areas and was 
slightly below control values in the centrilobular regions. At the 
following examination period, week 11, the activity of G6PDH pathway I 
had decreased to basal levels and with the exception of two peaks at week 
30 and week 86, remained unmodified at all subsequent intervals (Fig.
3.2 ). By week 11, the activity of total G6PDH was moderatly augmented, 
but declined to control levels at week 16, and from week 30 onwards 
showed a sustained moderate increased in activity (Fig. 3.30). At week 
11, G6PDH pathway II exhibited a significant regain in activity before 
declining at the subsequent interval. From week 42 onwards, although 
showing pronounced fluctuations, the activity of G6PDH pathway II was 
always significantly increased. At week 68, some of the paraffin 
embedded sections were stained with polyclonal antisera raised against 
cytochromes: P-448 major g-naphtoflavone induced form, P-450 major
phénobarbital induced form, and P-452 major clofibrate induced form.
In morphologically normal areas of liver from treated animals the 
reaction product was distributed throughout the hepatic lobule. The 
cytoplasm of the liver cells stained evenly and the concentration of 
cytochromes was higher in the centrilobular region. The liver cells 
reacted for all three isoenzymes but stained more intensely for 
cytochrome P-452 (Fig. 3.31).
No evident modifications in the activity of Y-GT was observed during 
the two initial periods of test, 3 days and two weeks. At all subsequent 
examination periods the activity of Y-GT was substantially below that 
of the control groups. The values varied between 50% and 70% of those of 
the controls (Fig. 3.4 and 3.32; Table 3.7).
The values for GSH were markedly depressed throughout the study, this 
change was more pronounced in the centrilobular area (Fig. 3.5, 3.3 3; 
Table 3.8).
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The administration of clofibrate for 3 days elicited a significant 
augmentation in the activity of catalase. The activity of this enzyme 
further increased during all subsequent intervals, reaching frequently 
more than a threefold increase (Fig. 3.10, 3.34; Table 3.13).
Uricase activity was unmodified during the two initial periods of test. 
From week 4 onwards it was significantly depressed (Fig. 3.11 and 
Table 3.14). Both NAD linked and flavoprotein dependent a-GPDH activities 
were significantly enhanced throughout the study. The mitochondrial type 
attained a four fold increase, whereas the NAD linked type varied by 
190% and 250% of the mean control values (Fig. 3.6 and 3.7; Table 3.9 
and 3.10).
With the exception of a considerable augmentation at week 59, no other 
significant changes were observed at any of the examination periods 
in the levels of acid phosphatase (Fig. 3.9; Table 3.12). 5*-Nase showed 
a fluctuating activity throughout the study. The levels of this enzyme 
varied from moderate increases to values comparable with those of control 
groups (Fig. 3.8; Table 3.11).
3.1.5 Later cytochemically detectable changes in the liver
In the clofibrate treated rats, the first focus of cellular alteration 
detected cytochemically was found at week 42. This lesion retained 
GSH (Fig. 3.35; Table 3.20) and showed catalase levels similar to those 
of the mean control values (Table 3.25). At this examination period, no 
other focal enzymic changes were observed. Two animals showing foci with 
the same cytochemical characteristics were found at week 52 (Table 3.20 
and 3.25) in all these focal lesions GSH and catalase values did not 
significantly differ from those of controls. As the study progressed 
the number of rats with foci of cellular alteration increased (Table 
3.2). This was paralleled by a greater heterogeneity in their enzymic 
activity. This variation in reactivity was qualitative and quantitative.
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Although virtually all the foci of cellular alteration examined at all 
subsequent intervals retained GSH their catalase activity varied from 
sometimes total absence, to often moderate depressions and occasional 
considerable increases (Table 3.25). These variations were observed 
frequently in different foci of the same animal and were independent of
the length of the treatment. None of the foci showed any reactivity for
Y-GT at any of the periods of test examined (Table 3.19). The activity of
5*-Nase was always reduced in all focal lesions examined in most of them
this depression was significative (Fig. 3.36; Table 3.23).
The first foci of cellular alteration reacting for total anaerobic 
G6PDH was found at week 68 (Fig. 3.37), the enzyme activity was markedly 
increased when compared with both mean control values and surrounding 
host liver tissue. Enhanced total G6PDH was observed in all the foci 
tested at all the following intervals (Table 3.15). The values varied 
markedly, however they were always significantly over those of the 
controls examined at the same periods of test. Both G6PDH pathway I 
and II varied greatly in most of the foci of cellular alteration observed. 
The range of variation was between significant losses of more than 90% to 
increases of over 200%. The higher values of G6PDH pathway I corresponded 
to the lowest values of G6PDH pathway II and viceversa (Tables 3.16 and 
3.17). None of the foci examined in the group treated continuously with 
clofibrate was positive for aerobic G6PDH.
The reactivity for cytochromes P-448, P-450 and 452 tested immunocytoche- 
mically in some of the focal lesions revealed an extremely heterogenous 
pattern. Some foci stained markedly for one or two of the isoenzymes 
while others hardly reacted for any of the three forms tested. However 
most of the foci examined showed variable concentrations of cytochrome 
P-452 greater than those of controls (Fig. 3.38).
Substantial increases in the activity of flavoprotein linked a^GPDH 
was a constant finding in all the foci tested for this mitochondrial
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enzyme. The values were three to four folds those of controls 
(Table 3.22). On the other hand, the activity of the NAD linked a-GPDH, 
although often significantly increased, occasionally fluctuated between 
marked losses of less than 90% to increases of more than twice the mean 
control values (Table 3.21).
Many foci showed variable losses in the activity of uricase. The levels of 
uricase were generally similar to that of controls and markedly higher 
than those of the surrounding host liver tissue.
The levels of acid phosphatase, as for those of many of the other 
enzymes tested, varied from substantial losses to considerable increases. 
However, in most foci it did not differ significantly from control 
values (Table 3.24). The majority of the foci examined stored glycogen 
(Fig. 3.42). No evident changes were seen in lipid content in any of 
the foci observed.
The enzymic pattern of all the foci of the control group examined cyto­
chemically did not differ from that of the rats treated continuously. 
However most of the focal lesions acquired Y-GT and towards the end of 
the experiment a few reacted positively for aerobic G6PDH.
Liver nodules
In contrast with the rather regular cytochemical reactivity observed 
within the foci for the various enzymes tested, the nodules induced by 
chronic exposure to clofibrate showed a considerable heterogeneity, 
within the lesion and as for foci, between different liver nodules; Marked 
variations were seen within different areas of the same nodules, in the 
same rat.
While the catalase activity showed a similar pattern to that observed in 
the foci of cellular alteration (Fig. 3.39; Table 3.25), a marked reduc­
tion of GSH content was found in all the liver nodules throughout the
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study (Fig. 3.40; Table 3.20). No traces of Y-GT were seen in any of 
the nodular hepatocellular lesions (Fig. 3.41; Table 3.19).
In spite of a considerable variation in the intensity of the reactions 
for total G6PDH, its activity was generally significantly increased 
(Fig. 3.42 ; Table 3.15). In contrast G6PDH pathway I showed the
opposite pattern, with few exceptions its levels were intensively to 
moderatly reduced (Fig. 3.43; Table 3.16). The areas within the nodules 
showing the lowest levels of G6PDH pathway I corresponded to those in 
which G6PDH pathway II was substantially increased (Table 3.17). Some 
of the hepatic lesions induced by clofibrate were stained with purified 
polyclonal antisera against the following microsomal cytochrome isoenzy­
mes: P-448, P-450 and P-452. In the nodules, the staining was highly
heterogeneous but positive for all isoenzymes. The intensity for 
cytochrome P-452 reaction, the major clofibrate induced form, was often 
decreased when compared with surrounding liver tissue. The concentra­
tion of both P-448 and P-450 forms was very low and restricted to some 
parts of the cytoplasm giving a patchy appearance. The cytoplasm of 
some of the nodular cells, stained homogeneously, in other cells a 
scanty focal intracytoplasmic reaction was seen (Fig. 3.4 4 and 3.45).
The activity of mitochondrial a-GPDH was markedly increased in most of 
the hepatic nodules examined. Only in one nodule the levels observed 
did not differ significantly from control values (Table 3.22).
Moderate to substantial increases was the dominant feature for NAD 
linked a-GPDH, however occasional slight losses were found in some of 
the nodules (Fig. 3.46; Table 3.21).
The activity of uricase was reduced to less than half that of the controls 
in 50% of the nodular lesions examined (Table 3.26).
The levels of 5*-Nase were extremely variable. The values ranged from 40% 
up to near 180% of that of controls. However in most of the nodules 
5*-Nase tended to be moderatly depressed (Table 3.23).
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Although acid phoshatase exhibited a variable pattern similar to most 
of the other enzymes investigated a trend towards a moderate, nonetheless 
significant increase was observed (Fig. 3.47; Table 3.24).
A patchy distribution of glycogen was noted in all the nodules examined 
(Fig. 3.48). The liver cells of the nodules sometimes retained large 
vacuoles of fat, however, in most of the nodular lesions there was little 
fat. -
Hepatocellular carcinoma
The two unequivocal hepatocellular carcinomas observed in this experi­
ment were found in two unscheduled dead rats at week 100 and 102 
respectively. Since the tissues were unsuitable due to autolytic 
changes, no histochemical tests were performed.
3.1.6 Early ultrastruetural appearance of livers
Ultrastructural examination of the livers of rats treated with clofi­
brate revealed marked changes after only three days of treatment, these 
changes are shown in Fig. 3.53. A marked increase in peroxisomes was 
observed in all treated animals, most of the peroxisomes had the 
cristalloid seen in peroxisomes of controls. Also, proliferation of 
mitochondria with increased density of their inner matrix was observed 
although the internal structure appeared well preserved. All treated 
animals showed a consistent proliferation of the smooth endoplasmic 
reticulum. The rough endoplasmic reticulum was apparently normal although 
a slight increase in free ribosomes was present. These changes were more 
pronounced in the centrilobular liver cells. The appearance of bile 
canaliculi, lysosomes and nucleus did not differ greatly from those of 
untreated rats. No changes were seen in the cellular membranes.
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After two weeks of treatment similar electronmicroscopic modification 
were observed in the hepatocytes of treated rats.
At week 4 (see Fig. 3.54), the number of peroxisomes was as previously, 
greatly increased, but at this time most of the peroxisomes lacked the 
core, little striations and a moderate increased density was observed in 
their matrix. The mitochondria seemed augmented in both number and size 
and appeared more dense. Autophagosomes containing myelin figures were 
also found. The bile caniculi were dilated but their microvilli seemed 
normal. The intercellular membrane spaces also appeared dilated. The 
smooth and rough endoplasmic reticuli showed changes similar to those 
observed during the two initial examination periods. All these features 
were present at all subsequent intervals. In addition, from week 2 
onwards increasing numbers of fat droplets of variable size and larger 
quantities of autophagosomes containing dense figures were apparent.
3.1.7 Later ultrastructural changes in liver
A striking feature of the hepatic nodules induced by clofibrate as shown 
in Fig. 3.55, was the scanty numbers of peroxisomes. The majority of them 
were coreless. The smooth endoplasmic reticulum was normal in quantity 
and appearance whereas the rough endoplasmic reticulum seemed slightly 
augmented in surface and partially degranulated. Substantial numbers of 
free ribosomes were observed. Also large numbers of autophagic vacuoles 
containing abundant dense figures were present. The nuclei were enlar­
ged, the chromatin and the nucleoli prominent and frequently marginated.
No duplication of cell basement membrane was evident. Although the 
mitochondria looked generally normal, they were sometimes swollen and 
the cristae absent.
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3.1.8 Progression of liver lesions
In the groups of rats in which clofibrate treatment was discontinued 
only one hyperplastic nodule was found (Table 3.2). This lesion was seen 
in an animal which died after having been treated for 86 weeks and with­
drawn from clofibrate eleven days before. Morphologically this nodule 
did not differ greatly from those observed in the groups treated chroni­
cally. In the majority of the animals of these groups no nodular lesions 
were present (Table 3.2). However, considerable zones of scarring were 
evident. No nodular structures were seen in these zones, although staining 
changes were present in groups of viable cells included in the fibrous 
tissue. These modifications were increased basophilia and sometimes 
moderate eosinophilia that appeared similar to those seen in the foci 
of cellular alteration of the groups exposed continuously to clofibrate 
(Fig. 3.49 and 3.50). The zones of scarring tissue contained abundant 
lipofuschin pigment . No evidence of necrosis was seen.
The numbers of clear cell and basophilic foci found in these groups 
were similar to those seen in the groups in which treatment was 
continuous. However, only a few eosinophilic foci were present and 
in addition moderate numbers of cystic foci and some foci of vacuolated 
cells were found.
Ultrastrutural studies
Numerous autophagosomes containing abundant dense figures was the only 
noteworthy change observed in the liver cells of all rats withdrawn from 
treatment (Fig. 3.56).
Cytochemical studies
In all the rats of the reversibility groups, the values of all cytoche­
mical parameters examined returned to near basal levels after 18 week
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of cessation of treatment. This occurred regardless of the length of 
exposure to clofibrate (Fig. 3.12 to 3.22; Tables 3.4 to 3.14).
The enzymic pattern of many foci of cellular alteration seen in the 
reversibility groups did not differ essentially from that of the rats 
fed clofibrate continuously. However, a number of the persisting foci 
had acquired Y-GT activity and a few of them reacted for aerobic G6PDH. 
These latter were only seen in the groups of rats removed from clofibrate 
after week 86 and in the corresponding untreated controls (Fig. 3.51 and 
3.52 ; Tables 3.18 and 3.19).
The liver hepatomegaly returned to normal in all the groups of rats in 
which treatment was stopped (Table 3.1).
3.2 Discussion
3.2.1 Non nodular liver
In accordance with Best and Duncan observations (1964) clofibrate caused 
liver enlargement within a few days of treatment. A plateau was reached 
within the first two weeks and was maintained in rats exposed chronically 
to the compound up to 113 weeks. The liver enlargement induced by clo­
fibrate has been shown to be the result of both cellular hyperplasia and 
hypertrophy (Moody and Reddy, 1976; Moody et al., 1977; Kolde et al;, 
1976). This hyperplastic response is observed during the first few days 
of treatment. During this time increases in total hepatic DNA and (^ h] 
thymidine incorporation indices were observed in rodents fed different 
hypolipidaemic drugs (Moody and Reddy, 1978; Reddy et al., 1979; Reddy 
and Lalwani, 1983). The cytochemical and morphological changes seen 
during the earlier phases of the present experiment such as substantial 
increases in the activity of total and G6PDH pathway II together with a 
transient burst of mitoses are consistent with these published observa­
tions. G6PDH pathway II, according to Chayen et al., 1973, is the
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fraction which remains at a very negative electrode potential for use 
in cellular biosynthetic mechanisms, G6PDH pathway II is also involved 
in the production of ribose, an essential component of nucleic acids 
(Lehninger, 1982; Mayes, 1981). The presence of enlarged, often indented 
nuclei bearing large dense marginated nucleoli, observed ultrastrueturally 
in this study is indicative of active protein synthesis (Ghadially, 1982) 
which correlates with the G6PDH II changes.
The mechanism underlying the early hyperplastic phase is not known.
The minimal single cell necrosis observed in most of the livers examined 
at this stage, appears insufficient to stimulate a hyperplastic reparative 
process.
According to Reddy and Lalwani (1983), (Inestrosa et al., 1979; Lazarow 
et al., 1978; Osumi et al., 1978; Reddy et al., 1981; Reddy et al.,
1979 and 1980; Hess and Staübli, 1965) and others the hepatomegaly 
induced in rodents by peroxisome proliferators is always associated 
with hepatocytic hypertrophy resulting from an increase in the numbers 
of intracytoplasmic peroxisomes. Both cytochemical and ultrastructural 
results observed in the present study are in accordance with these and 
other published results (Svoboda and Azarnoff, 1966; Reddy, 1974;
Reddy et al., 1969; Reddy and Lalwani, 1983).
After 3 days of treatment a significant increased in catalase positive 
particles was found in the clofibrate treated group. At week 2, second 
examination period, the activity of catalase had further increased. 
Thereafter the catalase levels remained considerably about control values 
at all the intervals examined. The cytochemical results were paralleled 
by the electronmicroscopic observation of large numbers of peroxisomes 
during the two initial intervals. However, this increase in catalase 
was found not to be proportional to the increase in number of peroxisomes 
(Reddy et al., 1969). Also, it was demonstrated by Reddy and coworkers 
(1970) that the augmented peroxisome population is not an expression of 
the increase in catalase synthesis and that peroxisomes proliferated 
considerably in clofibrate treated rats even catalase synthesis was
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inhibited by allylisopropylacetamide. In the present study, these 
peroxisomes appeared normal, most of them had the core seen in pero­
xisomes of control rats. This was reflected cytochemically by normal 
levels of uricase observed in treated rats during this early phase 
and is explained by the core localization of uricase in normal rodent 
hepatocytes (Ghadially, 1982; Cohen and Grasso, 1981). However, since 
peroxisome proliferation had occurred, each peroxisome presumably 
contained less uricase than controls. By week 4, the proliferating 
peroxisomes displayed considerable variation in size and shape and most 
of them lacked the normal core. This change was accompanied by a marked 
fall in uricase levels. This reduction in the activity of uricase, as 
well as the absence of normal peroxisomes in rats treated continuously 
was a repeated finding throughout the remainder of the study, and is 
in contradiction to the increases reported in the activity of this 
enzyme by Svoboda and Reddy (1974).
Peroxisome fatty acid 3-oxidation has been demonstrated in rodent liver 
(Lazarow and DeDuve, 1976; Lazarow, 1978; Goldenberg et al., 1976;
Hess et al., 1965; Moody and Reddy, 1978). Lazarow (1977) showed an 
increased activity of this enzyme complex in the liver of rats fed 
clofibrate and other hypolipidaemic drugs. Recently other hypolipidae- 
mics and phthalate esters were shown to enhance the activity of this 
metabolic system (Lazarow, 1977; Hayashi et al., 1981; Inestrosa 
et al., 1979). The induction of peroxisomal g-oxidation parallels 
apparently the increase in peroxisome population (Lalwani et al., 1981). 
In addition, a marked increase in the content of a polypeptide, with a 
molecular weight of 80.000 (polypeptide PPA-80), was observed in liver 
peroxisomes of rodents treated with clofibrate and other peroxisome 
proliferators (Reddy et al., 1981; Reddy et al., 1982; Lalwani et al., 
1981; Reddy and Kumar, 1979; Ishii and Suga, 1979). This polypeptide 
is immunochemically identical with the multifunctional protein displaying 
the activity of two enzymes of the peroxisomal g-oxidation spiral (Osumi 
and Hashimoto, 1979; Reddy et al., 1981). Peroxisomal g-oxidation is 
currently assessed in liver homogenates, or isolated organelles, by
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reduction of NAD to NADH in presence of palmitoyl-CoA (Moody and Reddy,
1978). At the present time, there is no cytochemical test available 
to evaluate this process. However, indirect indication of peroxisomal 
g-oxidation activity is given by changes in NAD linked a-GPDH. The 
existence of three pools of a-GPDH has been proposed by Gee and 
coworkers (1974): cytoplasmic, peroxisomal (both NAD linked) and
mitochondrial (FAD-linked). Peroxisomal a-GPDH differs from that in 
the cytosol in Km values, electrophilic mobility, inhibition by NADH 
and latency. The global activity of both forms measured cytochemically, 
was markedly augmented in all chronically treated rats throughout the 
present experiment. Clofibrate treatment, as well as obesity or fat 
diet, has been reported to increase peroxisome g-oxidation and the 
activity of NAD dependent a-GPDH similarly (Gee and Tolbert, 1982). 
Peroxisomal a-GPDH is a component of the glycerol-3-phosphate shuttle 
between the peroxisomes, the cytoplasm and mitochondria. It is thought 
that through this mechanism energy is removed from peroxisomes to reduce 
NAD (Gee and Tolbert, 1982). The increased peroxisomal g-oxidation of 
fatty acids appears to cause an excessive generation of H2O2 (Inestrosa 
et al., 1979). This is because the first dehydrogenation step in 
peroxisomal g-oxidation involves the reduction of O2 to H2O2 by the 
flavin adenine dinucleotide-dependant fatty acyl-CoA oxidase (Lazarow 
et al., 1978). Increased generation of H2O2 by proliferated peroxi­
somes probably results in production of hydroxyl radicals catalyzed by 
cellular iron (Reddy and Lalwani, 1983). The hydroxyl radical is an 
extremely powerful oxidant which represents a danger to cells. Cellular 
membranes are largely composed of phospholipids (40 - 70%) many of which 
contain unsaturated acyl fatty acids. Due to the unsaturated nature of 
the fatty acid chain of phospholipids and because allylic hydrogen atoms 
can easily be abstracted from methylene sites, cellular membranes are 
naturally predisposed to oxidation reactions mediated by radicals. 
Consistent with this view is the excessive accumulation of lipofuscin 
seen in this study in the livers of rats treated chronically with 
clofibrate. As mentioned before, the induction of peroxisomal catalase 
activity caused by clofibrate and other peroxisome proliferators is 
disproportionally small compared with the increase in peroxisome
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population (Reddy and Lalwani, 1983) and H2O2 generated by fatty
acid 6-oxidation. Peroxisomal catalase is one of the cellular defensive
' '
mechanisms responsible for the destruction of most of the H2O2 produced 
in this organelle (Chance et al., 1979). In normal untreated livers 
approximately 2% of the H2O2 produced within peroxisomes diffuses 
out (Poole, 1975), whereas in isolated peroxisomes from hypolipidaemic 
treated rats, 11 and 42% of the H2O2 generated has been found to 
diffuse into the external medium (Reddy and Lalwani, 1983). Accordingly, 
it is very likely that sustained increase in peroxisome proliferation 
could lead to changes in peroxisomal permeability to H2O2. Whilst under 
normal circumstances, peroxisomal catalase would be expected to cope with 
moderate increases in H2O2, high continual doses of clofibrate would 
be likely to produce a break-down of homeostasis and thus excess H2O2 
which would not be totally degraded because of the insufficient supply 
of catalase (Cohen and Grasso, 1981). Since no significant evidence of 
marked toxicity was observed throughout the present experiment and in 
many other published studies (Hess et al., 1965; Svoboda and Azarnoff, 
1966; Svoboda et al., 1967; Barnard et al., 1980; Reddy et al., 1974) 
it seems probable that other cellular defenses are stimulated. A marked 
depletion in GSH content was a constant finding in the present clofibrate 
experiment; Younes and Siegers (1981) reported an inverse relationship 
between hepatic GSH concentration and lipid peroxidation. y-GT activity 
increased slightly during the first two weeks. The increases of Y-GT 
activity induced by many xenobiotics was shown to be triggered by GSH 
conjugation with intermediate metabolites, this process being catalyzed 
by GSH-S-transferases (Trush et al., 1982). Short term treatment with 
clofibrate has been shown to induce GSH-S-transferase(s) as well as other 
xenobiotic metabolizing enzymes (Lake et al., 1984; Hammock and Ota, 
1983). It is well established that the main role of Y-GT is the hydro­
lysis of gamma-glutamyl compounds (Curthoys and Hughey, 1979; Me Intyre 
and Curthoys, 1979). This initial increase in Y-GT activity paralleled 
by a marked GSH depletion seems to represent a stimulated conjugative 
process. However, from week 4 onwards Y-GT activity dropped considera­
bly, but GSH concentrations remained markedly low. These changes suggest 
that at later times GSH is depleted through a different mechanism. Non
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enzymic conjugation and oxidation via the GSH-peroxidase pathway are other 
known processes by which hepatic GSH is utilized for defensive purposes 
(Arrick and Nathan, 1984). The latter could seem to be the most likely 
to be involved in the detoxicating process elicited by peroxisomes 
proliferators. GSH is a co-factor for selenium dependant GSH-peroxidase 
which reduces lipid peroxides and H2O2 (Burk et al., 1978; Trush 
et al., 1982), it thus plays an important role in the prevention of 
toxicity caused by lipid peroxidation (Anundi et al., 1979; McKay 
et al., 1976). The low concentration of GSH and the lack of significant 
general hepatic toxicity at any stage can be explained by a continual 
reduction of GSSG to GSH by GSH dehydrogenase which is rapidly utilized 
by the liver cells. The capacity of liver cells to respond to oxidative 
stress by increasing the activity of GSH-peroxidase has been demonstrated 
(Tappel, 1980). The depletion of GSH was paralleled by sustained increa­
ses in G6PDH (total and pathway II). As pointed out before increases 
in G6PDH levels reflect a stimulated pentose phosphate shunt, which 
generates the large quantities of NADPH that are needed for reduction 
of GSSG by GSH dehydrogenase (Trush et al., 1982; Rossi and Cecchini,
1983). Thus these changes are consistent with the biological need to 
protect the cells from lipid peroxidation. The substantial losses in 
uricase activity measured, are compatible with this view: Ames and
associates (1981) have shown that uric acid is a powerful antioxidant 
and a scavenger of oxygen free radicals. Low levels of uricase probably 
result in increased concentration of uric acid which may also take part 
in the protective mechanism against active oxygen.
The livers of the rats receiving clofibrate for three days showed 
cytochemical modifications compatible with a considerable induction 
of the MFO enzymes. There were significant rises in total G6PDH, G6PDH 
pathway II and particularly in G6PDH pathway I. Increases in the latter 
according to Chayen and coworkers (1973), reflect an enhanced metabolism 
of glucose via the pentose-phosphate shunt in response to greater requi­
rements for NADPH to sustain the induced levels of drug metabolizing 
enzymes. Strengthening this view ultrastructural examination revealed 
a marked proliferation of smooth endoplasmic reticulum and a moderate
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increase of both rough endoplasmic reticulum and free ribosomes. 
Essentially similar changes were found in the activities of all forms of 
anaerobic G6PDH after two weeks of treatment. However, the activity of 
G6PDH pathway I, after having increased during the initial three intervals 
disminished at week 11 to levels slightly below those of mean control 
values. During the remaining examination periods it recovered slightly 
and with some fluctuations was always just about basal values. The 
amounts of smooth endoplasmic reticulum on the other hand were always 
greater than in controls. As mentioned above G6PDH pathway II showed 
the opposite pattern. In week 4, G6PDH pathway II had declined to 
near basal levels, thereafter with the exception of a second drop at 
week 30, its activity was constantly significantly augmented.
The changes occurring up to week 4 are in accordance with results 
reported by many workers on the effects of clofibrate and a limited 
number of other hypolipidaemic agents given to rats for short periods 
of time (Orton et al., 1979; Salvador et al., 1970; Lake et al., 1984). 
A common feature in all these experiments was increases of hepatic 
microsomal P-450 with no parallel increases in the metabolism of model 
xenobiotic substrates (Orton and Parker, 1982; Elek and Jambor, 1978). 
The pattern of liver microsomal haemoproteins induced by clofibrate 
has recently been shown by several methods to differ from those induced 
by phénobarbital and 3-methylcholanthrene treatment (Odum and Orton,
1980; Tamburini et al., 1984). The major clofibrate induced isoenzyme 
termed cytochrome P-452, was found to increase specifically and markedly 
the (o-hydroxylation of lauric acid (Orton and Parker, 1982). Based upon 
the participation of clofibrate induced cytochrome P-452, in the oxida­
tion of unsaturated fatty acids, and the probable production of fatty 
acids and epoxides. Lake and associates (1984), have put forth the 
hypothesis that microsomal cytochrome fatty acid metabolism may result 
in increased formation of potentially toxic oxygen metabolites which 
can contribute to the well established lipid derangement including 
lipofuscin deposition. The induction of microsomal xenobiotic metabo­
lising P-450 enzymes by clofibrate and other lipolipidaemic compounds 
is transient in rats and thus follows a similar pattern to the G6PDH
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pathway I activity (Unpublished results: S.C. Price, R.H. Hinton,
J.W. Bridges and P. Grasso). The nature of these changes are not clear 
and remain to be elucidated. Lipid peroxidation may account for this 
moderate depression following the initial increased of MFO activity.
Lipid peroxidation was shown to destroy or depressed cytochromes P-450 
activity under various circumstances (Levine, 1982; Levine et al., 1973; 
Miles et al., 1980). A trend towards a moderate increase in the activity 
of the cellular membrane 5*-Nase was observed. The levels of this enzyme 
were generally slightly above that of the controls, however, a significant 
rise was only seen at weeks 59 and 68. A fluctuating pattern appears to 
be one of the characteristics of 5*-Nase. A circadian rythm in its 
activity at different sites of the cell has been reported (Von Mayersbach 
and Klaushofer, 1979). Involvement in cell growth and differentiation has 
been proposed as one of the functions of 5*-Nase. Variable depressions 
in its concentration have been observed in different stages of the cell 
cycle and during cell maturation (Lelievre et al., 1971; Sivak et al., 
1972). However, the results obtained in the present experiment do not 
agree with this hypothesis. Neither during the early hyperplastic 
growing phase nor during the remainder examination periods, in which 
hepatomegaly was evident, were significant losses of 5*-Nase seen. The 
significance of the two peaks of activity with time is not clear, and 
remains to be explained.
The administration of clofibrate for 103 weeks did not induce significant 
modifications in the activity of acid phosphatase. This in spite of the 
increasing concentrations of lipofuscin pigment observed histologically 
and the large number of vacuoles containing dense figures detected 
ultrastructurally. Lack of acid phosphatase activity in "globular 
vacuole-like areas" examined electromicroscopically has been reported 
by Essner and Novikoff (1961).
In agreement with previous published results a marked increase in the 
activity of mitochondrial a-GPDH was seen at all examination periods 
(Krishnakantha and Kurup, 1972), (Holloway and Orton, 1980). This 
stimulation of a-GPDH has been suggested to be Initiated by displacement 
of thyroxine from serum binding protein (Krishnakantha and Kurup, 1972).
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In close correlation with these observations increases in the numbers 
and density of mitochondria were observed during chronic treatment 
with clofibrate. Mitochondrial protein content in the liver was 
augmented by 50-100% (Kurup et al., 1970; Krishnakantha and Kurup, 1972; 
Gear et al.> 1974). Clofibrate was also found to increase mitochondrial 
carnitine acyltransferases levels and to accelerate ^-oxidation of 
fatty acids in these organelles (Kahonen and Ylikahri, 1979). Slight 
increases in the activity of cytochrome C-oxidase were observed by other 
groups (Chandoga et al., 1984). The fate of acetyl-CoA, the end product 
of peroxisomal 3-oxidation, is unknown but the presence of carnitine 
acetyltransferases in peroxisomes is suggestive of a role in transporting 
"active acetate" to the mitochondria for further oxidation (Cohen and 
Grasso, 1981). These findings are consistent with some of the ultra- 
structural changes observed such as large numbers of dense, enlarged 
mitochondria.
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3.2.2 Hepatic lesions
A number of peroxisome proliferators have been shown to increase the 
incidence of liver tumours in rodents; It has been suggested that 
these compounds constitute a new class of chemical carcinogens (Reddy 
and Lalwani, 1983; Reddy et al., 1980). Clofibrate, as well as other 
peroxisome proliferators, do not appear to be directly genotoxic, being 
neither mutagenic in the Ames test (Warren et al., 1980; Reddy et al., 
1982) nor binding covalently to DNA after "in vivo" administration 
(Von Daniken et al., 1981).
It has been proposed by Reddy and coworkers (Reddy and Lalwani, 1983) 
that liver tumour formation is initiated by leakage of H2O2 from 
peroxisomes which ultimately results in damage to intracellular 
membranes and/or alterations to DNA.
The carcinogenicity of clofibrate has been investigated by oral 
administration to male Fisher rats (Reddy and Qureshi, 1979; Svoboda 
and Azarnoff, 1979) and to rats of both sexes (Blane and Pinaroli, 1980). 
A variable incidence of hepatocellular carcinomas was found in these 
experiments. Svoboda and Azamoff (1979) successfully transplanted 
some of these tumours. In addition, they demonstrated that in rats 
removed from treatment after different periods of clofibrate adminis­
tration, the liver tumours persisted.
In the present study, the administration of 400 mg/kg of clofibrate for 
103 weeks to male Sprague-Dawley rats induced the entire sequence of 
hepatocellular changes associated with liver cancer.
The first foci of cellular alteration induced by chronic exposure to 
clofibrate were seen at week 42. These foci, although few in number 
varied in type, however the majority were either eosinophilic or clear 
cell in type, and only a few were basophilic. Those examined cytochemi-
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cally retained GSH but lacked Y-GT. These findings, also observed at 
all subsequent intervals, contrasted with the presence of Y-GT in the 
majority of the foci induced by many structurally unrelated liver 
carcinogens (Pugh and Goldfarb, 1978; Cameron et al., 1978; Fiala 
et al., 1976; Pitot et al., 1978; Farber et al., 1979). Absence 
of Y-GT activity in foci of cellular alteration induced by Wy-14,643, 
an hypolipidaemic compound chemically unrelated to clofibrate, has been 
reported by Rao and coworkers (1982). The significance of this obser­
vation is unclear. Whether the absence of expression of Y-GT activity 
in these foci is a consequence of adaptation to hypolipidaemic compounds 
or an intrinsic characteristic of the altered cells induced by the 
treatment, remains to be demonstrated. The liver cells forming the 
foci of cellular alteration seemed to retain a certain degree of norma­
lity with regard to GSH and Y-GT. Normal untreated hepatocytes contain 
high levels of GSH but lack Y-GT (Phares and VenderIan, 1979). If one 
of the detoxicating mechanisms triggered by increased cellular H2O2 
following clofibrate is stimulation of GSH-peroxidase, the unchanged 
levels of GSH, within the focal lesions suggest that neither this 
mechanism nor non-enzymic oxidation occur in the foci themselves.
However, cytochemical changes compatible with peroxisomal 3-oxidation 
such as depressed uricase levels and marked increases in NAD dependent 
a-GPDH, (Gee and Tolbert, 1982) were present in most of the foci 
induced by chronic treatment with clofibrate. Also high levels of 
mitochondrial a-GPDH were seen in all the foci examined. These modifi­
cations were paralleled by focal catalase levels comparable with controls, 
this may be interpreted as an abnormal response of these altered cells 
to clofibrate. Both total G6PDH and pathway II were markedly augmented 
in most of the focal hepatocellular lesions indicating, as discussed 
elsewhere, an enhanced biosynthetic process (Chayen et al., 1973;
Altman et al., 1970). The activity of G6PDH pathway I was generally 
very low although in a few foci it attained levels similar to those 
of total and G6PDH pathway II.
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The G6PDH pathway I represents the fraction of NADPH generated at a 
redox potential accessible to the NADPH diaphorase system, this is 
related to the microsomal respiratory chain (Chayen et al., 1973).
Among the typical functional abnormalities of foci is their resistance 
to the cytotoxic effects of chemicals requiring enzymatic activation 
(Williams et al., 1976; Kitagawa, 1971; Soit et al.,1977). However, 
in the particular situation of clofibrate probably this enhanced resist­
ance is the result of a depressed microsomal metabolism of endogenous 
fatty acid substrates (Lake et al., 1984).
Varying losses in 5*-Nase activity were a characteristic feature of all 
foci induced by clofibrate. In the majority of them this depression 
was significant. Low levels of 5*-Nase have been reported by several 
groups (Butler and Hempsall, 1981). This change is thought to be 
consistent with stimulated cellular growth (Graham, 1979). Although 
the function of 5*-Nase is not yet clear, it is thought to regulate 
the supply of nucleoside precursors for nucleic acid synthesis (Graham, 
1979).
The acid phosphatase pattern of the foci examined in this study was 
extremely heterogeneous. The levels varied widely from one focus to 
another and within the cells forming a single focus. This variation 
suggests, as proposed by Butler and Hempsall (1981), different stages 
of maturation of the hepatocytes composing the foci of cellular 
alteration.
Under the present experimental conditions, seventeen animals receiving 
clofibrate continuously had liver nodules between weeks 68 and 103. 
Irrefutable evidence of malignancy such as metastasis or local invasion 
was not observed in any of these nodules. These liver nodules showed 
many of the enzyme abnormalities found in the foci of cellular alteration. 
This is in conformity with the widely accepted hypothesis that liver 
nodules are an advanced stage of foci of cellular alteration (Williams,
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1980; Farber, 1980; Bannasch, 1978; Newberne, 1976). However, the nodules 
should not be considered as enlarged foci for considerable biological 
and enzymic differences exist between the two types of lesions.
Discontinuity of the plates of the cells of the nodules with those of 
the liver and the compression of the surrounding parenchyma are indica­
tors of a loss of intercellular association that is maintained in the 
foci. Furthermore, hyperplastic nodules show a decrease in portal blood 
supply with a relative increase in arterial blood, as indicated by the 
characteristic absence of normal portal triads (Soit et al., 1977). In 
agreement with the literature, none of the nodules retained GSH and all 
showed considerable variations in their enzyme phenotypes, not only 
between different nodules but also within the same lesion (Farber 1980;
Ogawa et al., 1980; Williams, 1980; Pitot and Sirica, 1980). All the 
cytochemical changes compatible with an increased peroxisomal and 
mitochondrial g-oxidation, described in the foci were also present in 
the nodules. Elevated levels of both NAD and mitochondrial a-GPDH were 
found in all the nodules investigated. This was accompanied by a marked 
reduction in the activity of uricase. Consistent with this, the number 
of peroxisomes examined ultrastrueturally was slightly increased when 
compared to controls, and the majority of them were coreless. Mitochon­
dria had also proliferated to a certain degree and were more dense and 
larger. Gytochemically, the overall catalase activity was slightly 
depressed and varied widely, within and between the nodules. Areas and 
single cells staining intensely for catalase alternated with zones that 
had concentrations well below those of both surrounding host tissue and 
control livers. These findings, indirectly confirmed previous observa­
tions in liver tumours induced by other hypolipidaemic compounds. Liver 
lesions diagnosed as hepatocellular carcinomas arising after exposure to 
Wy-14,643 and methyl clofenapate revealed increases in the activity of 
carnitine acetyltransferase (Reddy et al., 1979) and the peroxisomal 
B-oxidation system (Lalwani et al., 1981). These lesions also showed 
an increased amount of peroxisome-proliferation associated 80.000 
molecular weight polypeptide (Reddy and Lalwani, 1983) suggesting that
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the nodular liver cells respond to some extent to the enzyme inducing 
effect of hypolipidaemic drugs. As for non nodular liver tissue the 
interaction of an enhanced peroxisomal B-oxidation and insufficient 
catalase production probably accounts for the marked GSH depletion.
As mentioned before one of the possible defensive mechanisms stimulated 
by excessive H2O2 could be the GSH-peroxidase pathway (Trush et al.,
1982; Anudi et al., 1979; McKay et al., 1976).
Examination of the clofibrate induced nodules showed a weak irregular 
activity of G6PDH pathway I. Moreover when these nodules were studied 
by means of immunocytochemical techniques they stained weakly but none­
theless, rather uniformly for clofibrate isoenzyme, and in a faintly and 
very heterogeneous manner for both B*naphthoflavone and phénobarbital 
induced forms of P-450. Studies in which the activities of xenobiotic 
metabolizing enzymes were determined in both hyperplastic nodules 
and hepatocellular carcinomas revealed considerable decreases in the 
concentration of microsomal cytochromes and MFO system enzymes. These 
microsomal alterations might play a crucial role in the selection and 
proliferation of initiated cells because the production of potentially 
toxic metabolites is decreased (Cameron et al., 1976; Farber, 1980; 
Williams, 1980; Gravela et al., 1975; Astrom et al., 1983). However, 
their relevance in the case of clofibrate is to active oxygen and not to 
active metabolites of xenobiotics (Lake et al., 1984). The absence of 
lipofuscin pigment within the liver nodules induced by clofibrate, supports 
this hypothesis. Although the exact mechanism by which peroxisome 
proliferators produce their toxic effects has not been elucidated, the 
prolonged administration of these compounds is associated with increased 
deposition of lipofuscin (Reddy et al., 1982; Cohen and Gras so, 1981). 
Recently, it has been shown that cytochromes P-450*s may be involved in 
the oxidation of unsaturated fatty acids, and this may include the 
production of fatty acid epoxides (Lake et al., 1984). Since peroxisome 
proliferators have marked effects on lipid metabolism, it seems possible 
that the enhanced cytochrome P-450 dependent metabolism of endogenous
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fatty acids may result in augmented formation of potentially toxic 
products and these may contribute to the well established derangement 
of lipid metabolism including lipofuscin deposition. Generally hyper­
plastic nodules retain many enzyme regulatory mechanisms that are lost 
in carcinomas. For instance, their enzyme activity can be modified 
by dietary stimuli or fasting: Kitagawa and Pitot (1975) have found
a marked increase in G-6Pase and serine dehydratase in hyperplastic 
nodules of animals receiving a diet containing 90% of protein. Also a 
gradual loss in hepatic G-6Pase and its induction by starvation in 
both non nodular parenchyma and nodules has been reported by Teebor 
and Seidman (1970).
Also hyperplastic nodules respond to phénobarbital, increasing to some 
extent MFO activity whereas carcinomas do not (Schulte-Hermann et al., 
1984; Feo et al., 1978; Kaneko et al., 1980).
Farber and coworkers (1959) were among the first to emphasize the 
importance of the "hyperplastic nodule as a possible precursor to 
hepatocellular carcinoma. The association between hyperplastic nodules 
and hepatocellular carcinomas was further emphasized by Goldfarb and 
Zak (1961). Their conclusions were based not only on morphology but 
also on deficiency of glucose-6-phosphatase in these nodules, a feature 
observed in many hepatocellular carcinomas. However, Teebor and Becker 
(1971) reported that if the stimulus inducing the liver nodules was 
removed, under certain conditions, they regressed. More recently, it 
has been demonstrated that many of the liver nodules that occur during 
liver carcinogenesis with chemicals reverse to normal appearing tissue 
and only a few persist with subsequent development of liver cancer 
(Farber, 1980; Ogawa et al., 1980). On the other hand, when exposure 
to carcinogens was prolonged sufficiently, the majority of the nodules 
persisted and a considerable number of hepatocellular carcinomas 
developed (Teebor and Becker, 1971; Hirota and Williams, 1979).
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Farber and his group (Farber, 1976; Lin et al., 1977) demonstrated with 
immunochemical procedures that a number of cells within liver nodules 
induced by genotoxic carcinogens expressed a new antigen, epoxide 
hydratase previously designated as "preneoplastic antigen". Using this 
antigen and y-GT as markers, Farber further showed that upon regression, 
many cells of the nodules became remodeled into liver parenchyma which 
appear normal using conventional histological methods but retained high 
levels of both epoxide hydratase and y-GT (Farber, 1976; Ogawa et al., 
1980; Enomoto and Farber, 1982). Thus, although many liver nodules 
remodelled following withdrawal of the carcinogenic stimulus, cells
within these lesions retain some of the characteristics of initiated
:
hepatocytes.
In this study, no liver nodules were found in the groups of rats with­
drawn from treatment for 16 to 18 weeks, after periods of administration 
of clofibrate of up to 95 weeks. In one case a liver nodule was seen 
in a rat found dead eleven days after cessation of exposure to clofibrate, 
this lesion showed changes considered as degenerative such as cystic 
vacuolation and marked fatty infiltration (Reuber, 1965; Svoboda et al., 
1966; Newberne and Wogan, 1968; Kalengayi and Desmet, 1975). In most 
of these animals zones of scarring and foci composed of vacuolated cells 
were seen. These features suggest that these zones were the sites of 
regressed nodules since no identical changes were seen in either controls 
or rats treated chronically with clofibrate. These observations can be 
interpreted as evidence that the nodular lesions induced by clofibrate 
retain the capacity to regress after exposure to the stimulus for up to 
95 weeks. It was also noted that two hepatocellular carcinomas were 
observed in rats found dead at about the time that liver neoplasm occur 
spontaneously in this rat strain.
Foci of cellular alteration persisted in all rats. The majority of 
these foci were eosinophilic in type and showed enzymic changes similar 
to those seen in the foci of the corresponding controls. The number of
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foci in both groups increased with age and a wide variation in their 
phenotypic expression, as reported previously, was observed (Kalengayi 
and Desmet, 1975; Bannasch et al., 1979; Farber, 1980; Pitot and 
Sirica, 1980; Ogawa et al., 1980). Although, the cells of the focal 
lesions found in the clofibrate treated rats subsequently withdrawn from 
treatment (reversibility group) had some cytochemical features in common 
with the foci of the rats treated continuously, the latter did not show 
signs of remodelling into normal tissue, and, in addition, displayed 
some noteworthy differences. None of the foci in the groups removed 
from treatment nor those found in the controls showed cytochemical 
evidence of enhanced peroxisomal B-oxidation. Particularly interesting 
was the acquisition of y-GT by most of these foci and the detection of 
aerobic G6PDH in a few of them. Aerobic G6PDH and y-GT are part of a 
variety of histochemical reactions described as valuable markers for 
the identification of carcinogen-induced rat liver lesions (Fiala et al., 
1976; Altman et al., 1970; Butler et al., 1981; Pugh and Goldfarb, 1978; 
Kalengayi et al., 1975; Farber et al., 1979). The similarity in the 
alterations of phenotype found in foci of both control and reversibility 
groups suggest a return to a steady or dormant stage of the latter after 
cessation of the treatment.
These findings seem in accordance with the effects of several tumour 
promoters reported by Schulte-Hermann and coworkers (1983; 1981).
Foci of phenotypically altered cells have been observed in the livers 
of old untreated rats of various strains (Popper et al., 1960; Hollander 
and Burek, 1978; Schulte-Hermann and Parzefall, 1981; Haseman et al.,
1984). These foci showed characteristics similar to those of focal 
lesions developing after exposure to carcinogens, such as basophilia, 
y-GT expression and increased DNA synthesis (Ogawa et al., 1981, 
Schulte-Hermann et al., 1983). When these rats were treated with a 
single dose of known liver tumour promoters such as PB, a-hexachloro- 
cyclohexane, the rates of DNA synthesis increased markedly. Extending 
these studies Ward (1983) demonstrated that if old rats bearing
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spontaneous Y“GT positive foci were exposed to PB for periods up to 
33 weeks the foci not only increased in number but developed into 
liver cell "adenomas". These results indicate that the liver cells 
forming the spontaneous foci appear to have an impaired growth control, 
which renders them more susceptible to endogenous and exogenous stimuli. 
Classically, one of the principal mechanism whereby promoting agents 
are thought to act is through an effect on cell replication (Sivak, 1979), 
Enhanced cell replication appears necessary to fix any damage potentially 
leading to progression (Schulte-Hermann et al., 1983). The promoting 
action of several hypolipidaemic agents (Reddy and Rao, 1978; 
Schulte-Hermann et al., 1981) including clofibrate (Mochizuki et al.,
1982) on livers previously initiated with strong carcinogens, has been 
clearly demonstrated. As mentioned elsewhere this class of compounds 
induces liver enlargement by the combination of transient hyperplasia 
and sustained hypertrophy. However, it has long been known that the 
induction of cell replication itself is insufficient to explain the 
tumour-promoter effects of promoting agents in general (Sivak, 1979;
Pitot and Sirica, 1980). In untreated liver the control of normal 
and probably dormant transformed cells is believed to be mediated by 
intercellular communication. Chalones, which are auto-inhibitory 
factors controlling cell growth by reduction of multiplication, appear 
involved in this process (Nadal, 1979; Williams, 1981). Inhibition of 
intercellular communication can therefore, liberate the spontaneously 
transformed or chemically initiated cell, for progressive growth and 
proliferation (Williams, 1981; Schulte-Hermann et al., 1983).
This mechanism may be reasonably envisaged as being the basis for the 
promoting effect of clofibrate and other peroxisome proliferators. It 
is well established, as already discussed, that peroxidation of unsatu­
rated lipids forming cell membranes is a characteristic feature of this 
class of compounds. This process would at least partially, inhibit 
cell communication. Toxic concentrations of H2O2 or other reactive 
species generated, could also induce neoplasia either by direct action
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on DNA or through a mechanism involving hepatocyte damage leading to 
reactive nodular hyperplasia (Cohen and Grasso, 1981). Liver enlargement 
associated with sustained microsomal enzyme activity, is considered to 
represent an adaptative work hypertrophy (Crampton et al., 1977a; Grasso,
1979). Long term studies on compounds such as Ponceau MX and safrole 
(Crampton et al., 1977b; Grasso and Gray, 1977) have revealed liver 
enlargement with biochemical and histochemical alterations indicating 
hepatoxicity. Chronic administration of these compounds resulted in 
depressed centrilobular G-6-Pase, autophagy and fatty infiltration, 
alterations which reflect an unequivocal toxic response (Grasso et al., 
1974; Feuer et al., 1965; Crampton et al., 1977b). These changes were 
associated with a transient increase in microsomal activity followed 
by a progressive depression. Subsequently nodular hyperplasia and 
ultimately some hepatocellular carcinomas developed. A certain parallel 
can be established between these compounds and clofibrate. Liver enlar­
gement and early stimulation of microsomal activity preceding a return 
to normal or less than normal levels of activity and indications of 
toxicity such as accumulation of lipofuscin and a progressive loss of 
body weight were seen in this study during long term treatment. Finally, 
liver nodules and some hepatocellular carcinomas developed.
Based on a clear dose-response, Grasso (1979) concluded that nodular 
lesions developed in the liver after prolonged treatment with Ponceau MX 
and safrole only at dosage levels which induced subcellular liver damage. 
Accordingly, the nodular response is probably reactive hyperplasia to 
sustained damage rather than neoplasia (Grasso, 1979). Similarly, 
low doses of hypolipidaemic agents at levels in which peroxisome 
proliferation does not occur did not induce liver nodules (Price et al., 
unpublished observations, 1981; Blane and Pinaroli, 1980). However, 
the interaction of defective intercellular communication and subcellular 
toxicity in the genesis of hepatocellular lesions induced by clofibrate 
should not be excluded. In this case, promotion would occur at dosage 
levels causing an hyperplastic effect, and cell membrane alterations 
would impair normal cell growth control in these hyperplastic lesions.
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3.2.3 Conclusion
The clofibrate treatment experiment confirmed morphologically and 
cytochemically many of the widely published characteristic toxic 
alterations produced by peroxisome proliferators, and also induced the 
entire sequence of hepatocellular changes leading to liver cancer. The 
appearance of tumours was preceded by nodular hyperplasia according 
the following sequence of events: chronic liver injury, nodular hyper­
plasia, carcinoma. However, in contrast with well known genotoxic 
compounds, the focal, nodular and neoplastic lesions only developed after 
prolonged treatment at a high dose level (400 mg/kg/day) and the lesions 
induced were always well differentiated hyperplastic nodules and tumours 
of hepatic cell origin. No other types of hepatic tumours developed and 
neoplasms did not appear in other sites. All these features are 
characteristic of substances having the ability to induce tumours 
through epigenetic mechanisms.
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Table 3.4
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic total glucose-6-phosphate dehydrogenase
COKTNOL CLOriBKATE *** W W E R S l B I L m
PE MZ CL PP MZ CL PP MZ CL
DAT 3 30.87^1.66 26.33*1.69 21.68*^1.68 36.61*3.92 3I.8%45.62
**
29.320 . 76 
**
WEEK 2 33.91*2.35 26.38*1.51 21.16*0.75 50.75*6.27
•
39.63*0.86 36.09*1.29
■
WECX 4 .32. 79^,78 28.22^.95 22.76*1.32 60.07*2.53 35.26*2.36 31.770.10
*
■
WEEK II 33.66*1.01 28.69^.97 26.93H.57 38.62*1.95 36.39*1.09 31.23*1.53 - > -
WEEK 30 35.35*1.29 30.68*1.63 28.30*1.09 39.88*0.62 35.55*3.39 33.71*2.79 - - -
WEEK 62 26.97H.78 19.09*0.62 16.69*1.09 23.38*^1.97 17.76*1.30 26.0 *3.28
■
WEEK 52 2l.73jjO.77 19.62*0.60 17.62jjl.03 31.16*^1.07 27.17*1.60 25.510.12
WEEK 59 28.86*3.00 26. 76*2. 78 21.02*1.72 36 . 26j-2.65 29.21*2.25 25.57*2.15
•*
32.08* 1.60 27.560. 76 23.70*0.75
WEEK 68 26.56*0.73 23.22*0.65 19.30*0.61 32.37*3.07
**.
28.31*0.29 26.570.67
**
26.80* 0.96 23.560 .13 19.690.16
WEEK 11 28.86*1.6 7 22.65*0.58 19.33*1.61 36.85*1.21 3I.08H .82 27.26jjl.32 32.52* 5.07 268. 72 0  . 31 22.56 0  . 65
WEEK 86 27.80*2.01 22.07*^1.71 20.IC^.79 37.26H.73 30.56*1.27
*
27.620.66 26.63* 2.09 26.110.77 19.960.25
WEEK 95 36.20*1.91 28.63jj).97 21.65*1.20 37.65*3.29 29.9W  .20 25.72*1.36 66.l0jjl3.36 31.73*6.05 23.800 . 67
WEEK 103 30.80*2.82 26.0H2.99 21.32^2.76 61.89*6.23
*
31.95*3.06
tr*
27.370.86 31.20*
. •
1.69
•
27.l9jj3.l5 23.70*2.97
WEEK 113 31.71*1.77 27.39*1.86 23.85*1.98 - - - 30.36* 0.72
#
25.230.18 22.130.92
* significantly different from control at 5%
** Significantly different from control at 12 
8 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values * standard deviation of 3 x 12 measurements 
carried out In three hepatic lobular zones (PP: periportal, MZ: mldzonal and CL: centrilobular) 
of all rats of each group, expressed In mean Integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (I.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.5
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic glucose-6-phosphate dehydrogenase pathway I
cowrmoL CLOFIBRATE *** REVERSIBILITT
PP MZ CL PP MZ a PP HZ CL
DAT 3 8.61*0.62 9.03*0.68 11.20*0.66 11.56*0.70 13.5CK1.06 16.22H .81
■
WEEK 2 8.68*0.30 10.11*0.66 11.67*0.56 16.03*0.83 17.910.95 19.89*1.81
**
■ ■
WEEK A 9.86^.33 10.61^.68 12.77*0.99 15.28*0.96 17.660.63 23.08H.96 - - -
WEEK 11 9.97^.53 11.12*0.68 12.66*1.03 9.62*0.81 10.330.83 11.22H.22
**
- - -
WEEK 30 5.91*0.56 6.99*0.65 7.88*0.79 7.630.19 
**
7.880.33
**
9.6^0.22
WEEK 62 7.29*0.62 8.70*1.02 10.25*1.26 7.660.26 9.10*0.72 10.950 . 70 - -, -
WEEK 52 8.53*0.78 10.33*0.76 12.56*0.77 8.530.39 10.680.39 12.580.80 - - -
WEEK 59 9.3H0.61 11.02*0.65 13.10*0.36 9.630.88 12.350.52 15.090.85 8.760.30 11.620.39 13.680.29
WEEK 68 8.20*0.57 10.07*0.63 11.95*0.60 8.360.60 10.720.65 12.760.77 9.11H.62 10.540.15 12.390.75
WEEK 77 8.10*0.19 9.68^.78 11.50*0.78 7.600.53 9.620.85
*
11.140.39 7.460.18 9.490.35 11.130.17
WEEK 86 8.60*0.73 10.33^.52 11.90*0.70 10.180.91 13.160.65 16.16*1.12 8.09*1.01 10.110.46 11.850.57
WEEK 95 9.81^.97 11.87*0.78 16.83^0.76 9.780.37 11.35*1 07 13.99*1.76 10.060.52 11.870 . 36 16.710.96
WEEK 103 8.26*1.63 9.65^.61 12.170.52 8.720.72 9.600. 75 11.36*1.05 7.850.61 9.390.67 10.80*0.70
WEEK 113 9.27*0.90 10.66*0.86 12.30*1.76 - - - . 8.830.58
■
10.230.80 11.660.86
* Significantly different from control at 5%
** Significantly different from control at 1% . 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values * standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP; periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3,6
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic glucose-6-phosphate dehydrogenase pathway II
CDWT80L CLOPIBKATE *** REVEKSIBILITT
PF MZ CL PP MZ CL PP MZ CL
OAT 3 22.51*1.24 17.11*1.13 10.34^.89 24.82*3.43 19.08*3.71 13.910.01 _ —
w u x 2 24.95*2.04 16.13*1.40 9.33*0.57 34.3^.21
**
21.49*0.78
**
13.580.40 - -
WEEK 4 22.79*0.63 17.39*0.67 9.88^.51 24.63H.4I 17.56*1.83 8.60*0.89 - - -
WEEK II 22.98*1.14 17.20*1.55 12.22*1.27 28.90*1.67 24.65*1.53
**
19.740.41 - - : -
WEEK 30 16.25*0.99 10.35*1.67 7.24H.26 16.84*0.65 11.710.85 7.490.69 - - -
WEEK 42 I7.5%*l.85 I0.37H.I9 6.38*1.16 15.93*2.06 8.550.11 15.30*1.30 - - -
WEEK 52 I3.67H.09 9.10*40.92 5.22H.07 22.32*0.99 16.290.21 12.870.99 - - -
WEEK 59 I8.I8H.43 II.77H.62 7.IIH.08 24.30*2.97 16.740.34
**
10.170.59 23.040 . 44 15.930.85 9.920 . 68
WEEK 68 18.09*1.08 13.05*0.99 7.29*0.45 23.760.02 17.46*0.27 11.70*1.89 18.090.99 12.870.09 7.060 . 34
WEEK 77 20.52H.48 12.62*0.82 7.74^.50 29.980.26 21.420.73 15.930.17 24.84*4.39 17.19*3.51 11.25*3.42
WEEK 86 I9.26H.98 11.99^.72 8.37*0.56 27.630.44 18.00*1.44 11.340.56 20.38*2.00 13.86*2.29 8.010. 74
WEEK 95 30.78H.87 20.27^.81 9.35*0.89 32.52*3.05 22.560.17 14.950 .19 31.96*2.96 20.390.83 11.280.97
WEEK 103 23.03H.79 17.75*2.11 9.87*1.60
•*
31.96*3.31 22.09*2.12
**
15.980.41
•
23.030.50
■
17.860.91
•
12.78*2.54
WEEK 113 22.I8H.27 16.69*1.31 ll.2(^.70 - - - 21.150.77 15.040.59 10.34*2.21
* significantly different from control at 5X 
** Significantly different from control at 1%
6 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values ± standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.7
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic gamma-glutamyltransferase
OONTROL CLOFIBRATE *** REVERSIBILITT
PP MZ CL PP MZ CL PP MZ CL
DAY 3 87.73*2.05 - - 86.40*17.26 — _ . « » _
WEEK 2 57.78*3.97 - - 68.54* 1.63 - — — -
WEEK 4 59.52*5.70 - - 35.71*^3.20 - - - -
WEEK It 72.32*4.93 - - 30.03* 5.57 - - - -
WEEK 30 42.25*3.04 - - I8.02*j 2.05 - - - -
WEEK 42 58.50*0.90 - - 51.25* 2.22 - - - -
WEEK 52 39.50*5.75 - - 28.00* 6.75 - - - -
WEEK 59 55.00*6.37 - -
**
32.45* 4.97 - - — — -
WEEK 68 52.37^8.82 - -
**
26.55* 5.82 - - 41.50*15.15 -,
WEEK 77 42.150.45 - - 27.15* 1.45 - - 41.85* 3.75 - -
WEEK 86 49.95*9.90 - - 28.35* 6.75 - - 45.30* 6.09 -
WEEK 95 47.25*3.15 - - 24.00* 2.40 - - 37.80* 4.27 -
WEEK 103 41.55*1.88 - - 25.20* 2.58 - -
#
39.63^1.03
WEEK 113 68.43*5.71 - - - - - 64.38^ 6.36 -
* Significantly different from control at 5%
** Significantly different from control at 1%
8 Only two rata
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values ± standard deviation of 12 measurements 
carried out in the periportal hepatic lobular zone of all rats of each group, expressed in mean 
integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
295
Table 3.8
Effect of the administration of 400 mg/kg per day of clofibrate on
hepatic glutathione concentration
œ x n o L CLOPlBXATt *** tXVXUlBlLlTY
PP KE a PP KZ CL PP M2 CL
DAT 3 M . 3 5 M . 5 0 76.53*8.35 54.15*2.70 20.56*4.00
**
25.20*7.29 18.78*3.87 -
H U Z 2 61.60*1.55 67.37*4.77 52.20*3.30 25.72*2.47 27.97*1.76 18.470.08 - - ■ -
W B 4 62)33*1.70 66.78*3.15 49.03*3.42 28.12*1.83 30.00*1.97
**
22.790.76 - - -
W B 11 62.74*^2.23 65.47*3.15 41.60*3.46 28.30*3.95
*«
30.15*5.07
**
18.150.30 - - -
V U X 30 69.00*3.34 69.08*4.75 63.03*3.39
*•
47.580,32 45.770.24 23.09*2.48 - -
W U X 42 63.85*3.89 64.47*5.47 64.320.29 40.86*5.35 32.620 . 29
•* ,
23.220.72 ■ - -,
W U X 52 64.39*4.58 62.07^.90 58.04*5.45 37.70*8.59 30.80*7.73
**
21.90*4.99 - - -
W U X 59 70.83*5.62 68.66*5.2 59.00*3.40 49.42*9.50 36.830.61 25.27*1.66 70.4CK 5.87 66.20* 4.72 56.33* 2.40
W E B U 71.40*5.01 72.930.17 46.83^.67 53.00*5.38 52.30*8.57 25.080.78 70.67^ 4.84 73.84* 5.10 45.83^ 3.25
W S B 77 72.25jj6.20 71.80*5.52 53.06*7.31
* *
42.58*5.95 44.85*6.28 16.370 . 93 70.17* 3.92 71.02* 7.50 49.17* 4.12
W E B M 65.73^.41 66.97*2.53 46 53*3.92
■ * *
47.38*5.47 49.07 0  . 32 21.200.87 64.17* 3.06 65.87* 3.72 47.20* 4.47
W E B 95 61.38*3.64 63.20*4.40 46.270.22 41.20*4.92 42.850.45 20.44*2.27 59.07* 5.02 60.40* 6.10 46.40* 2.94
W U X 103 58.0^3.50 60.33^.69 46.80*3.64 31.92*4.69 35.140.25
* *
13.80*3.89 54.47* 9.61 56.30*12.08 42.02*11.11
W U X 113 64.95^.83 68.83*3.65 40.65*3.15 - - - 65.65*23.72
•
67.37jj 6.30 40.83* 3.80
* Significantly different froa control at
** Significantly different from control at IZ 
6 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values * standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.9
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic alpha-glycerophosphate dehydrogenase NAD dependent
OONTKOL CLOPIBKATE *** REVEKSIBILITT
PP MZ a PP HZ CL PP KZ CL
DAY 3 31.85*2.38 27.010.90 21.620.22 47.070.26 44.290.42 42.20*6.98 - . - -
WEEK 2 30.90*1.05 27.26*2.22 20.70*1.28
**
56.14*4.27 50.82*3.04 47.640.99 * -
WEEK 4 30.21*1.38 25.9^.76 21.010.96 56.330.14 52.380.40
**
48.91*3.61 ' - -, - -
WEEK 11 29.73*1.11 25.6W.43 21.85*^1.78 51.30*3.89 48.97*4.27 44.55*2.94 - - -
WEEK 30 30.96*1.49 25.92*2.52 22.32*2.39 46.98*3.06
**
47.70*4.14 47.520.10 - - -
WEEK 42 21.19*3.36 20.07^.81 17.70*0.99 39.3W.71
**
39.420 . 63 41.400.34 - ■ ' -
WEEK 52 24.39^2.25 20.730.98 17.910.35 40.720.98
**
39.870.34 39.80*1.98 - - , -
WEEK 59 25.11*2.11 22.41*2.36 19.080.30 52.20*4.99
** ,
49.0W.51 46.980 . 51 25.380.52 22.59*2.57 19.890.85
WEEK 68 28.44*2.25 25.070.35 21.62jjl.68 38,970.05
**
40.860.85 43.29*6.57 28.80*1.80 25.170.85 21.870.82
WEEK 77 28.640.44 24.190.75 19.8W.44 39.060.43 38.610.71 39.150.70 26.820 . 30 23.13jjl.05 18,900.99
WEEK 86 32.15*2.26 26,320.97 21.71*2.16 71.44*8.79 61.57*7.94 59.36*8.46 27.540.70 25.270.31 21.85*^2.46
WEEK 95 28.620.50 23.12jp.70 18.56*1.04 42.390.67
**
45.49*5.92
. **
48.120,87 25.610.03 23.55jj2.86 19.220 . 94
WEEK 103 26.60*1.97 21.330.17 16.920.62
**
49.540.57 51.980 . 83
**
51.61*4,65
, ■
26.550.32
•
21.290.11 15.880.91
WEEK 113 29.09^.87 23.31*2.02 18.710.32 -, - -
•
29.700 . 03 24.510,16 19,69jjl.01
* Significantly different from control at 5%
** Significantly different from control at 1%
8 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of A rats (unless 
otherwise stated). The figures represent mean values ± standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.10
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic alpha-glycerophosphate dehydrogenase FP dependent
C0WT80L CLOPIBKATE *** REVERSIBILITY
PP MZ a PP MZ CL MZ CL
DAY 3 13.96*1.01 17.9W.32 23.03*1.97 53.67_* 6.11
**
56.50*6.49
** .
63.17*2.30 _
WEEK 2 15.74*1.32 20.89*1.32 27.02H.79 51.04* 4.32 55.65*1.64 58.42*4.17 - -
WEEK A 15.46*1.17 20.1W.08 25.00*1.61
**
46.06* 2.73
**
52.780.43
**
59.22*3.76 - -
WEEK II I4.87H.22 18.94^1.84 22.32^.95
**
48.64* 3.52 53.16*3.99 58.190.42 - - -
WEEK 30 16.68*1.63 19.66*1.96 24.5W.43 54.72^ 2.50 55.67*5.18
**
61.94*4.14 - -
WEEK 42 15.69*1.66 17.38*0.87 19.20*1.74 42.8W2.12 46.60*5.70
**
50.72*4.41 - - -
WEEK 52 16.61*1.34 I8.9W.45 21.49*1.35 47.14* 4.43 50.34*3.32
. **
54.23*4.69 - - -
WEEK 59 18.38*1.76 19. 7 W .  78 21.42^1.66 (1) (1) (1) 19.680.04 23.020 . 50 26.420 . 62
WEEK 68 16.34*1.01 18.39*1.53 21.67*1.20 (1) (1) (1) 18.140.20 20. 760.44 24.950.96
WEEK 77 18.17*1.05 20.82*1.51 23.27*^1.40 59.35* 6. 10 59.41*3.73 61.820.80
*
23.090.27 27 . 30* 3 . 30 33.070 . 99
WEEK 86 16.87*1.86 21.26*3.81 27.30*2.96 61.53* 4.51 68.290.38
’ **
80.370.51 18.80*3.76 24.910.22 29.950.21
WEEK 95 17.66*1.55 20.30*2.63 26.88*^2.60 61.79* 3.44 62.68*5.92 65.280 . 74 18.990.14 23.810.22 28.480.12
WEEK 103 14.20*1.05 16.59*1.53 22.35*1.75
**
34.16* 2.58
**
46.760.64 64.670.82
a
13.91*0.80 16.40*0.96
■ a
18.980.99
WEEK 113 19.59*1.70 24.35*1.58 29.11*2.79 - - -
a
20.80*2.05 26.460 . 60 31.880.55
* Significantly different from control at 5%
** Significantly different from control at IZ 
8 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated)« The figures represent mean values ^ standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16—18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.11
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic 5’-nucleotidase
ooirrwL aoPliKATC * * *  UVERS181LITY
PP « CL PP MZ CL PP MZ CL
DAY 3 34.70*3.24 42.79*3.43 53.18*2.44 41.12*5.12 4 8 .0 2 0 .1 8 5 8 .1 3 0 .7 9 - - -
wen 2 37.42*1.70 43.82*3.83 53.51*3.10 4 3 .4 9 0 .5 3 5 2 .7 5 0  . 54 6 0 .5 3 0 .1 0 - - -
w in A 35.84*2.79 4 4 .3 3 0 .8 0 50.64*3.11 4 0 .9 3 0 .3 5 4 4 .8 9 0 .8 9 52.52 0  . 61 - - -
wen 11 31.53*2.24 34.77*2.48 44.43*3.11 3 5 .5 8 0  . 95 4 2 .4 7 0 .4 9 5 1 .0 7 0 .0 9 - - -
w en 30 32 19*1.27 44.34*4.44 4 9 .0 9 0 .9 4 4 1 .4 8 0 .7 4 50.19*2.13 5 8 .5 2 0 .9 6 - - -
wen 42 24.89^2.77 27.44*2.28 2 8 .5 3 0  . 52 27 .250 .41 2 9 .1 8 0  . 23 33 0 1 0 .3 4 - - -
w en 52 25.84*2.58 31.23*2.44 3 7 .6 9 0 .4 5 2 5 .8 4 0 .1 4 31.27*3.85 4 3 .6 6 0 .5 3
* *
- - -
w en 59 28.57*1.39 33.34*1.65 3 4 .7 8 0 .2 3 33 .850 .21 39 9 0 0 .7  7 5 1 .1 1 0 .9 9
**
28 88*1.37 32 .7 2 0 .5 7 3 6 .8 6 0 .1 4
w en 68 27.89*1.40 33.55*3.04 4 5 .7 5 0 .4 7 3 4 .640 .72 4 4 .1 9 0 .6 5 5 0 .9 2 0 .6 4 31.01*1.40 3 7 .6 6 0 .4 6 44.46*4.22
w en 77 29.18*3.49 34.43*3.50 43.28*5.55 3 1 .310 .60 3 7 .8 1 0 .5 3 4 5 .7 5 0 .3 6 3 0 .8 2 0 .1 9 36.71*1.63 44.27*1.71
wen 84 31.49*1 18 40.51*3.80 4 8 .5 2 0 .4 7 33 .740 .34 4 3 .8 9 0 .9 1 5 2 .8 4 0  91 33.59*1.20 43.32*3.53 53.58*4.94
wen 95 34 .930 .14 4 2 .1 4 0 .0 3 51 .3 9 0 .3 4 45.02*4.38 5 0 .8 8 0 .2 7 62.19*4.74 3 4 .2 4 0 .1 9 4 3 .7 7 0 .1 4 5 3 .0 0 0 .0 1
w en 103 39.53*3.05 44.39*3.15 50.34*3.55 48.30*5.30 5 3 .1 5 0 .2 8 6 0 .3 3 0 .1 4 41 8 1 0 .3 5 44.58*3.53
•
5 1 .2 3 0 .6 0
wen 113 35.33*3.26 41.30*3.77 4 8 .3 4 0 .2 3 - - -
•
3 4 .5 3 0 .2 1
#
4 1 .7 6 0 .9 5
•
47.78*3.05
* Significantly different from control at 5%
** Significantly different from control at 12 
8 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values ± standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x lOO).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.12
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic acid phosphatase
COHTIOL CLOPIBKATE *** REVERSIBILITY
PP NZ CL PP KZ CL PP MZ CL
DAY 3 45.92*3.85 41.24*2.95 43.29*3.57 45.59*3.36 45.26*2.21 42.97jjl.23 - - -
WEEK 2 42.39*2.30 42.400.53 40.26*1.83 50.670.79 49.20*2.80 47.40*2.79 - -
WEEK 4 43.30*3.69 42.61*1.89 39.85*1.74 45.510.05 45.260.12 45.06*2.92 - - -
WEEK 11 45.5W.2I 45.02*2.13 43.95*2.38 48.540.87 49.360.25 48.380.46 - ' - -
WEEK 30 50.04*2.7 50.580.98 51.840.16 57.42*5.76 62.10*2.34 68.04*4.50 - -
WEEK 42 36.72jjl.62 35.280.21 36.18jj2.91 42.030.30 42.39*3.80 40.320 . 24 : - - -
WEEK 52 37.62jj3.42 37.150 . 46 37.62jj3.51 40.68jj2.52 39.96jj2.52 40.140 . 70 - . - -
WEEK 59 40.68jj2.45 40.50*3.58 41.76jj2.34 60.480.44 60.660.24 61.20*5.09 41.220.16 41.040. 74 41.580.39
WEEK 68 36.18*^1.80 34.90*^3.06 34.2(^3.42 46.26*6.31 44.73*5.47
•
42.84*7.61 35.64*0.50 34.560 . 75 32.560.84
WEEK 11 47.860.96 48.24*4.23 47. 70*^ 2.71 50.320.52 50.040.52 49.66jj2.86 43.92*4.16 44.460 . 39 44.470.52
WEEK 86 45.36*3.06 45.540 . 40 44.64*4.18 59.40*4.32 57.760.34 55.53*4.14 45.720 . 44 45.36*3.24 43.02*4.97
WEEK 95 41.82 0  . 87 43.460.23 41.41*3.48 46.74*4.92 46.330 . 26 45.510.56 41.000.46 40.550.72 42.410.87
WEEK 103 45.92*5.04 45.50*^6.23 44.190.81 58.22*8.20
■ *
57.40*^8.00 56.580.40
•
45.92j4.18
•
46.74*4.59 45.430. 70
WEEK 113 45.3 70.44 44.260.95 42.64*2.46 - - - 43.780.39
•
43.550.62 41.32 0  . 75
* Significantly different from control at 52
** Significantly different from control at 12 
6 Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of A rats (unless 
otherwise stated). The figures represent mean values * standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP; periportal, MZ; midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3,13
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic catalase
OOKTIOL CLOrilKATE *** BEVERSIBILITY
PP MZ CL PP MZ CL PP HZ CL
DAY 3 24.92*1.41 21.13*1.65 16.990.83 31.38^ 1.94 29.95* 2.06 28.292 2.73 ■ —■ -
Vt tt 2 25.76^1.65 21.26*1.54 17.53*1.16 49.15* 3.71 47.502 4.13 44.192 4.62 - -
wttz 4 24.78*1.36 21.06*1.24 16.520 . 36 39.23^ 2.89
**
39.65* 2.48 38.412 2.63 - ■ - -
WEEK 11 23.95*2.06 19.01X2.44 16.10*1.86 40.89* 4.96 38.822 4.17 37.172 3.71 - - -
WEEK 30 23.12j*l.07 21.09*1.48 19.980.85 52.17^ 4.07 45.512 1 59
**
41.812 4.44 - -
WEEK 42 36.15*2.60 35.52*2.40 34.26*2.40 59.20* 9.62 60.682 9.05
**
67.71218.60 - - -
WEEK 52 28 . 980.68 25.760.53 23.46*2.53 46.23^ 3.91 51.292 5.52 61.412 8.97 - - -
WEEK 59 30.88*2.08 30.08*2.10 27.52*2.24 66.88* 6.40 73. 79* 8.80
**
84.322 8.00 32.6423.04 31.3624.00 29.120.99
WEEK 68 31.520.60 26.980.44 22.560 . 34 46.72^ 2.08 54.4 2  2.24 66.882 2.47 31.680 . 97 33.9221.28 22.4021.76
WEEK 77 32.020.15 23. 780.91 18.45*2.05 44.69* 6.56 53.712 6.97 64.782 6.97 30.9122.46 26.2420.82 22.5523.69
WEEK 86 37.670.28 28.70*1.60 25.01*2.05 43.052 4.11
**
55.352 1.64 70.522 1 68 35.6721.74 27.4721.23 25.4222.87
WEEK 95 23.370.76 19.27*0.86 16.40*1.49 41.41* 6.15 43.052 b 2) 42.232 5.45 25.0321.77 20.3721.34 16.8220.97
WEEK 103 32.80*2.39 34.90*2.52 35.06*3.88
**
95.28*11.48 93.1504.59 91.02215.82
**•
43.4622.22 35.6323.28 28.8329.43
WEEK 113 22.370.64 20.910.88 18.160.63 - - - 23.5220.87 21.1320.57
•
17.6420.80
* Significantly different from control at 5%
** Significantly different from control at IZ 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values * standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP; periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
The animals were dosed and allowed to recover for 16—18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
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Table 3.14
Effect of the administration of 400 mg/kg per day of clofibrate on the
activity of hepatic uricase
CONTROL CLOFIBRATE *** REVERSIBILITY
PP MZ CL PP HZ CL PP HZ CL
DAY 3 21.4121.21 14.5321.82 11.8220.86 20.21215. 50 14.1221.07 10.70*0.99 - - -
WEEK 2 21.8421.55 18.89*2.10 13.6721.17 22.452 1.47 13.8721.68 13.24*0.77 - - -
WEEK 4 22.972l.24 18.3321.22 14.3220.86
**
13.542 0.63 10.73*0.97
**
8.42*0.76 — -
WEEK 11 21.4621.55 17.6120.82 13.4920.79 12.752 0.58
**
9.6320.49 7.7120.69 - - -
WEEK 30 21.4322.33 19.8320.73 17.5321.71 13.30* 1.13 9.48*0.93 7.80*0.66 - - -
WEEK 42 26.4922.27 19.0721.08 15.9420.82 12.30* 1.53 8.72*0.70 7.33*0.84 - -
WEEK 52 24.0121.87 17.5421.45 15.2221.03
•*
11.612 1.43 9.3321.02
**
7.57*0.52 - - -
WEEK 59 25.7120.86 18.2321.60 14.3221.79 13.912 0.94 10.2820.72
**
8.0(X0.70 25.8821.72 18.1121.86 12.0121.70
WEEK 68 23.1322.28 15.2221.50 10.3220.73 9.332 0.99 7.40*0.52 4.90*2.24 24.3822.24 16.30*0.43 11.8?2l.20
WEEK 77 25.8021.81 17.1121.25 13.6721.72 13.762 0.77
**
9.55*0.69 7.18*0.95 25.3?2l.63 19.6921.72 14.6221.50
WEEK 86 30.1021.03 25.93*0.99 21.1121.07 17.892 3.82
**
13.6022.84 10.4521.93 30.4922.06 24.4222.06 18.1822.06
WEEK 95 23.8221.46 18.2720.64 14.3220.58
<*•
13.762 1.72
**
9.8921.17 7.5221.27 24.0821.55 18.1921 18 13.07*0.47
WEEK 103 22.4221.95 17.8021.25 13.9321.25 11.522 1 03
**
9.0320.77 6.6620.39 21.6322.02
#
16.6821.33 12.8121.33
WEEK 113 21.6221.25 16.00*1.20 11.7821.33 - - - 22.36*0.95 16.6821.40 13.2721.26
* significantly different from control at 5%
** Significantly different from control at IZ 
s Only two rats
Each control and treated groups consisted of 5 rats; each reversibility group of 4 rats (unless 
otherwise stated). The figures represent mean values ^ standard deviation of 3 x 12 measurements 
carried out in three hepatic lobular zones (PP: periportal, MZ: midzonal and CL: centrilobular) 
of all rats of each group, expressed in mean integrated extinction units x 100).
*** The animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week
77 and animals sacrificed at week 95).
302
G
«H
(UCO
G 0)000 
u 
0) D
Ciu
G
x:
CL00
ê
f-
v£>1O
CQ
O
U
3r4
00
G 
O4-1
—  \ô
♦I +1 *1 ♦* *1 *1 *1 +«
G4J
G
U
Xi
•H44O
*1 *1 ♦I *1 +1
2 § 
j;' A'
T30U3
.1
01 
G O 
• H
ta
O
+( +1 +1 +» ♦• *1 +1 +1o\ t/> —  o  0> o# — ô— —  o 00 m  o» n
*' ♦» *« +1 ♦» ** +» *1 *1 +1'O.7co<oo.o.oa«o>o — o> r» r~ o» r.. in O.AO r»
: =
lO
en
G
$-4
3
£p
• H
.54JO
<
303
2 — s ^
to
5 3 5 s
% G «
m \X
!• V«A m  e%
d os r^
: s
*1
•o
1•l-l
§o
: 1
m
m
G1-4•s
H
& :
I Î
304
G4J
GM
•H44O S R s
ïn.o
"G
G0
1
•H
m
§ 
• H
G
G
s 2' %
— 0 0 0 0 0
G
•H
H
î4J
GCL
G
0]
5
6 
g
I
GTJ
G
4J
I09
5
OU
Ivo
I
G(QO
UG
r 4
00
4 4O
•H
.54J
U
<
305
o! tü A' »
13G
G
•HU
GO
U
♦ I a
: 1
vO
<n
G1-4
I
i
5
a I
g a
306
I
44o
G
I
•H
m
GO
•i4m
G
s S
8 K 8
<0 m
2 3 s
s a s
*« ♦• +1*« —  ir» —O f» <o
2  2  o  2  s
«4 m in .#
5 s A' ÿ aCD ^  lO
5 s R
d  r> r*>
s à'2
s s  3
6  R K m M !o
^ m ^  ^ #n ^
2 2 2 g î g
3 R 2 R 3 R
S  S
d
5' s'
m
G
r4
î
I
G
Pu
G
n
gÙO
I
•G
G4J
G
•g.n
?
vo
i>
mO
g
»
44O
•H
.54J
<
1
307
8 R S 2
^ «À «4 m
2 2 5 g
s 2 3 S
g
g
g g
♦ I
I
•G
i
4J
§G
en
G
1-4
$
!|
î
3
II
308
o e o
♦I *1 *1 *1
= 3 2 :
GV4
X•M
44
O
Ps
Xi
•GG
U
3
g
GCQ
S
G
00
O
M
•G
XZ
G
•G
G4-t
G
jc
eu
G
0 
JZ 
Cu
1vO
I
GGO
U
3^4
00
u
• r4  
mOOu
G
G
>% 
4-1 
• p4
•S
4J
<
309
R s 
♦< ♦! 
O' «
♦ I
•GV
G
C
• •4 4J
coU
CO
m
Gm4
t
I I
♦ I g
M
• .2
I:
310
m  «o m «a
S R’ è’ i? A'm ^ @0 m m
^ V ±*2 3 s o  o o o
o o o o  o o  o o  o o
o o o o  o o o
ON
en
G
rH
I
311
= «
3 2 I' =
j;' A'
£ 2 2
d ri oî.» »n r)
*1
s
I
?
:  s
I 8
•G
I•H
4J
GOo
ON
cn
G1-4
I I i
!i
M
!i
312
«N o o <>
A* A' A'
O N O
A' ÿ A' A' I' A* A*
.» >o ïN o 5 m o
G4J
G
M
Xi• H
♦ I
O
CM
en
•§
H
Ps
Xi
•G
G
U3
g
§•<44J
GU*J
G
G
U
G0 Ü
1
•H
Xiu
G
U
I
i
rj
0
s
1  i
I -
l i
!l
h
313
s
a
•S
I
m
§ 
• H 
G G
ï'î g a' S'
— o r-
*1 *1A' A' 1'
os 00 90 09 «• 09
m  m  Ml m  «A m
2 S A I* -o« <n n  o  co
P« CM is A  oien .* «a m (M
G
G
I 
I
i
es
en
G
r4
t
G
G
i
GU
G
•g.
G0
■g
1 
t
1—4
G
44
O
ù•f4
.54J
U
<
314
♦ 1 ♦!
«M n
— o
A'
♦ I
a
•V0)
S•H
4J
Co
u
es
en
G
1-4
g
11
II
h
i :
£ î
315
G
U
.•S44
O
•GG
UG
g
•H
G
i
• H
G
G
<a M e» «M
g i ' s s g
g s
3 3 3 a 83 S
•* -0 ^ r*.
5 5 8
A d A
2 l'g
a
S 3 R 
S «M
C
• H
4J
g
•S
G
P.
■§
£
G
G§&
I
I
•G
G
4Jg
a
G
0
1
u
G
U
>1fH
60
I
G
g
es
es
en
g
44
O
•H
.544
<
316
S :
*1
S
I
Is
•oG
I4J
C
o
u
li
es
es
en
g
! « 
. 3
II
317
2A3
•H44
O
e s s s e i t }
%  o  2 
m A *M
3 8 £
*1 +1 41
S 3 S  8 8 =  S 2 S 8 8 S
M  m  m  m  A  m  A  A  A  A
f  f s  £ s  S 2 2 g 2 g
J U R A S S E ;  S S E i s s S f
5 3 
A A
41 41
en
es
en
Gt—4
g
>1pO
•G
G
I
•H
§o
•H
G
G
M
I
G
•H
G
GG•G
•H44
O
GtH
U
i
m
44
O
I
318
: I’ g
A A A
CM o
A  A
% s
I!
T3I
I
O
li
cnCNJ
CO
G
1-4
t
i :
319
.5
G
mG44
G
t 
I
•H
8
f a s g g g g g I' 
%
g
gg
^ m  «o
g g g
90 m  w%o %n 90
09 f9|
a s g
s s £
A A d
g g i
M  m  m  o  O  09•• M ^ N 90
f» #A O  #n
♦ I ♦! cfl 4>t <HS û «O ^ ®«n «c (M ® o
m  00 "O 90 m  0990 90 o ® %n
2 g'
G
4J
GP
pO•H44O
PiA3
13
GI
i#p4
000)
os d
3 g
CM
m
•§
H
fr
•H
•S
44
<
320
*t *4
♦ I 
O
•GG
G
• H  JJ
g
O
es
en
§
g
i l
: K
I J
i0
1
il
321
^ 3' A' A" A' A' A' A'
S S R s
m  N  d N
g s s.s'
S A' â' r A'
9A m  (s o  <r
90 * %o CM
cn *o CM ®  ®
G 
4J 
G 
U A3 • H 44 
O
S Î'
è
13
G
U
I
•H
â' s
m
es
G
m
Gr-4
G
4J
G
G
«W
O
en
3
’>
•H
4J
<
322
3! A A?
♦ I 
a
G
§ • H44
GOu
II
ÏI
m
cs
cn
G1—4
3 I
! « 
ii
323
S 3  = S R
s s
(M CM o  «o o i <n
A A' A' A' 1'
00 n  00 o  o
♦  I *1 *1
i'5
G>4A3
•H
X
Xi
•GGI
ng
•H
G
G
vOes
m
3
G
•H
G
G
G
U
•H
S
■g
I4J
<
324
3 R S S
CM CM —
A' A' A A?
rj A M pj
•a  <0
S £
*1
s
I
s 
t i
1.H44g
U
vo
es
m
3
" i
:,ï
il
il
325
Fig. 3.1
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic total glucose-6—phosphate dehydrogenase
>  ..
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I..B
â A I ll
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones; peri­
portal, midzonal and centrilobular.
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Fis, 3.2
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic glucose-6-phosphate dehydrogenase pathway I
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic glucose-6-phosphate dehydrogenase pathway II
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic gamma-glutamyltransferase
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Average results from 12 measurements carried out in the periportal hepatic lobular zone of 
five treated rats. The measurements obtained in integrated extinction units xlOO, are 
expressed as percentage of 12 mean periportal readings of five control rats * standard 
deviation.
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Fig. 3.5
Effect of oral administration of 400 mg/kg per day of clofibrate on
hepatic glutathione concentration
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.6
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic alpha-glycerophosphate dehydrogenase NAD dependent
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic alpha-glycerophosphate dehydrogenase FP dependent
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats* The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats *  standard deviation.
Each group of histograms represents from left to right the three liver lobular zones; peri­
portal, midzonal and centrilobular.
♦  Not performed for technical reasons.
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Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic 5*-nucleotidase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig- 3.9
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic acid phosphatase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal 
midzonal and centrilobular) of five treated rats* The measurements obtained in integrated
results
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones; peri­
portal, midzonal and centrilobular.
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Fig. 3.10
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic catalase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats* The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation*
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular*
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Fig* 3.11
Effect of oral administration of 400 mg/kg per day of clofibrate on the
activity of hepatic uricase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of five treated rats. The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 3x12 mean (periportal, midzonal and 
centrilobular) readings of five control rats * standard deviation.
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.12
Fffset of stopping oml administration of 400 mg/kg per day of clofibrate
on the activity of hepatic total glucose—6—phosphate dehydrogenase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats * standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.13
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic glucose-6-phosphate dehydrogenase pathway I
>
i
èig
[fIi rlr At à
3DS 2WK5 HWK5 I IWKS 38WC5 HBHCS 52MCS SSMCS EBMCS 77MCS BEMCS SSMCS IB3MC5 I I3WKS
Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover, for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig- 3.14
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic glucose-6-phosphate dehydrogenase pathway II
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.15
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic gamma-glutamyltransferase
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Average results from 12 measurements carried out in the periportal hepatic lobular zone of 
four treated rats (unless otherwise stated). The measurements obtained in integrated 
extinction units xlOO, are expressed as percentage of 12 mean periportal readings of five 
control rats * standard deviation. The animals were dosed and allowed to recover for 
16-18 weeks (i.e. dosing stopped at week 77 and animals were sacrificed at week 95).
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Fig. 3.16
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on hepatic glutathione concentration
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xIOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.17
Effect of stopping oral administration of 400 mg/kg per day of
clofibrate on the activity of hepatic alpha-glycerophosphate
dehydrogenase NAD dependent
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.18
Effect of stopping oral administration of 400 mg/kg per day of
clofibrate on the activity of hepatic alpha-glycerophosphate
dehydrogenase FP dependent
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.19
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic 5’-nucleotidase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats * standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.20
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic acid phosphatase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.21
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic catalase
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Average results from 3x12 measurements carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xIOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats ^ standard deviation. The 
animals were dosed and allowed to recover for 16—18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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Fig. 3.22
Effect of stopping oral administration of 400 mg/kg per day of clofibrate
on the activity of hepatic uricase
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Average results from 3x12 mcasursswnts carried out in three hepatic lobular zones (periportal, 
midzonal and centrilobular) of four treated rats (unless otherwise stated). The measurements 
obtained in integrated extinction units xlOO, are expressed as percentage of 3x12 mean (peri­
portal, midzonal and centrilobular) readings of five control rats * standard deviation. The 
animals were dosed and allowed to recover for 16-18 weeks (i.e. dosing stopped at week 77 and 
animals sacrificed at week 95).
Each group of histograms represents from left to right the three liver lobular zones: peri­
portal, midzonal and centrilobular.
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mPig. 3 . 2 3  Section taken from the liver of a rat treated with
clofibrate. There is accumulation of lipofuscin at the periphery 
of a liver nodule (Schmorls’ staining, % 2 7 O).
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MFig. 3*24 Microphotograph of a clofibrate induced hyperplastic 
nodule. The nodular lesion compresses but does not infiltrate the 
adjacent normal liver tissue (Toluidine Blue, i 325).
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Pig. 3*25 Clofibrate induced liver nodule. The liver cords are formed 
by more than one cell. The cells composing the nodule are large, 
granular with large clear nuclei and prominent nucleoli (Toluidine 
Blue, X 3 2 5 ).
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Fig* 3*26 Histological appearance of one of the two clofibrate 
induced hepatocellular carcinomas. Note the multicellular cords and 
the distorted glandular structures (H and E, x 125).
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Fig. 3*27 Frozen liver section stained with ORO, taken from a rat 
fed clofibrate for three days. The lipid is located predominantly 
in the periportal and midzonal areas (z 1 2 5 ).
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Fig. 3 . 2 8  Frozen liver section showing a diffuse lobular distribution 
of lipid in a rat treated with clofibrate for eight weeks (ORO, z 2 7 O).
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ïFig* 3*29 Frozen liver section stained with PAS from a rat fed 
clofibrate for three days. Centrilobular loss of glycogen is seen
(i 2 7 0 ).
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Fig. 3 .3 0 Frozen liver sections stained for total G6PDH (x 125).
a) Liver of untreated control rat fed normal diet for eleven weeks.
b) Liver of a rat treated with clofibrate for eleven weeks. In this 
section there is a definite increase of total G6PDH.
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Fig. 3*31 Liver section of a clofibrate treated rat stained with 
antisera raised against cytochrome P-4 5 2» major clofibrate induced 
form. Note the centrilobular concentration of cytochrome P-452 
(PAP, z 325).
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Fig. 3 .3 2 Frozen sections shov/ing the hepatic distribution of Y— CTT
(z 2 7 0 ).
a) Control rat, bile ducts and some of the adjacent hepatocytes stained 
positively for y—GT.
b) Clofibrate treated rat, y— GT activity is restricted to bile ducts.
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Fig. 3 .33 Frozen liver sections stained for GSH (z I 2 5 ).
a) Section taken from a control rat, fed normal diet for four weeks.
b) Section taken from a clofibrate treated rat for four weeks. Note 
the marked depletion in both centrilobular and midzonal areas.
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Pig. 3*34 Frozen liver sections stained for catalase.
a) Control rat having received normal diet for eleven weeks (z 125).
b) Rat treated with clofibrate for eleven weeks. In this section 
there is a marked increase of catalase positive particles (z 270).
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Fig# 3*35 Focus of cellular alteration retaining GSH. Frozen section 
taken from a rat fed clofibrate for forty two weeks (z 2'JO),
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Fig. 3 . 3 6  Focus of hepatocellular alteration devoid of 5*-&uolGoti. 
dase. Frozen section from a rat treated with clofibrate for ninety 
five weeks (z 1 2 5 ).
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Fig* 3*37 Frozen liver section of a clofibrate treated rat for 
seventy seven weeks showing a focus of cellular alteration reacting 
for total anaerobic G6PDH (z 270).
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Fig. 3 . 3 8  Immunocytochemical demonstration of cytochrome P-452 in
an hepatic focus of cellular alteration. Rat treated with clofi- 
hrate for eighty siz weeks (PAP, z 270).
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Fig* 3*39 Frozen section showing reduced levels of catalase in a 
liver nodule. Rat treated with clofibrate for eighty siz weeks 
(z 125).
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Fig. 3*40 Frozen section of a liver nodule showing a marked 
reduction of GSH content (z 125).
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Fig. 3 . 4 1  Microphotograph of a frozen section taken from a liver 
nodule found after eighty siz weeks of clofibrate administration. 
The nodular lesion is totally devoid of y-GT, only the background 
yellow staining is present (z 12$).
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Fig. 3 . 4 2  Enhanced activity of total anaerobic G6PDH in a liver 
nodule found after eighty siz weeks of treatment with clofibrate
(z 125).
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Fig. 3*43 Same as Fig. 3«42, showing a marked depression of G6PDH 
pathway I in the liver nodule (z 12$).
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Fig* 3*44 Pormalin-fized, paraffin-embedded section of a liver 
nodule stained for cytochrome P-452. The cells of the nodule 
stained weaker and more irregular than the host liver tissue 
(PAP, X  3 2 5 ) .
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Fig. 3*45 Formalin-fixed, paraffin-embedded section of a liver 
nodule showing a scanty intracytoplasmic reaction for cytochrome
P- 4 5 0  (pap, z 3 2 5 ).
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Fig. 3 . 4 6  Frozen liver section showing increased activity of NAD 
linked a-GPDH in a liver nodule induced by clofibrate (x 2 7 O).
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Fig* 3*47 Frozen section taken from liver nodule of a rat fed 
clofibrate for ninety five weeks, stained for acid phosphatase. 
Note the enhanced activity of the enzyme (x 2'JO),
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Fig. 3 . 4 8  Liver nodule showing an irregular distribution of 
glycogen. Right side of the microphotograph, non nodular tissue 
Left side, liver nodule. Frozen sample taken from a rat fed 
clofibrate for ninety five weeks (x I2 5 ).
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mFig. 3*49 Formalin-fixed, paraffin-embedded liver section of a rat 
having received clofibrate for eighty six weeks, in which the treat­
ment was discontinued for eighteen weeks. There is abundant fibrous 
tissue containing large amounts of pigment (H and E, x I 2 5 ).
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Pig. 3 . 5 0  Similar lesion as shown in Pig. 3*49• Note the absence
of normal liver structure and a marked fibrosis. The abundant 
pigment observed stained positively for lipofuscin (not shown)
(H and E, x 2 7 0 ).
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Fig. 3 . 5 1  Frozen liver section of a rat of the group withdrawn from 
clofibrate treatment. The presence of a persisting focus having 
acquired Y-GT is seen (i 270).
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Fig. 3 . 5 2  Frozen liver section showing a persisting focus positive 
for aerobic G6PDH. The focal lesion was found in a rat fed clofibrate
for eighty sii weeks and allowed to recover for eighteen weeks
(i 125).
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Fig. 3 . 5 3  Ultrastructural appearance of a liver cell of a rat 
treated with clofibrate for three days. Increased number of pero­
xisomes is present in the cytoplasm. Many of them have the 
cristalloid seen in the peroxisomes of controls (x I8OOO).
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Fig. 3*54 Liver electron micrograph of a rat treated for four weeks 
with clofibrate. The peroxisomes are numerous and most of them lack 
the normal cristalloid. A large number of mitochondria is also 
observed (x 3OOOO).
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Fig. 3 . 5 5  Portion of nucleus and cytoplasm of an hepatocyte from
a clofibrate induced liver nodule. Note the marginated nucleolus 
and the scarce number of peroxisomes (x I8 OOO).
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Fig. 3.)6 Electron microphotograph of an hepatocyte from a rat 
treated with clofibrate for sixty eight weeks and allowed to recover 
for eighteen weeks. Numerous autophagosomes containing dense residual 
bodies are present in the cytoplasm. The bile canaliculus and the 
mitochondria appear normal and the peroxisomes are rare (x I 8 OOO).
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The results presented in this thesis show that the effects on rat liver 
after long term administration of PB following pretreatment with DENA, 
or PB alone, differed markedly from the effects of clofibrate. In the 
non-nodular liver, the changes induced by PB were essentially identical 
in the rats initiated with DENA and in those exposed to PB alone. The 
morphological changes observed throughout the period of treatment were 
early transient enhanced mitotic rates, centrilobular hypertrophy and 
proliferation of SER. Cytochemical examination revealed changes compatible 
with induction of d m g  metabolizing enzymes such as increased activity 
of all forms of anaerobic G5PDH augmented y -GT and GSH depletion. These 
results support the concept that liver enlargement accompanied by 
induction of drug metabolizing enzymes represents an adaptative response. 
(Crampton et al., 1977 a ; Schulte-Hermann, 1979).
Although having some features in common with PB the changes elicited 
by clofibrate in the non-nodular liver differed considerably. Clofibrate 
induced changes characteristic of a marked stimulation of fatty acid 
metabolism, such as peroxisome proliferation and increased activity 
of mitochondrial and NAD linked a-GPDH. Liver enlargement with a brief 
burst of mitosis was also found after short administration of clofibrate. 
However, centrilobular cell hypertrophy and SER proliferation were less 
evident and the induction of microsomal cytochrome activity was short­
lived. The loss of microsomal inductive response was associated with 
morphological changes such as proliferation of abnormal coreless peroxi­
somes, increasing amounts of myeline figures and accumulation of pigment 
(which stained, positive for lipofuscin). The presence of a patchy loss 
of glycogen and an abnormal midzonalperiportal distribution of fat was 
also observed.
As in many models of hepatocarcinogenesis, foci of cellular alteration 
preceded the development of nodules and tumours. However, according to 
the treatment given, marked differences were evident with respect to 
the time of the appearance of the lesions.
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The DENA-PB treatment induced rapidly focal liver lesions (week 4, 4 1/2,
6 and 8) ; most of which were only detectable on cytochemical grounds.
At later stages larger numbers of foci were seen both morphologically 
and cytochemically. Phénobarbital alone advanced the onset of foci 
slighty when compared to those occurring in controls.
Although the latency of focal changes with clofibrate treatment was 
decreased in relation to controls, no foci were found before week 42, 
well before the detection of foci in the untreated controls (week 68) ; 
thereafter the freguency of focal lesions augmented considerably.
Both clofibrate and PB had the capacity to modulate the enzyme expres­
sion of foci of cellular alteration, liver nodules and tumours. However, 
while PB following DENA elicited irreversible changes, those seen in the 
clofibrate induced lesions were modified by withdrawal of treatment.
One of the purposes of this experimental work was the search for cytoche­
mical markers for the early detection of changes indicating potential 
neoplasia. In the DENA-PB situation y -GT and aerobic G6PDH appeared 
as the most suitable markers. y -GT confirmed its well established 
utility in experimental rat hepatocarcinogenesis. Aerobic G6PDH, though 
probably used less because of more demanding technical reasons, was 
however, a better marker. Although the association of Y-GT activity 
with early carcinogen-induced changes occurs frequently enough to merit 
consideration of its particular significance to carcinogenesis, many 
normal adult tissues contain high levels of y -GT. Thus enhanced y-GT 
activity is not unique to tumour tissue. On the other hand, marked 
aerobic G6PDH activity is found exclusively in tumoral tissue and in 
presumed preneoplastic lesions.
The first foci reacting positively for aerobic G6PDH were observed 
very early, at the end of the initiation period. After 3 days of expo­
sure to PB, all the foci examined reacted strongly for aerobic G6PDH and 
y-GT. Subsequently high levels of both enzymes were found in most of 
the foci, in some of the hyperplastic lesions, and in all hepatocellular
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carcinomas examined. These findings strongly suggest a relationship 
between the expression of these two enzymes and development of liver
The ability of clofibrate to induce hepatocellular carcinomas has been 
known for some years. The carcinomas found in two rats after about 
100 weeks of exposure to clofibrate are probably related to treatment 
as such tumours seldom arise spontaneously (Haseman et al.,1984 ; Pfizer 
historical data, unpublished results). In the present experiment, the 
main finding following the long term administration of clofibrate was 
a high incidence of liver nodules. The nodular lesions preceded the onset 
of hepatocellular carcinomas, and provided an useful basis to study 
their potential reversibility. Between week 68 and week 103, nineteen 
rats had liver nodules, none of the rats treated for the same period 
followed by 16 to 18 weeks of cessation of treatment showed similar 
lesions. Moreover, in the latter, the presence of zones of scarred tissue, 
altered cells and abundant deposition of pigment suggest regression of 
the nodules. These observations can be interpreted as evidence that the 
liver nodules induced by clofibrate retain the capacity to regress after 
continuous administration of the stimulus for up to 95 weeks.
In the clofibrate experiment none of the cytochemical markers assayed 
appeared sufficiently early or was completly reliable. None of the liver 
lesions in the group treated chronically showed evidence of y-GT or 
aerobic G6PDH.
Retention of GSH was only found after 42 weeks and was subsequently 
shown to be restricted to foci.
A general lack of homogeneity was observed in the activity of most 
enzymes tested in the foci and nodules examined in this experiment. 
Although the activity of total G6PDH was consistent throughout the 
the study, the first positive foci were only seen at week 68. These 
changes were apparently irreversible since similar modifications
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were found in the livers of rats removed from treatment. However increased 
total G5PDH is not necessarily associated with neoplasia since it was 
present in the focal lesions of controls. In addition, high levels of 
this enzyme were found in liver nodules induced by clofibrate, which 
subsequently regressed.
The present clofibrate study has confirmed previous published work 
on hypolipidaemic drugs and plasticizers. It has also been shown 
that clofibrate shares noticeable characteristics with other unrelated 
substances such as safrol. Ponceau MX and coumarin and xylidine.
While the mechanism underlying the biochemical changes produced by these 
compounds differ from those elicited by clofibrate, some common features 
occur. Thus, apart from the initial microsomal enzyme induction, 
enlarged liver and hepatocyte hypertrophy are stimulated to a greater 
extent than is microsomal cytochrome activity. Grasso (1979) and Crampton 
and associates (1977 b ) suggest that these changes are representative 
of hepatotoxicity, which when prolonged sufficiently are at the basis of 
the development of liver nodular hyperplasia and ultimately hepatocel­
lular carcinomas. Thus, the association of hypofunctional SER, liver 
enlargement and signs of toxicity seems to appear rapidly and frequently 
enough to be considered as a valuable factor in early predictive assays 
for hepatocarcinogenicity of this category of compounds with little 
or no genotoxicity. However, more work is needed on compounds with 
such properties in order to confirm the value of this "marker".
Other consequences of treatment with this class of compounds and other 
types of promoters should be explored. The working hypothesis is that 
the function of promoters of carcinogenesis may be regarded as gene 
activation. Promoters are thought to cause the phenotypic expression 
of changes in phenotype such as altered metabolism followed by changes 
in morphology and, finally, neoplasm. The intrinsic mechanism involved 
in the expression of phenotypic changes is still not clearly understood. 
Alteration of phenotypes of certain cells, blockage of terminal 
differentiation in various cell types, stimulation of protein, RNA, DNA
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and prostaglandin synthesis, phosphorilation of histones are among the 
many suggestions of the mechanism underlaying promoter effects. A large 
body of evidence suggests that the primary or initial effect occurs at 
the cell membrane. Promoters may be conceived as agents that perturb 
cell membranes, probably by many different mechanisms, which then 
transmit the perturbation via a complex concatenation of biochemical 
reactions to de-repress or repress certain genes. Detection of early 
changes occurring in membranes therefore warrant further investigation. 
Although in the present clofibrate experiment the study of cytochemical 
membrane markers gave inconclusive results, more investigation is 
required on cytochemical and biochemical grounds.
Modifications occurring in the cytoskeleton, gap junction functions 
and assembly of microtubules may provide valuable information on 
changes involved in cell membranes and associated cellular structures. 
Study of changes occurring in surface glycoproteins using specific 
lectines and modifications of phospholipid metabolism may contribute 
to the understanding of the role played by cell membranes in the 
development of neoplasm induced by non-genotoxic substances. Several 
of the above described responses to promoters have been investigated 
in many species, organs and development stages. It has not yet been 
determined which are the early alterations implicated in the develop-
Land and coworkers (1983) have suggested that the progression of tumours 
from precancerous growths into autonomously growing malignant tumours 
have an underlying molecular basis involving oncogenes. Monoclonal 
antibodies directed against a synthetic peptide reflecting sequences 
of the human T 24 ras gene product has been used to define ras p21 
protein expression in a spectrum of colonic lesions (Thor et al., 1984). 
The antibodies also immunoreact with antigens present in rat mammary 
tumours. It would be interesting to extend this experimental work to liver 
carcinogenesis providing there is a cross reaction with proteins 
produced by neoplastic hepatocytes. This or similar types of immunocyto-
387
chemical assays would perhaps allow the identification of the incidence 
of the already initiated cells and the latency of their transformed 
genetic expression.
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